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INTRODUCTION. 
INFECTIOUS DISEASE DURING PREGNANCY 
The health and well-being of both mother and child largely depend on the 
environmental factors, which in other words is the environment that can influ-
ence the fertility of women or the outcome of pregnancy or of the foetus. To-
day, increased knowledge about basic virology and immunology, better diag-
nostic techniques and the development of vaccines and efficient antiviral open 
new perspectives for women in childbearing age, in pregnancy and for the foe-
tus. 
Infections in pregnancy are one of the major causes of foetal morbidity and 
mortality. Infections are quite easily diagnoses and can, in many cases, be pre-
vented; hence, risk assessment to the developing foetus is primarily based on 
the positive diagnosis of maternal infection. The foetus may be affected only if 
the causative agent is transmitted to it. This generally occurs in less than half of 
the cases of primary maternal infection, and to a much lesser degree in maternal 
reinfection. It was therefore important to develop methods for the direct diag-
nosis of foetal infection and/or to prevent vertical transmission. 
Maternal infections may spread to the embryo and foetus in one of two ways: 
ascending infections, from the upper vagina via the uterine cervix, infecting the 
amniotic fluid, or by hematogenous spread as a result of maternal viremia or 
bacteremia. Ascending infections are more common in bacterial infections, 
while the hematogenous spread is more common in viral infections. 
The possible adverse effects on the embryo and foetus include, besides dis-
tinct congenital anomalies, neonatal and perinatal effects that may lead to em-
bryonic and foetal death, spontaneous abortions, premature labour and distur-
bances of foetal growth. In addition, the infection may have long term sequels, 
as for Congenital Toxoplasmosis, or, it may condition the life of the child and 
the adult it will be, as for HIV infection. 
In the 25 years since the first report, more than 65 million persons have been 
infected with HIV, and more than 25 million have died of AIDS. Worldwide, 
more than 40% of new infections among adults are in young people (15-
24years of age) and 60% are women. This crisis demanded a unique and truly 
global response. There is good evidence that available behavioural prevention 
strategies are effective, yet key prevention services currently reach less than 
10% of person at risk. In the meantime, there is also a need for research on new 
approaches to prevention (vaccines) and treatment. A comprehensive response 
to HIV should include intensified effort while simultaneously expanding access 
to treatment and care, this is especially true for women in childbearing age. 
While Toxoplasmosis infection in women is often benign, Congenital 
Toxoplasmosis can lead to severe consequences for the foetus and the newborn, 
such as visual or neurological impairment or death. To deal with this problem, 
European countries have adopted contrasting public health policies, ranging 
from focusing on primary prevention in the general population to intensive 
screening programs. One hypothesis to explain the lack of consensus is the fact 
that the epidemiology of Congenital Toxoplasmosis varies across countries and 
time. Another is that the evidence regarding the advantages and disadvantages 
of possible interventions is not clear. 
In Italy, both screening for HIV and Toxoplasmosis are strongly recom-
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mended during pregnancy.  
Behind the development of screening programs, as a special type of public 
health intervention, there is a precious rational and a decision-making process. 
The main factors can be summarised as: 
1. The severity of the public health issue. The usual starting point, for a pub-
lic health program to be justified, is the severity of the target health prob-
lem or its consequences.  
2. The interventions. They can be aimed at preventing causes of a disease 
(primary prevention) or at detecting early dysfunction (secondary preven-
tion) or, one consequences are unavoidable, to solve the problem or to 
avoid worsening of consequences (treatment, rehabilitations and correc-
tive actions). 
3. The risk/effectiveness ratio of the intervention. An intervention should be 
recommended only if its positive effects outweigh its negative effects. 
4. The efficacy of the intervention. The efficiency of an intervention will 
consider: a) the minimal resources requirement needed to maximize the 
positive effect and minimize the negative effects; b) the costs of imple-
ment the intervention; and c) whether the expected effects justify these 
costs. 
The first part of chapter 1 deals with HIV infection background trying to ex-
plain why this infection is considered a relevant public health problem spe-
cially during pregnancy and what have been done since now to reduce foetal 
risk related to the infection. In particular, in the second part, it has been re-
ported the description of the population of HIV infected women that attend the 
University Hospital of Naples. The second chapter, describes the ongoing 
European Collaborative Study on HIV and in particular examines the rate of 
repeated pregnancy in HIV infected women in the European setting, trying to 
recognise predictive factors for maternity desire. Moreover in this chapter, the 
most recently results from the European Collaborative Study are discussed. The 
third chapter deals with Toxoplasma infection, in particular the efficacy of the 
screening program and the effect of targeted ultrasound are discussed. Chapter 
4 and chapter 5 report some rare and challenging conditions that have been ob-
served during the study period. 
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CHAPTER 1. 
HIV INFECTION IN CAMPANIA REGION 
1.1. Scientific background: HIV and pregnancy 
According to the Joint United Nations Program on AIDS (UNAIDS) about 
19,2 million of women are HIV (Human Immunodeficiency Virus) infected in 
the word and 800.000 children become infected every year mainly through ma-
ternal-to-foetal transmission of the virus (1). There is particular concern for the 
increasing numbers of infected people reported from Eastern Europe, where the 
current infrastructure may be unable to cope with a rapidly evolving epidemic. 
HIV infection and transmission thus remain an important issue in Europe. 
HIV is an enveloped retrovirus whose infection results in profound deficien-
cies in cell-mediated and humoral immunity, secondary to both quantitative and 
qualitative defects, leading to a progressive dysfunction of the immune system 
with depletion of CD4 cells. 
Diagnosis of HIV infection as part of routine prenatal care of pregnant wo-
men is very important because preventive therapies are now available. Prenatal 
diagnosis in the foetus is difficult because of the risk for bleeding and contami-
nation of the sample with maternal blood or the possibility for accidental iatro-
genic infection of the foetus. 
HIV infection in infants and children has a different presentation from adults. 
Growth delay is an early and frequent finding of untreated perinatal infection, 
children are more likely than adults to have serious bacterial infections. The 
initial symptoms may be subtle, premature birth has been reported in 19%. 
Common clinical features seen during the course of HIV infection in children 
are lymphadenopathy, fevers, malaise, loss of energy, as well as recurrent and 
chronic otitis and sinusitis. Also commonly encountered are failure to thrive, 
sometimes associated with chronic diarrhoea, failure to grow, the presence and 
persistence of mucocutaneous candidiasis and many non-specific cutaneous 
manifestations (2). 
Mother-to-child, or vertical, transmission of HIV-1 can take place before, du-
ring or after birth, with most transmission occurring around the time of deliv-
ery. The risk is associated with maternal HIV disease status, foetal exposure to 
infected maternal body fluids and breastfeeding, but the exact mechanism is not 
understood. Knowledge about the timing of mother-to-child transmission of 
HIV is sought in order to determine the period of greatest risk for the infant, as 
this would suggest approaches to help to prevent HIV infection and to suggest 
the optimum time of their initiation. If infection occurs mainly during early 
gestation, interruption of transmission may be difficult, whereas intervention 
may be more feasible if transmission occurs mainly during late gestation or at 
the time of delivery. If transmission at the time of delivery occurs through ex-
posure of the foetus to infected maternal secretions, Caesarean section delivery 
or reduction of viral load in the birth canal would be beneficial. On the other 
hand, if transmission at the time of delivery occurs through maternal-foetal 
transfusion during labour, prophylactic antiretroviral treatment of the infant 
would be appropriate. Knowledge about postnatal transmission through breast-
feeding would inform guidelines regarding infant feeding practices (3-6). Cur-
rent data suggest that the majority of children are infected during immediate 
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peripartum period. The risk of vertical transmission without any intervention is 
about 25% (7). High viral load and low CD4 count have been suggested as risk 
factors for HIV vertical transmission. However there is not a viral load under 
which the transmission never occurs even if it is considered very rare when the 
woman has a undetectable viral load (HIV-RNA <1000 copies/ml) near the 
time of delivery (8,9). On the other hand, the risk of vertical transmission is in-
creased in case of prolonged rupture of membranes (>4h) because of the expo-
sure to maternal fluids (10), episiotomy, corioamnionitis and concomitant 
sexually transmitted diseases (11). 
An important goal in the care for HIV-infected women is the prevention of 
foetal/neonatal infection. Identifying pregnant women who are HIV infected is 
essential, not only for the potential initiation of therapy but also for the coordi-
nation of optimal prenatal care. In theory mother-to-child transmission may be 
avoided by antiretroviral prophylaxis during pregnancy, elective caesarean sec-
tion (12,13) and refraining breastfeeding. In Western Europe, where these in-
terventions are available, the rate of vertical transmission has decreased from 
about 15 to 2% or less (7). The European Collaborative Study of 1254 HIV-
infected mothers and their children estimated that caesarean section resulted in 
a 50% reduction of the transmission rate (14). The success of the AIDS Clinical 
Trials Group 076 (PACTG 076) protocol has had a major impact on the preven-
tion of perinatal transmission of HIV-1 and has resulted in new guidelines. In 
that landmark study pregnant HIV-infected women received oral zidovudine, 
starting at 14 to 34 weeks of gestation, and intravenous zidovudine during labor 
and delivery, while the infants were treated with 6 weeks of oral zidovudine 
post partum. This resulted in a 67% reduction in the perinatal transmission rate 
from 25% to 8.3% (P=0.00006) (15). 
Since the mid-1990s, potent and effective antiretroviral therapy (HAART) to 
delay progression of disease in HIV-infected adults has become the standard of 
care. Such regimens are now usually applied, as a consequence HIV-infected 
women may now make a positive choice to become pregnant and those who do 
become pregnant are less likely to have this pregnancy terminated, because 
their own disease is well managed and interventions to reduce the risk of verti-
cal transmission are available (16). Pregnancy should not preclude the use of 
optimal therapeutic regimens. However, recommendations regarding the choice 
of antiretroviral drugs for treatment of infected pregnant women are subject to 
unique considerations. They include: 
a. Possible changes in dosing requirements resulting from physiologic 
changes associated with pregnancy, 
b. potential effects of antiretroviral drugs on the pregnant woman, and the 
potential short- and long-term effects of the antiretroviral drug on the foe-
tus and newborn, which may not be known for certain antiretroviral 
drugs. 
Although the protective effect of antiretroviral therapy for vertical transmis-
sion has been confirmed in many clinical trials (17-22) and in European (22,23) 
or American (24) observational cohorts, data are conflicting as to whether re-
ceipt of combination antiretroviral therapy during pregnancy is associated with 
adverse pregnancy outcomes such as preterm delivery or other pregnancy com-
plications. 
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1.2. Epidemiological and clinical features of pregnant women with HIV: a 
21-year perspective from a highly specialized regional center in Southern 
Italy 
The HIV epidemic has seen many important changes over the past 20 years, 
especially the significant declines in AIDS incidence and deaths (16).  
In Italy governmental HIV surveillance, based on reports of AIDS cases has 
shown, as elsewhere in Europe, a decline in AIDS cases since 1996 (25). Pro-
gressive changes in the characteristics of the HIV-infected population in 
Europe have also been reported with a gradual shift from injecting drug use 
(IDUs) sharing to heterosexual acquisition of infection. In the same time, the 
proportion of women among newly diagnosed HIV infections in Europe has in-
creased, from 10% in 2001 to 29% in 2005 (26).  
In this context we have judged mandatory to monitoring the demographic 
and biological characteristics of HIV infected pregnant women in our region 
(the Campania) and the extent and type of antiretroviral treatment and other in-
terventions to reduce mother-to-child transmission given before, during or after 
pregnancy, to estimating the rate of vertical transmission in Campania. All this 
aspects have indirectly the mean goal to act as a public health resource on a re-
gional basis.  
Since our Department of Prenatal Care has been recognised as a referring 
centre for HIV/AIDS and other sexual transmitted diseases, we were providing 
with a unique opportunity to describe the changing characteristics of women 
with HIV in a region of the South West of Italy (Campania) over the past 21 
years. 
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1.3. Our experience: Materials and Methods 
• Type of study: This is a prospective cohort study; 
• Inclusion criteria: The study population consisted of all HIV-infected preg-
nant women attending the Antenatal Clinic of the Department of Obstetrics 
and Gynecology of the University of Naples Federico II; 
• Data collection for pregnant women: All HIV-infected women attended to 
our Department were enrolled and follow with their infected and uninfected 
children. The management of the pregnancies was based on standard proto-
cols that were progressively updated according to advances in clinical care 
and treatment guidelines. Informed consent was obtained for the use of per-
sonal data and no woman declined to enter the study. We recorded socio-
demographic data (date of birth, marital status, ethnic group, work), and in-
formation about clinical status (current HIV staging according to the 1993 
CDC classification symptoms and date of onset), maternal antiretroviral 
therapy (ART) with details about the date of starting and adverse effects, vi-
rological and immunological status(quantitative HIV-RNA PCR, total lym-
phocytes, CD4 and CD8 cell counts), route of transmission, HIV status of 
the partner, and concomitant infectious diseases (TORCH, Lue). Data on 
pregnancy and neonatal outcomes were also recorded by our multidisclipi-
nary team constituted by obstetricians and pediatricians. The data collected 
were entered into a Microsoft Access Database which holds all information 
on child and maternal follow-up. 
• Results: By December 2006, 230 deliveries in 159 women had been moni-
tored. The following were the main results we obtained: 
1. Deliveries in HIV-infected women increased from 0.16% (4/2,499) of all 
deliveries in 1985 to 0.73% (15/2042) in 2006; 
2. The socio-demographic profile of the women changed greatly over the 
study period. There was a shift from injecting drug use to heterosexual 
contact as the main transmission route, and an increased proportion of 
foreign women; 
3. The proportion of infected pregnant women receiving antiretroviral 
treatment increased from 27% (17/63) before 1996 to 81% (63/78) in 
2006, with a corresponding decrease in the mother-to-child transmission 
rate from 36% (16/44) to 0.6% (1/157). Similar changes in the overall 
scenario of HIV and pregnancy are occurring in various parts of the 
world. 
This work concluded with the publication of a paper on an international jour-
nal as reported above. 
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Abstract 
Purpose: To analyze the changes over two decades in HIV-infected pregnant women 
followed at a highly specialized regional center for antenatal care in southern Italy. Method: 
Since 1985, all HIV-infected pregnant women attending our center have been monitored 
using progressively updated protocols. Results: By December 2006, 230 deliveries in 159 
women had been monitored. Deliveries in HIV-infected women increased from 0.16% 
(4/2,499) of all deliveries in 1985 to 0.73% (15/2,042) in 2006. The sociodemographic profile 
of the women changed greatly over the study period, and there was a shift from injecting drug 
use to heterosexual contact as the main transmission route and an increased proportion of 
foreign women. Subsequent to improvements in clinical care, the proportion of infected 
pregnant women receiving antiretroviral treatment increased from 27% (17/63) before 1996 to 
81% (63/78) in 2006, with a corresponding decrease in the mother-to-child transmission rate 
from 36% (16/44) to 0.6% (1/157). Conclusion: The increasing number of HIV-infected 
pregnant women can be attributed to nonselective antenatal HIV screening, the spread of HIV 
infection through heterosexual contacts, and the desire of HIV-infected women to have 
children. In this context, highly specialized reference centers can play an important role in 
providing HIV-infected pregnant women with optimal care and in reducing mother-to-child 
transmission rates to very low levels. Key words: AIDS, HIV, epidemiology, Italy, pregnancy  
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The HIV epidemic has seen many important changes over the past 20 years, perhaps the most 
striking being a significant decrease in the incidence of AIDS and AIDS-related deaths.1 In 
Italy, 56,076 cases of AIDS were reported between 1982 and 2005. The number of cases 
progressively increased between 1982 and 1995, decreased between 1995 and 2001, were 
stable between 2001 and 2004, and decreased between 2004 and 2005.2  
 
Also the characteristics of the HIV-infected population in Europe have changed in the last two 
decades. Since 1998, a gradual shift from injecting drug use (IDU) needle sharing to 
heterosexual acquisition of infection has been recorded in Europe (infections through 
heterosexual contacts increased from 43% in 1998 to 59% in 20033). Also in Italy, the cases 
of AIDS due to heterosexual contacts increased from 12% before 1994 to 42% in 2004–
20052. Although the proportion of women among newly diagnosed cases of HIV infection in 
Europe increased from 10% in 2001 to 29% in 2005, the mother-to-child transmission 
(MTCT) rate declined from around 15%–18% to below 2%.4,5  
 
In 1995, the Italian Ministry of Health recommended that HIV testing be included in 
screening for women during pregnancy.6 Since 1985, all HIV-infected pregnant women in 
Campania (southwest Italy) have been followed at our Antenatal Clinic. Consequently, we 
had a unique opportunity to monitor the changing characteristics of women with HIV over the 
past 21 years.  
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[h1]METHOD 
[h2]Population 
 
The study population consisted of all HIV-infected pregnant women attending the Antenatal 
Clinic of the Department of Obstetrics and Gynecology of the University of Naples Federico 
II in the Campania region (which has one of the highest birth rates in Italy) in southwest Italy. 
Our Antenatal Clinic has been designated a highly specialized regional center for antenatal 
care. HIV-infected women were followed according to standard protocols that were 
progressively updated according to advances in clinical care and treatment guidelines. 
Informed consent was obtained for the use of personal data, and no woman declined to enter 
the study. We recorded sociodemographic data and information about clinical status, maternal 
antiretroviral therapy (ART), virological and immunological status, route of transmission, 
HIV status of the partner, and concomitant infectious diseases. CD4 cell counts were 
monitored since 1991. Stage of infection was classified according to the 1993 Centers for 
Disease Control and Prevention (CDC) classification.7 Data on pregnancy and neonatal 
outcomes were also recorded by our multidisclipinary team of obstetricians and pediatricians. 
Preterm delivery was defined as delivery before 37 completed weeks of gestation; iatrogenic 
preterm deliveries resulting from the mother’s condition were excluded. A child was 
classified as HIV-infected after the onset of an AIDS-defining disease or detection of the 
virus by DNA polymerase chain reaction (PCR) on two different occasions or the persistence 
of antibody beyond 18 months.8 
 
[h2]Statistical Analysis 
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Microsoft Office Access 2003 was used to manage and store data. Associations between 
categorical variables were tested with the chi-square test, Fisher exact test, and the chi-square 
test for trend. All p values were two-sided, using .05 as threshold of significance. Calculations 
were performed using the EPI-Info software, version 3.1 (CDC, Atlanta, Georgia, USA).  
 
[h1]RESULTS 
[h2]Maternal Characteristics 
 
From January 1985 to December 2006, 192 HIV-infected women were followed, for a total of 
230 pregnancies. Four of these pregnancies were ongoing and seven were lost to follow-up. 
Seventy-one women had more than one pregnancy during the study (56 had two pregnancies 
and 15 had three). Overall, four pregnancies were twin pregnancies, 12 ended in spontaneous 
abortion, 5 in a voluntary pregnancy termination, and 1 in a therapeutic abortion (because of 
fetal malformation). After exclusion of abortions and patients lost to follow-up, deliveries to 
HIV-infected women as a proportion of total deliveries increased from 0.16% (4/2,499) in 
1985 to 0.73% (15/2,042) in 2006 (p < .001; Figure 1).  
 
The mean (±SD) maternal age of women at their first prenatal visit was 30 ± 5 years, with an 
increase from 25 years in 1991 to 32 years in 2006 (p = .054). The median gestational age at 
first antenatal visit was 16 weeks (range 4–42 weeks), with a shift toward an earlier first visit 
from late in the third trimester or at delivery (median gestational age, 31 weeks; range 10–41 
weeks) in the pre-HAART era (1985–1996) to early in the second trimester (median 12 
weeks; range 4–42 weeks; p < .001) in the HAART era (1997–2006).  
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The sociodemographic characteristics of the women are summarized in Table 1. It is 
interesting to note differences between the pre- and post-HAART eras. Indeed, after the 
advent of HAART, more women were in a stable relationship (married or cohabiting) than 
were single or divorced/separated/widowed (p =.06), and more women were infected through 
heterosexual contact than were infected through IDU (p < .001).  
 
At enrollment in the study, 197 women (86%) provided information about the time of their 
first positive HIV test. In 134 cases (68%), HIV was diagnosed before conception; in the 
remaining cases, it was diagnosed during pregnancy (first trimester, 57%; second trimester, 
20%; third trimester/delivery, 22%). Preconception diagnosis was more common among 
Italian women (95/142, 67%) than among other nationalities considered collectively (38/88, 
43%; p = .06). There were no significant differences between ex- or current IDUs (28/50, 
56%) and women infected heterosexually (97/152, 63%; p = .62).  
 
In the pre-HAART versus the post-HAART era, HIV testing was carried out before 
conception in 73% (16/22) and 67% (118/175) of cases, respectively, and after conception in 
27% (6/22) and 33% (57/175) of cases (p = .61). Before HIV screening was introduced for 
pregnant women in Italy in March 1995, 67% (8/12) of women were diagnosed before 
conception and 33% (4/12) after conception. After 1995, 68% (126/185) of women were 
diagnosed before conception and 32% (59/185) after conception (p = 1.00).  
 
Figure 1 shows the temporal trends for proportions of deliveries from women with HIV and 
mode of acquisition of HIV infection. The proportion of heterosexually acquired infection 
increased significantly from 28% (3/11) in 1985–1990 to 42% (16/33) in 1991–1996, to 77% 
(54/70) in 1997–2001, and to 68% (79/116) in 2002–2006 (p for trend = .008).  
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[h2]Maternal Management  
 
In 1996, when zidovudine (ZDV) was approved for the prophylaxis of vertical transmission of 
HIV in Italy, we adopted the three-part (prenatal, intrapartum, and postnatal) AIDS Clinical 
Trial Group (ACTG) 076 regimen9 to prevent vertical transmission of HIV. Before 1996, 
ZDV monotherapy was used in 12/44 (27%) pregnancies, depending on the mother’s 
condition. Among the 157 pregnancies followed subsequently (excluding cases of 
spontaneous abortion, voluntary interruption, therapeutic abortion, and ongoing pregnancies), 
141 (89%) received ART:  31 women were already undergoing ART at conception, and in 
110 women treatment was started during pregnancy, at a median gestational age of 18 weeks 
(range 3–37). The 16 untreated women in the HAART era presented very late in pregnancy 
(at delivery or in the 10 preceding days) and there was not sufficient time to administer 
prophylaxis in some cases, whereas the women’s health status had not been completely 
evaluated by an infectious disease specialist before labor started in other cases. Among the 
141 women treated during pregnancy, 30 (20%) received ZDV monotherapy, 31 (22%) a two-
drug therapy, and 80 (58%) a HAART regimen. The proportion of women receiving HAART 
increased from 27% (17/63) in 1997–2001 to 81% (63/78) in 2001–2004 (p < .001). (One 
woman received a two-drug regimen in the first half of pregnancy and then HAART.) The 
most common HAART regimens were ZDV + lamivudine (3TC) + nevirapine (NVP) (33/80; 
41%) and ZDV + 3TC + nelfinavir (NFV) (19/80; 24%). Administration of HAART was not 
associated with nationality (p = .28) or mode of acquisition (heterosexual vs.IDU; p = .49). 
Few side effects (mild anemia fever, myalgia and rash) were recorded. 
 
[h2]Pregnancy Outcome and Complications 
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Most women delivered by elective cesarean section after 37 weeks of gestation; vaginal 
delivery decreased from 32% (14/44) in the pre-HAART era to 6% (9/157) in the HAART era 
(p < .001; Table 2). ZDV intrapartum prophylaxis was applied in 98% (154/157) of the 
pregnancies in the HAART era: three did not receive intravenous ZDV because of very rapid 
labor after arriving at hospital, but they received the antenatal treatment and their babies the 
neonatal therapy.  
 
Obstetrical complications were few: two cases of pre-eclampsia (one woman was on HAART 
from the first trimester, and the other from the second trimester), and one case of abruptio 
placentae (ZDV monotherapy since second trimester). Two women had major postpartum 
complications (rate of major postpartum complications was 1.2 per 100 deliveries): one 
postcesarean hysterectomy secondary to uterine atony after an elective cesarean section, and 
one had a wound dehiscence of a previous emergency cesarean section. There were three 
cases of fetal malformation: one cardiac malformation (mother not treated), one bilateral renal 
hypoplasia (mother treated with d4T+3TC+NFV before conception), and one gastroschisis 
(mother treated with AZT+3TC+NVP before conception). The congenital malformation rate 
was 1.3% (2/153) among ART-exposed infants and 2% (1/48) among those without ART 
exposure (p = .56, Fisher exact test). Complete follow-up regarding HIV infection status was 
available for 193 children (8 were lost to follow-up). Two cases were stillborn at 27 and 36 
weeks: there were no maternal complications. The first mother received no ART because she 
delivered in 1992. The second mother started HAART (ZDV, 3TC, lopinavir/ritonavir) before 
conception. There were two neonatal deaths (at 3 days, attributable to a cardiac malformation 
[38 weeks gestation] and at 7 days because of neonatal sepsis [32 weeks gestation]). The 
overall mother-to-child transmission (MTCT) rate was 8% (17/201, 95% CI 5%–12%), but 
 9
only one infant acquired HIV infection vertically after 1996. In this case, the parents 
interrupted neonatal prophylaxis with ZDV at discharge. The MTCT rate prior to application 
of the ACTG 076 protocol and introduction of HAART was 36% (16/44, 95% CI 22%–51%) 
compared to 0.6% (1/157; 95% CI 0%–3.5%) in the HAART era.  
 
Forty-seven women were HCV coinfected. Among their newborns (n = 48; 36 since 1996), 
there were no dual transmissions, nine transmissions of HCV infection (18.8%, 95% CI 8.9–
32.6), and two cases of HIV transmission (4.2%; 95% CI 0.5–14.3). ART was not 
administered in either case. 
 
Postnatal information on maternal health status was available for 111 mothers (80%): 105 
(95%) were alive at a median of 4 years postpartum, and 6 (5%) died at an average of 4.5 
years (range 1– 8) after delivery. Of these six deaths, only one was HIV-related (one woman 
who delivered in 1991 and died from AIDS in 1993); the remaining four women died from 
non-HIV related causes.  
 
[h1]DISCUSSION 
 
The experience of our highly specialized center reflects diverse aspects of the HIV epidemic 
and the advances that have been made in the care of pregnant HIV-infected women over the 
last 20 years. The  increase by almost 4.5-fold  in the HIV-infected caseload in our antenatal 
clinic since 1985 is probably a composite effect of various factors, namely, the desire for 
maternity among HIV-infected women, the general shift in the epidemic toward 
heterosexually acquired infections, the increasing number of infected women of foreign 
provenance in our region, and changes in the management of infected pregnant women (i.e., 
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an increased use of ART, particularly of HAART), and support for childbearing provided to 
HIV-infected women by specialized reference centers.  
 
Similar changes in the overall scenario of HIV and pregnancy are occurring in various parts 
of the world. Because pregnancy seems to have little influence on the progression of infection 
and given the actual low rate of vertical transmission, many people with HIV now 
contemplate having offspring.9 A national study in the United States revealed that 69% of 
HIV-infected women and 59% of HIV-infected men expect to have at least one child.10 A 
prospective cohort study in Europe found a substantially increased likelihood of subsequent 
live births after 1995 and shorter birth intervals among women on HAART and among Black 
women.11  
 
We found that after the introduction of HAART, the vast majority of pregnant HIV-infected 
women in our population had a stable relationship (89%, 144/161). This condition probably 
strongly favors the desire for parenthood. Moreover, the high 5-year postdelivery survival rate 
among the subgroup of women with postnatal data is also reassuring with regard to future 
family life and confirms the good prognosis associated with HAART demonstrated in other 
cohorts.12 However, our survival data should be interpreted with some caution because we 
lack follow-up information for about 20% of the women.  
 
The increase in deliveries among our HIV-infected women may also reflect the introduction 
of screening programs for all pregnant women in Italy. In Italy, HIV screening started in 1995 
and was recommended for all women only during the first trimester.6 In 1998, HIV testing 
was recommended and was available free-of-charge for all women at a preconception visit, in 
addition to the first visit in pregnancy and the last visit before delivery.13 The Italian policy of 
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first trimester screening includes, in addition to HIV testing, testing for antibodies against 
rubella, toxoplasma, and the Venereal Disease Research Laboratories (VDRL) and 
Treponema Pallidum Hemagglutination (TPHA) tests.  
 
Our results indicate a shift in the characteristics of HIV-infected women from an easily 
recognizable high-risk population consisting largely of IDUs to a more heterogeneous 
population that includes an increasing number of women from countries with a high 
frequency of HIV infection. Our finding that 3/11 pregnant women in 1985–1990 compared 
to 88% in 2002–2006 were infected through heterosexual contact, with a concomitant decline 
in IDU-related acquisition, is similar to results obtained in other European countries.14,15 In 
Latium, Italy, heterosexual contact surpassed IDU as the primary mode of acquisition among 
women in 1992, and in 2000 nearly 60% of HIV-positive women had acquired infection 
sexually.16 In Sardinia, the overall rate of heterosexual transmission of HIV was 61%, and the 
rate was even higher rate among women (78% vs. 47% among men).17 This epidemiological 
scenario illustrates the importance of recommending universal voluntary antenatal HIV 
testing for all pregnant women and not just for particular groups.  
 
Notwithstanding national recommendations, a high proportion of women in south Italy are 
still diagnosed with HIV in the second or third trimester of pregnancy (14% in our population 
and about 40% in southeastern Italy).18 There are three possible reasons for the high rate of 
late diagnosis: (a) women in the general population do not consider the possibility of being 
HIV infected; (b) not all women are screened; and (c) some women, especially those from 
abroad, may not have easy, timely access to antenatal services. Given the potentially negative 
effects of delayed application of anti-MTCT measures, these observations suggest that more 
effort should be made to inform prenatal care providers about the importance of HIV 
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screening. They also suggest that foreign women should be guaranteed easy access to 
antenatal care services. 
 
The transmission rate of 36% in our early cases (pre-1997), which is higher than the 15%  
reported in another European context15 but similar to the 26.6% rate observed in the United 
States without ZDV prophylaxis,19 was obtained in a setting in which intervention measures 
were undefined, many of the infected women were drug users with concomitant morbidity, 
most had late antenatal care, and it was not possible to treat the majority of them effectively. 
Starting from 1997, infected pregnant women presented and were managed earlier during 
pregnancy and were treated more effectively. As a result, the rate of MTCT has decreased in 
our center to a very low level (0.6%), which is comparable to those of other European 
cohorts.4,5  
 
It is the policy of our center to offer elective cesarean section irrespective of maternal plasma 
viral load. This policy is based on the low rate of complications in our population and on 
epidemiological findings suggesting that elective cesarean section is effective in reducing the 
risk of MTCT regardless of whether or not the mother is receiving ART.4 We recorded one 
case of emergency peripartum hysterectomy, which corresponds to a rate (0.4%) similar to 
that observed in the general population (cesarean section and vaginal deliveries) of 0.8/1000 
births.20 The very low rate of preterm deliveries (7%) in our study might be related to the 
small number of complicated pregnancies that we observed.   
 
In terms of specific subgroups, there were no differences in time of diagnosis between women 
with and without an IDU history. However, the proportion of Italian women who knew their 
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HIV diagnosis before conception was higher than that of non-Italian women. This finding 
may reflect reduced access of foreign women to HIV testing in their countries of origin.  
 
Last, we also evaluated the HCV transmission rate in HIV/HCV-coinfected women. The HCV 
transmission rate of 19% that we observed is in line with a previous study showing an HCV 
transmission rate of 15% in coinfected mothers, which is higher than the 3.7% transmission 
rate among women with HCV infection only.21  
 
[h1]CONCLUSION 
 
In summary, in the fast evolving epidemiological scenario of HIV infection, specialized 
reference centers, by providing adequate and timely care and applying an updated standard 
protocol for obstetrical management and ART, may reduce the rates of vertical HIV 
transmission and obstetrical complications and may also reduce untoward effects of treatment. 
Despite the current low MTCT rates and the significantly earlier presentation for antenatal 
care in recent years, preconception testing and early presentation for prenatal care is still not 
optimal in south Italy. To ensure effective management of HIV-infected mothers, it is 
essential to obtain a timely diagnosis of HIV through adequate preconception counselling and 
HIV testing.  
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Table 1. Sociodemographic maternal characteristics pre-HAART and after the introduction of 
HAART 
Characteristics Pre-HAART  
(1985–1996) 
n (%) 
HAART 
(1997–2006) 
n (%) 
Gravidity (n = 214) 
1 
2 
3 or more 
31 (14) 
10 (32) 
8 (26) 
13 (42) 
183 (86) 
46 (25) 
46 (25) 
102 (56) 
Previous terminations (n = 214) 
0 
1 
2 
3 or more 
31 (14) 
24 (77) 
3 (10) 
3 (10) 
1 (3) 
183 (86) 
104 (57) 
40 (22) 
16 (9) 
23 (13) 
Previous spontaneous abortions (n = 214) 
0 
1 
2 
3 
31 (14) 
27 (87) 
3 (10) 
1 (3) 
0 
183 (86) 
153 (84) 
21 (11) 
6 (3) 
3 (2) 
Country of origin (n = 229) 
Italy 
Africa 
East Europe 
West Europe (excluding Italy) 
South America 
41 (18) 
35 (85) 
5 (12) 
1 (2) 
0  
0 
186 (82) 
107 (57) 
48 (26) 
16 (9) 
7 (4) 
10 (5) 
Marital status (n = 196) 
Single 
35 (18) 
4 (13) 
161 (82) 
11 (7) 
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Married 
Cohabitating 
Divorced/separated/widowed 
22 (63) 
4 (11) 
5 (14) 
90 (56) 
54 (34) 
6 (4) 
Route of transmission (n = 223) 
Heterosexual contact 
Injecting drug usea 
Blood transfusion 
Not known 
41 (18) 
18 (44) 
23 (56) 
0 
0 
182 (82) 
135 (74) 
26 (14) 
2 (1) 
19 (10) 
aPresent and past injecting drug users. 
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Table 2. HIV-related parameters and pregnancy outcomes pre-HAART and after the 
introduction of HAART 
Parameters and outcomes Pre-HAART  
(1985–1996) 
n (%) 
HAART 
(1997–2006) 
n (%) 
CD4 count/mm3 at delivery (n = 124) 
≥500 cells 
200–499 
<200 
16 (13) 
6 (37) 
7 (44) 
3 (19) 
108 (87) 
41 (38) 
59 (55) 
8 (7) 
CDC clinical stage7 at delivery (n = 192) 
A 
B 
C 
41 (21) 
36 (88) 
0 
5 (12) 
151 (79) 
122 (81) 
14 (9) 
15 (10) 
Pregnancy outcome (n = 230) 
Delivery  
Vaginal delivery 
Emergency cesarean section 
Elective cesarean section 
Spontaneous abortion 
Voluntary interruption 
Therapeutic abortion 
Lost  
Ongoing 
 
44 
14 (32) 
6 (14) 
24 (54) 
NR 
NR 
NR 
NR 
NR 
 
157 
9 (6) 
28 (19) 
120 (76) 
12 (6) 
5 (3) 
1 (1) 
7 (4) 
4 (2) 
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Gestational age at delivery (n = 176) 
Median (range) 
Preterm delivery 
 
29 (16) 
39 (36–42) 
1 (3) 
 
147 (84) 
38 (28–42) 
11 (7)a 
 
Birthweight (n = 166) 
Mean ± SD  
<2500 g 
≥2500 g 
29 (17) 
2868 ± 435 
5 (18) 
24 (82) 
137 (83) 
2869 ± 516 
24 (18) 
113 (82) 
 
Note: NR = not recorded; data not collected before 1997. 
aThree cases were excluded because we performed an iatrogenic preterm delivery because of the 
mother's condition: two cases of severe pre-eclampsia and one of severe diabetic nephropathy.   
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Figure 1. Deliveries to HIV-infected women as a proportion of total deliveries 1985–2006 
and distribution of maternal mode of acquisition. IVDU = intravenous drug use.  
 
 
High risk pregnancy subsequent to maternal infectious disease Annalisa AGANGI 9
CHAPTER 2. 
HIV INFECTION IN EUROPE 
2.1. The European point of view in HIV infection in pregnancy: the Euro-
pean Collaborative Study 
One of the reason of the success in the prevention of vertical transmission of 
HIV infection is the collaboration of most of the centres dedicated to the treat-
ment of HIV infection. The Department of Obstetrics and Gynaecology of the 
University of Naples Federico II collaborates with the long-standing and ongo-
ing European Collaborative Study (ECS).  
Since 1985, the ECS has substantially contributed to research internationally 
on HIV infection in pregnancy and childhood, influencing policy and manage-
ment. The ECS network includes more than 20 referral centres for HIV infected 
pregnant women and their children with central epidemiological expertise, and 
it currently expanding into Eastern Europe.  
The ECS is a multicenter European prospective study, it consists of a co-
ordinating centre at the Institute of Child Health in London and a network of 
export clinicians from 9 European countries.  
The aim of this project is to investigate the consequences of HIV infection in 
pregnancy and after delivery in women and their children, in the area of anti-
retroviral therapy and other interventions for treatment and prophylaxis. This 
includes: 
1. to monitor demographic and biological characteristics of HIV- infected 
pregnant women in Europe, and the extent and type of anti-retroviral 
treatment and other interventions to reduce mother-to-child transmission 
given before, during and after pregnancy, 
2. to document the rate of MTCT across Europe in relation to interventions 
to reduce transmission, 
3. to determine benefits and potential risks of these intervention, 
4. to assess the health and social circumstances of infected and uninfected 
children, in the era of antiretroviral therapy to delay disease progression, 
5. to act as a public health resource on a European basis. 
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2.2. General Methodology and data collection 
The ECS is a prospective birth cohort study with approximately 7000 
mother-child pairs. HIV-infected pregnant women are enrolled and followed up 
during pregnancy, with their children (both infected and uninfected) followed 
up prospectively from birth. Only women identified as HIV infected before, 
during pregnancy or at delivery are eligible for inclusion. The ECS uses only 
routinely collected data for its core study, including socio-demographic details 
and clinical and laboratory test results; thus no extra patient visits or tests are 
required as a result of enrolment in the study.  
ECS centres systematically identify HIV infected pregnant women according 
to local practice, thus in Italy we perform HIV screening test during the precon-
ceptional visit, during the first and third trimester of pregnancy. Clinical and 
laboratory information is collected from enrolled women 1-3 times during 
pregnancy; the amount of follow-up information depending on the trimester at 
which the women were enrolled. Initial information collected includes mother’s 
full obstetric history, marital status, ethnic group, likely route of HIV acquisi-
tion (injecting drug use, needle sharing, high risk sexual partner), HIV history 
and current HIV status including treatment details. During pregnancy and at de-
livery, virological and immunological data on both qualitative and quantitative 
HIV-DNA PCR and HIV-RNA PCR, total lymphocytes, CD4 and CD8 cell 
counts are reported. Required delivery information includes gestational age in 
completed weeks, birthweight in grams, the administration of prophylactic 
ART during labour or delivery including type of therapy and dose mode of de-
livery and any perinatal problems after delivery. Each child is followed accord-
ing to local centre policy. 
The collaboration consist, firstly,  in returning follow-up questionnaires to 
the co-ordinating centre in London on a regular basis. There is a high level of 
knowledge integration between the participants of the ECS, as the creations of 
knowledge and dissemination of results is a primary objective of the collabora-
tion. The ECS has a policy of publishing all its work under the ECS authorship. 
Anyway all ECS clinicians are involved in the writing of ECS papers and they 
all approve manuscript before submission to journals.  
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2.3. Maternity desire in HIV infected women in Europe 
Inside the ECS research group, there is an exchange of experience because 
researches from ECS centres are welcome to the co-ordinating centre for car-
ried out specific projects. 
On this basis, I made ad hoc visit to the coordinating centre to investigate 
how the subsequent childbearing of HIV-infected mothers enrolled in the ECS 
has changed over time and identify factors predictive of further childbearing. 
The specific background was that the maternity desire recorded in other in-
ternational study is growing and the feeling of the expertise that the number of 
subsequent pregnancy is increasing over the years. One national study of HIV-
infected individuals in the USA found that about 28% of participants wanted 
children in the future (1), and cohorts of HIV-infected women from Sub-
Saharan Africa, Europe and North America show that many HIV-infected 
women choose to have children after learning of their infection (2,3).  
There are few medical concerns that should affect HIV-infected women’s re-
productive choices. Pregnancy seems to have little influence on the progression 
of HIV disease, because the transient decline I maternal immunocompetence 
observed during gestation spears to resolve after delivery. For many HIV-
Infected women, these medical concerns can be outweighed by psychological 
factors influencing decision about fertility and contraception. Existing data in-
dicated that diagnosis with HIV modifies but does not remove the wish to have 
children for many women and men (2,3). For some, having a child might be 
perceived to help combat the dehumanising effects of living with HIV and re-
lated anxieties about the future (4,5). Importantly, the desire to have a child 
might be altered bt the availability of highly active antiretroviral therapy, be-
cause infected individuals receiving treatment can come to view HIV as a 
chronic condition (6).  
The psychological influences on fertility desires are paralleled by social nor-
ms, which view reproduction as an integral part of women’s life. Family and 
partner influences can be fundamental in shaping women’s decisions to have a 
child. The central role of childbearing in women’s social identities might be 
particularly marked in parts of Africa, where a woman’s failure to have chil-
dren can be accompanied by stigmatisation and discrimination rivalling that of 
HIV infection itself (7).  
Although some individual and societal factors might encourage reproductive 
desire, in other situations concerns about the possibility of an infected child, 
and/or a child orphaned because of AIDS, might discourage childbearing (4,5). 
To carry on this project all HIV infected women enrolled between end 1986 
and November 2003 were considered. From the total population of 3911 HIV-
infected women, two groups were distinguished: 3693 with only one and 218 
with subsequent live births. 
This analysis has allowed the publication of the paper reported below. 
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Increasing likelihood of further live births in HIV-infected
women in recent years
European Collaborative Studya,1
Objective To examine how the subsequent childbearing of HIV-infected mothers enrolled in the Eu-
ropean Collaborative Study (ECS) has changed over time and identify factors predictive of further
childbearing.
Design Prospective cohort study.
Setting Centres in nine European countries included in the ECS, enrolled between end 1986 and November 2003.
Population HIV-infected women (3911): 3693 with only one and 218 with subsequent live births.
Methods Univariable and multivariable logistic regression analyses to obtain odds ratios (OR) and 95%
confidence intervals (CI). Kaplan–Meier (KM) analyses to estimate cumulative proportions of women
having a subsequent live birth.
Main outcome measures Subsequent live birth.
Results In multivariable analysis adjusting for time period, ethnicity, maternal age and parity, black women
were more likely [adjusted odds ratio (AOR) 2.45; 95% CI, 1.75–3.43], and women >30 years less likely
(AOR 0.54, 0.37–0.80), to have a subsequent live birth. Time to subsequent live birth significantly
shortened over time, with an estimated 2% of women having a subsequent live birth within 24 months of
enrolment pre-1989 versus 14% in 2000–2003 (P < 0.001). Estimated time to subsequent live birth was
shorter for black than for white women (P < 0.001).
Conclusions The likelihood of subsequent live births substantially increased after 1995 and birth intervals
were shorter in women on HAART and among black women. Numbers are currently too small to address the
issue of advantages and disadvantages in the management of subsequent deliveries.
INTRODUCTION
The vast majority of HIV-infected women are in their
reproductive years, with an estimated 78% of women newly
diagnosed with HIV infection in West Europe in 2002 aged
between 13 and 39 years, 73% in Central Europe and 85%
in Eastern Europe,1 but little is known about the effect of
HIV on decisions regarding childbearing, or on the ability
to become pregnant.
In a study among HIV-infected women predating the
HAART era, an HIV diagnosis nearly halved the live birth
rate, from 10.2 per 100 women-years prediagnosis to 5.7
afterwards.2 In a large European study, the age-adjusted
pregnancy incidence before HIV diagnosis remained stable
in the first four years postdiagnosis but reduced signifi-
cantly four or more years after diagnosis.3 Although preg-
nancy rates did not change significantly in relation to the
availability of prophylactic zidovudine to prevent mother-to-
child transmission (MTCT),4 the proportion of pregnancies
continuing to a live birth significantly increased since 1995.3
It has recently been suggested that HIV-infected women in
Europe are now more likely to want to become pregnant,5
probably in response to the substantial reductions in the
MTCT rate to 1–2% now achievable6 – 8 and the availability
of highly active antiretroviral therapy (HAART) to delay
HIV disease progression in both the infected mother and
her infected child.9 – 12
To date, the growing group of HIV-infected women in
Europe who have had more than one live birth following
their HIV diagnosis has received little attention. These
women are not only of interest with regard to child-bearing
decisions, but also because there are some important ques-
tions regarding their optimal management. The main objec-
tives of this analysis were to examine how the subsequent
childbearing of HIV-infected mothers enrolled in the Eu-
ropean Collaborative Study (ECS) has changed over time
and to identify socio-demographic and HIV-related factors
predictive of subsequent live births. To examine this
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question, we compared the characteristics of women with
and without at least one subsequent live birth enrolled in
the ECS.
METHODS
The ECS is a cohort study, in which HIV-infected women
are identified during pregnancy and their infants prospec-
tively followed according to standard clinical and laboratory
protocols.13 The ECS was set up in 1986 and includes cen-
tres in nine European countries.13 In ECS centres, all preg-
nant women are offered antenatal HIV testing, and those
found to be infected invited to participate in the study; preg-
nant women already known to be HIV infected as the result
of earlier testing are also invited to take part. Informed con-
sent is obtained before enrolment, according to local guide-
lines, and local ethics approval has been granted. Infants
born to infected women subsequent to their index pregnancy
within the ECS are also enrolled in the study, with prospec-
tive follow up as above.
Information collected at enrolment and during pregnancy
includes current antiretroviral treatment (ART), maternal
immunological and virological status, maternal illicit drug
use (IDU) history and other socio-demographic character-
istics. Information on maternal CD4 cell count was routinely
collected from 1992 onwards and on RNA viral load from
1998. Laboratory tests including HIV RNA PCR, serology
and CD4 cell count measurements, were carried out locally,
with assays used recorded. Maternal CD4 cell count and HIV
RNA copy number nearest the time of delivery were used in
the analyses here.
In this analysis, children with a positive virological or
serological marker of infection and/or children aged more
than 18 months with persistence of antibody were included
as infected. If a child was HIV antibody-negative and no
virus or antigen had ever been detected, they were classified
as uninfected.
Women who had only the delivery at enrolment (index
pregnancy) were included in the ‘one live birth’ group and
women who had at least one additional live birth after the
index pregnancy were classed in the ‘subsequent live births’
group. Among the group of women with only one live birth,
72 delivered twins and 3 three infants, but no multiple preg-
nancies were observed in the group with subsequent live
births. IDU-related mode of acquisition included women
who had a history of IDU themselves, or who had sexual
partners who had a history of IDU.
Univariable comparisons were assessed with the m2 test
for categorical variables and a two-tailed unpaired t test for
continuous variables. Univariable and multivariable logistic
regression analyses were used to obtain unadjusted and ad-
justed odds ratios (OR) and 95% confidence intervals (CI).
Kaplan–Meier (KM) analyses were performed to estimate
the cumulative proportion of women having a subsequent
live birth,14 and the log-rank test used to test statistical
significance between strata. Data entry was carried out
using MS Access 2000 and analyses using SAS statistical
software (v8.02, SAS Institute, Cary, North Carolina, USA)
and STATA (version 6; College Station, Texas, USA).
RESULTS
By November 2003, 3911 HIV-infected pregnant women
had been enrolled, 3693 (94%) of whom had one live birth
and 218 (6%) had at least one subsequent live birth. There
were a total of 473 births in the group of women with sub-
sequent live births: of the 218 women who had a second
baby, 31 went on to have a third, of whom 5 went on to have
a fourth, and 1 a fifth baby. The time between the index birth
and subsequent infants was 32 months overall (min 7.7; max
170.6 months), varying from 42.15 F 29.26, 33.71 F 21.60
and 28.89F 10.30 months between the first and second, the
second and the third, the third and the fourth subsequent live
births, respectively. The main socio-demographic charac-
teristics and mode of acquisition of HIV infection of the
mothers at enrolment are presented in Table 1.
Black women (mostly born in sub-Saharan Africa) were
significantly more likely to have a subsequent live birth than
women of other ethnicities (Table 1). This was reflected in
the association between mode of acquisition of infection and
subsequent childbearing, with a significantly higher propor-
tion of women who acquired HIV infection in high preva-
lence areas having a subsequent live birth. Most women
were married or cohabiting at the time of enrolment, and
marital status did not significantly affect the likelihood of
subsequent childbearing. Previous obstetric history, both
prior pregnancies resulting in deliveries and previous
abortions, showed no influence on the number of subse-
quent live births. Women with subsequent live births were
significantly younger at their first delivery compared with
women without any further live births. With regard to char-
acteristics specific to HIV infection, women having a sub-
sequent delivery had a lower mean RNA level at enrolment,
although the proportions with viral loads 500 copies/mL
were not significantly different between the two groups
(Table 1), and they did not differ in terms of health status as
indicated by the CD4 count and maternal clinical stage at
enrolment. With regard to trends in subsequent child bear-
ing over time, 6.8% (56/819) of women enrolling in 1985–
1989 had a further delivery, decreasing to 5.3% (60/1133)
in 1990–1994, rising again to 7.6% (80/1058) in 1995–1999.
In the most recent time period, only 2.5% (22/882) of women
enrolling had gone on to have a subsequent delivery, but this
reflects their shorter time since the index delivery.
To further explore factors shown to be univariably asso-
ciated with the likelihood of a woman to have a subsequent
live birth, a multivariable logistic regression analysis was
carried out (Table 2). Adjusting for time period, maternal
ethnicity, age and parity, both ethnicity and maternal age
remained significantly associated with the likelihood of a
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woman to have a subsequent live birth (Table 2). Black women
were nearly two and a half times more likely to have a
subsequent live birth than white women, while women over
30 years at enrolment were about half as likely to have a
further delivery compared with those aged less than 25 years.
In a subanalysis involving 1960 women, adjusting for
maternal CD4 cell count, the increased risk of subsequent
live births among black women remained (OR, 3.49; 95%
CI, 2.16–5.63; P < 0.001), but the difference in terms of ma-
ternal age was not statistically significant. Maternal immune
status was not a significant predictor of subsequent live
births: compared with women with CD4 cell counts above
500 per mm3 the risk was similar in women with CD4 counts
below 200 (AOR, 1.11; 95% CI, 0.68–1.79;P¼ 0.58) and of
200–499 cells/mm3 (AOR 0.90; 0.43–1.84; P ¼ 0.61).
To investigate whether the abovementioned trend in
terms of subsequent live births was a real change in
childbearing in the study population or a reflection of other
factors such as the increased immigration of women from
sub-Saharan countries with higher fertility, we investigated
Table 1. Maternal socio-demographic characteristics at enrolment: women with only the index pregnancy (n ¼ 3693) compared with 218 women with
subsequent live births.
Variables Only index live
birth, n (%)
Subsequent
live births, n (%)
m2 (P)
Ethnicity n ¼ 3529 n ¼ 215 20.83 (<0.001)
White 2728 (77) 139 (65)
Black 656 (19) 67 (31)
Other 145 (4) 9 (4)
Mode of acquisition n ¼ 3693 n ¼ 218 18.87 (<0.001)
IDU related 2270 (61) 110 (50)
Origin area of high prevalence 595 (16) 59 (27)
Other heterosexual 556 (15) 33 (15)
Not stated 272 (7) 16 (7)
Marital status n ¼ 1914 n ¼ 142 1.95 (0.38)
Single 455 (24) 30 (21)
Married/cohabiting 1337 (70) 99 (70)
Divorced/separated/widowed 122 (6) 13 (9)
Parity n ¼ 3402 n ¼ 207 6.46 (0.09)
0 1916 (56) 132 (64)
1 911 (27) 48 (23)
2 361 (11) 13 (6)
3 214 (6) 14 (7)
Previous miscarriage n ¼ 3251 n ¼ 204 0.11 (0.75)
Yes 639 (20) 42 (21)
Previous terminations n ¼ 3302 n ¼ 204 1.13 (0.30)
Yes 1256 (38) 70 (34)
Timing of HIV test n ¼ 3557 n ¼ 211 2.74 (0.25)
Prepregnancy 1925 (54) 102 (48)
Antenatal 1333 (37) 88 (42)
At delivery 299 (8) 21 (10)
Maternal age n ¼ 3339 n ¼ 212 (<0.002)
Mean 28.28 26.72
SD 5.08 4.8
HIV RNA level n ¼ 997 n ¼ 66 (0.05)
Mean [SD] 24,169 [108,389] 13,914.79 [41,885]
Range 20– 1,980,000 40– 290,000
500 copies/mL 434 (44) 31 (45)
CD4 count at enrolment n ¼ 2027 n ¼ 89 1.12 (0.57)
Median (range) (cells/mm3) 420 (1 –2350) 390 (5– 1840)
<200 cells/mm3 271 (14) 11 (12)
200– 499 cells/mm3 978 (48) 48 (54)
500 cells/mm3 778 (38) 30 (34)
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predictors of subsequent live births within three years of
enrolment. From a multivariable logistic regression analysis,
involving 3471 women, adjusting for time period, maternal
ethnicity, age and parity, ethnicity was still a significant
predictor of subsequent live births (Table 2). Black women
were twice as likely to have more than one baby than white
women. In a subanalysis, adjusting for maternal CD4 cell
count, black women were nearly three times more likely to
have subsequent live births than white women (AOR, 2.80;
95% CI, 1.55–5.10; P < 0.001).
In KM analyses of time to subsequent live birth, stratified
by various explanatory variables, black women had a sig-
nificantly shorter time to subsequent live birth than white
women, with an estimated 9% and 14% having a subsequent
live birth within 24 months and within 36 months of the
index delivery, respectively, compared with 4% and 6% for
white women (P < 0.001) (Fig. 1). There was no significant
association between maternal age at enrolment and time to
subsequent live birth. Time to subsequent live birth de-
creased significantly over time: an estimated 2% and 3%
of women having a subsequent live birth by 24 months
after the index delivery in the periods 1989 and 1990–
1994, respectively, compared with an estimated 10% in
1995–1999 and 14% in 2000–2003 (P < 0.001) (Fig. 2).
As the increasing enrolment of black women in the more
recent years of the study13 could have biased this trend, we
carried out KM analyses separately for black and white
women. In both groups, differences over time remained
significant (P < 0.001), with an estimated 2% of black
women and 3% of white women having had a subsequent
live birth within 24 months after the index delivery in
1990–1994 compared with 16% and 15%, respectively, in
2000–2003.
In Table 3, the use of antenatal ART, neonatal prophy-
laxis, mode of delivery and pregnancy outcome in terms of
prematurity and infant HIV infection status for the two
groups (index pregnancy only group and subsequent live
birth group) are presented. There was no difference in the
prematurity rate between the index pregnancy only group
and the first pregnancy of the subsequent childbearing group.
The infection status of the index child did not affect the
likelihood of having a subsequent child (m2¼ 0.70; P¼ 0.40
for index and first child of women with subsequent births).
Comparisons of the use of interventions for PMTCT between
the index pregnancy only and the subsequent pregnancy
groups are complicated by the longitudinal nature of the
data. In a subanalysis, limited to the period since 1997, which
could be considered the established HAART era, there were
Table 2. Multivariable analysis of likelihood of a subsequent live birth.
Any subsequent live birth Subsequent live birth within three years of
index delivery
OR (95% CI) AOR (95% CI) OR (95% CI) AOR (95% CI)
Time period
1985– 1994 1.00 1.00 1.00 1.00
1995– 2003 0.95 (0.71– 1.25) 0.87 (0.63–1.19) 1.35 (0.92– 1.99) 1.24 (0.81–1.90)
Ethnicity
White 1.00 1.00 1.00 1.00
Black 2.10 (1.54– 2.85) 2.45 (1.75–3.43) 2.13 (1.41– 3.23) 2.15 (1.38–3.36)
Asian, oriental, other 1.30 (0.65– 2.62) 1.45 (0.71–2.93) 1.38 (0.55– 3.45) 1.40 (0.55–3.56)
Maternal age at delivery
<25 years 1.00 1.00 1.00 1.00
25– 30 years 0.65 (0.47– 0.90) 0.65 (0.46–0.91) 0.63 (0.40– 1.00) 0.60 (0.38–0.97)
>30 years 0.51 (0.36– 0.73) 0.54 (0.37–0.80) 0.66 (0.41– 1.05) 0.62 (0.38–1.03)
Parity
0 1.00 1.00 1.00 1.00
1 0.80 (0.57– 1.12) 0.81 (0.57–1.15) 1.0 (0.63– 1.54) 0.98 (0.62–1.54)
2 0.73 (0.48– 1.12) 0.73 (0.47–1.15) 0.76 (0.42– 1.37) 0.71 (0.38–1.31)
Fig. 1. KM analysis of time to subsequent pregnancy by ethnicity (n¼ 3911).
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no significant differences between the index pregnancy
group and the first pregnancy of the subsequent pregnancy
group in terms of receipt of HAART (P ¼ 0.13) (Table 4).
Comparison of the obstetric and therapeutic manage-
ment of the first and subsequent pregnancies reflected
changes over time in policy and practice. In a subanalysis,
limited to deliveries since 1997, the use of HAART in-
creased significantly with increasing pregnancy number
(mtrend
2 ¼ 7.14, P ¼ 0.008) (Table 4). Overall, there was
a high concordance between first and second pregnancies
with regard to antenatal ART: for example, of the 127 women
not receiving ART in their first pregnancy, 77 (61%) had
none in their subsequent pregnancy (reflecting the timing
of delivery, prior to 1994). Within the group of women re-
ceiving HAART in their first pregnancy (n ¼ 28), 22 (79%)
were also on HAART in their second delivery, with two
receiving dual therapy and four none. The elective CS rate
was higher among second deliveries compared with first
deliveries (m2 ¼ 7.16; P ¼ 0.007), but not between the sec-
ond and the third deliveries (m2¼ 0.09; P¼ 0.76), reflecting
the very high rate of emergency CS delivery (24%) recorded
for the latter group, which was associated with prematurity
(Table 3). Concordance in the obstetric management of de-
liveries within women was high: 91 (67%) of 135 women
had repeated vaginal/instrumental deliveries and 57 (89%)
of 64 had a repeated elective CS in the second delivery. Of
the women with three subsequent live births, 12 (32%) of 37
had a repeated vaginal/instrumental delivery and 5 (73%) of
11 women had a repeated elective CS compared with their
second live birth. Although the emergency CS rate was low
among second deliveries to women having a vaginal deliv-
ery or elective CS in their first delivery, it was high among
women with a previous emergency CS (4/16, 25%) suggest-
ing an underlying risk factor.
Because the study covers a long time period, what may
have been appropriate care at the time of the index pregnancy
may no longer be considered the optimum in subsequent preg-
nancies. We assessed the use of prophylactic ART in relation
to which interventions to reduce vertical transmission were
known to be effective at the time of the delivery. Prophylactic
ART was not used by 4/145 (3%) black, 14/166 (8%) white
IDU and 6/132 (5%) white non-IDU women, when this was
the standard of care of the time. The difference between white
non-IDU women and black women was not statistically
Fig. 2. KM analysis of time to subsequent pregnancy by time period (n¼ 3911).
Table 3. Use of PMTCT interventions in women with only the index pregnancy and for each pregnancy of women with subsequent live births.
Only index pregnancy (3693
mothers and 3771 infants*), n (%)
Subsequent pregnancy subgroup (218 mothers with 473 total
pregnancies since enrolment)
First child
(n ¼ 218), n (%)
Second child
(n ¼ 218), n (%)
Third or more
(n ¼ 37), n (%)
Antenatal ART n ¼ 3691 n ¼ 218 n ¼ 218 n ¼ 37
No therapy 2117 (57.5) 128 (59) 85 (39) 12 (32)
Monotherapy 598 (16) 46 (21) 37 (17) 5 (14)
Combination therapy 198 (5.5) 14 (6) 16 (7) 4 (11)
HAART 778 (21) 30 (14) 79 (37) 16 (43)
Mode of delivery n ¼ 3719 n ¼ 215 n ¼ 212 n ¼ 37
Vaginal or instrumental 1895 (51) 135 (63) 98 (46) 15 (41)
Elective caesarean 1360 (37) 64 (30) 96 (45) 13 (35)
Emergency caesarean 464 (12) 16 (7) 18 (9) 9 (24)
Neonatal prophylaxis n ¼ 1413 n ¼ 55 n ¼ 115 n ¼ 24
Yes 1159 (82) 46 (84) 93 (81) 20 (83)
Child HIV infection status n ¼ 3002 n ¼ 212 n ¼ 186 n ¼ 34
Infected 324 (11) 19 (9) (6.5) 4 (12)
Preterm delivery n ¼ 3771 n ¼ 218 n ¼ 218 n ¼ 37
<37 weeks 701 (19) 38 (17) 47 (22) 13 (35)
* Twins are included.
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significant (Fisher’s Exact Test, P ¼ 1.00), but that between
white non-IDUs and IDUs was (m2¼ 5.07; P¼ 0.024), which
reflects the lack of antenatal care in the IDU population.
DISCUSSION
Our results show that in Europe the number of HIV-
infected women who have subsequent live births has in-
creased in recent years. Reproductive decision making is a
difficult issue and in the early years of the HIV epidemic
physicians may have been asked to counsel women about
factors that were incompletely understood such as maternal
and fetal risks related to pregnancy in HIV-infected women.
Furthermore, aspects such as socio-cultural background,
past reproductive history, maternal disease progression sta-
tus and concerns about the risk of MTCT complicated the
decision-making process. However, in the past eight years
or so, advances have been made not only in the treatment
of HIV-infected women to preserve her own health and that
of their infected children,9 – 12 but also in the prevention of
MTCT. So whereas in the early studies HIV-infected women
may have been advised to postpone childbearing15 this is no
longer the case. The composite effect of these advances is
likely to underlie the increased number of subsequent live
births in HIV-infected women observed in our cohort.16,17
The main factors associated with the likelihood of
having a subsequent live birth were maternal ethnicity
and time of enrolment. Black women were more likely to
have subsequent live births even after adjusting for other
variables. This reflects the generally higher fertility in
women born in sub-Sahara Africa, even when living in
Europe. The temporal trend highlighted in the KM analysis
confirms the observations from physicians in Europe that
HIV-infected women are now more likely to become
pregnant than in the past.5 The time-related trend was seen
in both white and black women and suggests that all
women are likely to be influenced by the availability of
ART and prophylaxis.
In a longitudinal analysis of data from the U.S. Adult
Spectrum of HIV Disease Project, women on HAART were
more likely to become pregnant in the first instance, and to
have subsequent pregnancies, than women on other ART
regimens,18 while Massad et al.19 found termination of preg-
nancy to be significantly less common in the HAART era
than in previous years in the Women’s Interagency HIV Study.
Stephenson et al.2 showed that having a previous live
birth did not appear to influence the likelihood of termina-
tion of pregnancy. In accordance with these results, we found
little differences in parity and abortion/miscarriage rates
between the women with only one and those with more
children enrolled in the ECS. However, we do not have data
on miscarriage or termination of pregnancy after the enrol-
ment in the ECS. Several studies have shown that pregnancy
in HIV-infected women is more common in younger and
healthier women3,18 – 21 and this appears to be true for addi-
tional pregnancies as well, as shown here and elsewhere.16,22
HAART taken in pregnancy is highly effective in reduc-
ing risk of vertical transmission,6 – 8 although questions re-
main regarding the short and long term safety of these new
combinations on children.23 There is an increasing number
of women with long durations of exposure to HAART during
pregnancy, as seen here with the increase of HAART in
subsequent pregnancies. Elective CS delivery has a significant
independent effect in reducing vertical transmission.24 – 27
Our results show that the mode of delivery in a previous preg-
nancy affects that in a subsequent pregnancy. As the rate of
repeated emergency CS reported here shows, there is a higher
risk of emergency CS in some women probably independent
of both their HIV infection and their antiretroviral therapy.
Limitations of our study are that the number of subse-
quent live births is an under-estimation of the number of
pregnancies occurring in HIV-infected women after the
diagnosis of infection as we were only able to investigate
subsequent live births, and that we cannot distinguish the
group of women who become pregnant by choice from
those who experienced unwanted pregnancies. Also, our
subgroup of women with subsequent live births is still too
small to evaluate adequately fetal outcome in women with
subsequent live births, or to assess the impact of repeat ex-
posure to antiretroviral prophylaxis on maternal health and
MTCT risk.
In conclusion, we confirm the increasing number of sub-
sequent live births in recent years is more evident among
black women and this should be taken in account in the
planning of ART for women of childbearing age. If the in-
crease in subsequent live births is confirmed by others, the
number of children born to HIV-infected women will in-
crease faster than the number of HIV-infected mothers.
Attention should be focussed on improving health care for
childbearing women without adding potential risks for
planned or unplanned pregnancies.
Table 4. Use of ART in pregnancy in the HAART era (post-1997). Values are presented as n (%).
Only index pregnancy
group (n ¼ 1243)
Subsequent pregnancy group
First pregnancy
(n ¼ 51)
Second pregnancy
(n ¼ 119)
Third pregnancy
(n ¼ 24)
None 143 (12) 7 (14) 16 (13) 1 (4)
Mono or dual therapy 356 (28) 19 (37) 28 (24) 7 (29)
HAART 744 (60) 25 (49) 75 (63) 16 (67)
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2.5. The collaborative research on HIV in Europe 
During these 20 years, a vast amount of experience relating to the challenges 
of long-term, collaborative research has been accumulated. The result of this 
unique collaboration is evident in the impressive publication record of ECS, 
with important contribution to research internationally on HIV infection in 
pregnancy and childhood and informing management and policy.  
In the selected publications reported above, many and different aspects of 
HIV infection in pregnancy and childbearing are analysed. 
In the first paper (Increased risk of adverse pregnancy outcomes in HIV-
infected women treated with highly active antiretroviral therapy in Europe), we 
discuss about the potential risks of adverse pregnancy outcomes that may be 
associated with the spread of highly potent, complex combinations of drugs 
throughout pregnancy.  
In the second paper (Mother-to-Child Transmission of HIV Infection in the 
Era of Highly Active Antiretroviral Therapy) we investigate the effects of elec-
tive Caesarean section delivery, duration of rupture of membranes, and prema-
turity. We also describe the small number of infants who acquired HIV infec-
tion, despite maternal exposure to prophylactic interventions. 
The third paper (Time to Undetectable Viral Load after Highly Active Anti-
retroviral Therapy Initiation among HIV-Infected Pregnant Women) have ad-
dressed the question of which highly active antiretroviral therapy (HAART) 
regimens are more effective for optimal viral response in antiretroviral-naive, 
human immunodeficiency virus (HIV)–infected pregnant women.  
The fourth paper (HIV-infected pregnant adolescents and youth: results from 
a European cohort study) deals with the sub-group of young, pregnant HIV-
infected women aged<25 years enrolling in the study. This sub-group have di-
verse needs for services during and after pregnancy, including harm reduction 
services and psychosocial support, in addition to a universal need for preven-
tion of mother-to-child transmission services. 
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Successful therapy of hepatitis B with tenofovir in
HIV-infected patients failing previous adefovir and
lamivudine treatment
Oliver Schildgena, Carl Knud Scheweb, Martin Vogelc,
Martin Da¨umerd, Rolf Kaiserd, Lutwin Weitnerb, Bertfried
Matza and Ju¨rgen Kurt Rockstrohc
Three HIV-infected patients with chronic hepati-
tis B (genotype A) were switched to adefovir
therapy after unsuccessful lamivudine treatment.
Surprisingly, adefovir therapy failed, although
none of the virus isolates displayed mutations
known to be associated with adefovir resistance
(A181V, N236T). In two isolates we identified
hepatitis B virus DNA polymerase mutation
L217R, in one case we found multiple frameshifts
in the same region. In all cases adefovir was
replaced by tenofovir, resulting in a significant
drop in the viral load.
Current therapies for hepatitis B virus (HBV) infections
are based on the application of interferon, lamivudine
or combinations of both drugs. For lamivudine, the
development of resistant HBV strains has been ob-
served in 25% of treated patients per year. Moreover,
in HBV/HIV co-infected patients the development of
lamivudine resistance is more frequent than in HBV
mono-infected patients, making a therapy alternative to
lamivudine indispensable [1–4]. Therefore, the new
drug adefovir serves as an alternative therapy for the
treatment of chronic HBV infection. Adefovir passed
clinical studies successfully [5], and so far two mutations
mediating resistance to adefovir have been described
[6,7]. The frequency of the mutation A181V is
approximately 2.5% per year with hitherto unkown
relevance, whereas 1.7–2.5% per year of adefovir-
treated patients carry the resistance mutation N236T
[6,7]. Moreover, adefovir is also active against HIV,
but HIV-DNA polymerase mutations selected during
treatment with adefovir did not influence the sustained
response in viral load for 6–12 months [8].
Studies by Perrillo et al. [9] and Peters et al. [10]
demonstrated that 8–15% of patients infected with
lamivudine-resistant HBV exhibit initial non-response
to adefovir. Unfortunately, the reasons for adefovir non-
response in those studies remained unclear. In line with
those observations, we detected three out of 20 patients
chronically infected with HBV and co-infected with
HIV, who despite good compliance did not respond to
adefovir dipivoxil with a decrease in HBV DNA.
Patient 1 was a 39-year-old white man with a long-
term HIV infection [Centers for Disease Control and
Prevention (CDC) stage B2] and chronic hepatitis B e
antigen-positive hepatitis B. Antiretroviral therapy
(ART) was started in 1996; current ART consisted of
lamivudine/abacavir/efavirenz with an HIV viral load
below 25 copies/ml and good immunological recovery
(CD4 cell count 672 cells/l; 30%). Liver function tests
(LFT) fluctuated but never exceeded twice the upper
limit of normal (alanine aminotransferase; ALT). On
ultrasound examination the liver appeared normal.
Because of a high HBV load while receiving lamivu-
dine-containing ART, adefovir treatment was started
and was continued for 6 months without any response
in the HBV load (Fig. 1). Adefovir was replaced by
tenofovir, resulting in a significant drop in the HBV
load after 4 months and maintained virological control
of HIV infection.
Patient 2 was a 34-year-old white man with chronic
hepatitis B e antigen-positive hepatitis B and HIV
infection diagnosed on the occasion of a Pneumocystis
jeroveci pneumonia and cryptosporidial diarrhea (CDC
stage C3). ART was started initially with zidovudine/
lamivudine/indinavir/ritonavir and subsequently with
zidovudine/lamivudine/efavirenz, with good virologi-
cal and immunological response (HIV viral load less
than 25 copies/ml, CD4 cell count 487 cells/l, 21%).
Initially on treatment with lamivudine, LFT were
normal/minimally elevated and the HBV load was
1000 particles/ml, but increased 2 years after the
initiation of lamivudine therapy in parallel with LFT
(ALT up to four times the upper limit of normal). On
ultrasound examination the liver was moderately en-
larged. Adefovir was started, but no decrease in the
HBV load or LFT was observed over 5 months (Fig.
1). ART was changed to tenofovir/lamivudine/efavor-
emz. Two months later the hepatitis B viral load and
ALT decreased significantly.
The third patient was a 37-year-old white man with
HIV infection. ART started with didanosine/stavu-
dine/ritonavir when the patient became symptomatic
from HIV infection (CDC stage B2), with good
virological and immunological response. During ART
the patient acquired acute hepatitis B infection and
ART had to be interrupted. Later, ART with zidovu-
dine/lamivudine/efavirenz and IFN-Æ (12 months) was
started. Six months later zidovudine was substituted by
stavudine because of neutropenia. During this ART,
HBV-DNA became negative, whereas hepatitis B
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN 0269-9370 & 2004 Lippincott Williams & Wilkins 2325
surface and e antigen remained positive. However,
HBV-DNA rebounded, with the patient still being on
a lamivudine-containing ART with an HIV load below
25 copies/ml. LFT (ALT) ranged between twice and
five times the upper limit of normal. On ultrasound
examination, the spleen and liver were enlarged, with
increased echogenicity of the liver. Although adefovir
therapy was started, no decrease in the hepatitis B viral
load was observed after 3 months (Fig. 1). Under
treatment with tenofovir the HBV load dropped by
more than 3 log. ALT levels decreased in all three
patients after tenofovir treatment was started (data not
shown).
Adefovir was useless in all of the three patients.
Sequencing analysis [11] revealed no amino acid ex-
change at position 236 nor at position 181, the position
described to mediate resitance to adefovir [6,7]. All
patients shared the same HBV genotype (genotype A)
with the identical genotypical lamivudine resistance
pattern (YVDD, L180M) as determined by line probe
assay (Inno-LiPA HBV–DR, Innogenetics, Gent, Bel-
gium) upon baseline. Sequencing analysis of the isolates
revealed mutations at amino acid 217 (patients 1 and 3)
or 215–226 (patient 2). Sequences obtained from sera
collected immediatly before the initiation of adefovir
therapy showed that patients 1 and 3 displayed the
mutation before the treatment started, whereas patient
2 developed the domain exchange during ongoing
adefovir therapy.
Two further patients not described here included in a
tenofovir study exhibited the L217R mutation, and
responded well to tenofovir. Four control HBV strains
responding to adefovir sequenced in our laboratory
exhibited wild-type sequence L217.
No stop codons but single amino acid exchanges were
introduced in the overlapping hepatitis B surface open-
reading-frame by the polymerase gene mutations. Based
on GenBank data, the hepatitis B surface amino acid
exchanges did not have a significant impact on the
outcome of the hepatitis.
The observation that differences in genotypic pattern in
HCV and HIV correlate with subsequent virological
response to treatment [12,13] in combination with our
data suggest similar phenomena for HBV, of which its
polymerase shares high homology with the HIV poly-
merase. On the basis of our observations we (carefully)
conclude that: (1) the polymerase domain amino acids
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 1. Course of hepatitis B viral load in three chronically
HIV/hepatitis B virus-infected patients (adefovir-non-
responders) during antiretroviral therapy; antiretroviral ther-
apy was initially combined with adefovir and was switched
to combination with tenofovir after no signiﬁcant decrease
of hepatitis B viral load was observed as a result of adefovir.
All patients share the genotype A and identical lamivudine
resistance patterns (L180M/YVDD). Sequencing analysis of
the isolates revealed mutations at amino acid 217 (patients 1
and 3) or 215–226 (patient 2) (see main text). ABC, Abacavir;
ADF, adefovir; ANR, adefovir non-responders; BL, baseline;
D4T, stavudine; EFV, efavirenz; IDV, indinavir; TDF, tenofovir;
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215–226 might mediate adefovir resistance; (2) the
combination of the lamivudine resistance pattern
L180M/YVDD plus HBV genotype A may predeter-
mine resistance to adefovir; and most important (3) in
analogy to earlier observations [2–4], therapy changes
to tenofovir should be considered for adefovir non-
responders. Although an in-vitro assay confirming the
hypothesis that the amino acid region 215–226 might
be responsible for resistance is missing, this assumption
is confirmed by the recent patent application of
Bartholomeusz et al. [14].
In summary, at this stage, we recommend tenofovir for
the treatment of adefovir-non-responders, probably also
in HBV-mono-infected patients.
aInstitut fu¨r Medizinische Mikrobiologie und Immunolo-
gie, Universita¨t Bonn, 53105 Bonn, Germany; bPraxis St.
Georg, Brennerstrasse 71, 20099 Hamburg, Germany;
cMedizinische Klinik und Poliklinik I, Universita¨t Bonn,
53105 Bonn, Germany; and d Institut fu¨r Virologie, Uni-
versita¨t Ko¨ln, 50931 Cologne, Germany.
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Predicted genotypic resistance to the novel entry
inhibitor, BMS-378806, among HIV-1 isolates of
subtypes A to G
Penny L. Moore, Tonie Cilliers and Lynn Morris
BMS-378806 targets virus entry by inhibiting the
binding of HIV-1 gp120 to the CD4 receptor.
Env sequences (n 1226) of subtypes A–G were
analysed to determine the frequency of mutations
associated with resistance to BMS-378806. In line
with reported sensitivity data, background geno-
typic resistance to BMS-378806 among non-B
HIV-1 viruses was found to be higher than in
subtype B. These data suggest that BMS-378806
may have reduced efficacy against non-B viruses.
The increasing prevalence of HIV-1 isolates that are
resistant to reverse transcriptase and protease inhibitors
has resulted in a search for alternative therapeutic
targets. A new class of drugs termed entry inhibitors
have become the subject of increasing interest, particu-
larly since the licensing of the first drug in this class,
enfuvirtide (T20) (Roche/Trimeris Inc., Durham, NC,
USA) [1]. BMS-378806, a small molecule inhibitor of
HIV-1 [2], is a further candidate within the entry
inhibitor class that targets virus entry by inhibiting the
binding of HIV-1 gp120 to the CD4 receptor. The
affinity of BMS-378806 for the gp120 molecule is
similar to that of soluble CD4 cells, with binding
occurring close to the CD4 cell-binding pocket [2,3].
BMS-378806 exhibits potent antiviral activity against
subtype B HIV-1 viruses, including both R5 and X4
viruses [4]. Analysis of a limited number of viruses of
non-B subtypes suggest that the drug may be less
efficacious in these viruses; the EC50 value for subtype
C (EC50 243 nM) and the other subtypes (EC50
. 1000 nM) is reported to be higher compared with
subtype B viruses (EC50 61.5 nM) [4].
HIV-1 viruses resistant to BMS-378806 have been
selected in vitro, and mutations within the virus envel-
ope conferring resistance to BMS-378806 have been
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 1. Frequency of mutations conferring resistance to BMS-378806.
HIV-1 subtype
Fold
B (n ¼ 790) A (n ¼ 82) C (n ¼ 217) D (n ¼ 62) CRF01_AE (n ¼ 48) F (n ¼ 14) G (n ¼ 13)
Observed in vitro resistancea Freq (%) Freq (%) P Freq (%) P Freq (%) P Freq (%) P Freq (%) P Freq (%) P
M475I 40 0.63 1.23 NS 0 3.23 NS 83.33 , 0.0001 0 0
R350K, M475I 15 0.25 0 0 0 77.08 , 0.0001 0 0
D185N, R350K, M475I ND 0.25 0 0 0 12.5 , 0.0001 0 0
I595F 8 1.9 0 0.92 NS 0 0 0 0
M434I 4 0.76 36.59 , 0.0001 17.05 , 0.0001 4.84 0.0225 2.08 NS 0 0
M434I, I595F 498 0 0 0.92 0.0463 0 0 0 0
M434I, K655E ND 0.13 0 0 0 0 0 0
M434V ND 0.25 0 0.46 NS 0 0 0 0
V68A, M434I 77 0 0 0 0 0 0 0
V68A, S440R ND 0.13 0 0 0 0 0 0
M426L, K655E ND 0 0 0 0 0 0 0
S440R ND 65.4 6.1 , 0.0001 2.76 , 0.0001 4.84 , 0.0001 12.5 , 0.0001 0 0
Not observed alone in vitro
M426L 116 5.82 2.44 NS 4.61 NS 8.06 NS 0 0 15.38 NS
V68A , 4 0.38 0 0.46 NS 0 0 0 0
D185N ND 6.2 54.88 , 0.0001 53.46 , 0.0001 16.13 0.0073 16.67 0.0122 42.86 0.0002 53.85 , 0.0001
R350K 0.6 9.75 8.64 NS 5.07 0.0299 16.13 NS 87.5 , 0.0001 71.43 , 0.0001 15.38 NS
K655E ND 0.63 0 6.91 , 0.0001 3.23 NS 0 0 0
M434T ND 0.25 1.22 NS 1.38 NS 0 0 0 0
aLin et al. [4].Values in bold indicate P , 0.05, P values indicate signiﬁcance of mutation frequency compared with subtype B.
A
ID
S
2
0
0
4
,
V
o
l
1
8
N
o
1
7
2
3
2
8
identified [4]. These mutations result in the reduced
binding of g120 to BMS-378806, with many mutations
occurring near the CD4-binding pocket on gp120 [1].
Reported mutations include M475I, M434I/V,
M426L, D350K, D185N, K655E, I595F, V68A and
S440R. Some mutations have only been observed in
combination with other mutations, therefore the bio-
logical significance of some single mutations is not
known. Nevertheless, their existence may predispose
viruses to acquire a second mutation, resulting in
resistance to BMS-378806.
In this study we have analysed a total of 1226 Env
sequences of subtypes A–D, F–G and CRF01_AE,
obtained from the Los Alamos database in order to
determine the frequency of naturally occurring resis-
tance mutations to BMS-378806. The occurrence of
resistance mutations, either individually or in combina-
tion, was expressed as a percentage for each subtype
(Table 1). In line with sensitivity data [4], the level of
background resistance to BMS-378806 among HIV-1
subtypes other than B, including subtype C, which is
now responsible for the majority of new infections
worldwide, was found to be considerably higher than
that observed in subtype B. The results of this analysis
suggest some degree of genotypic resistance to BMS-
378806 in all subtypes, including subtype B in which
the majority of efficacy tests have been performed [4].
With the exception of the S440R amino acid change
that is common in subtype B (65.4%) and for which
the fold increase in resistance to BMS-378806 is not
known, and M426L (in 5.82% of sequences, shown to
increase resistance by more than 100-fold), all other
mutations reported to confer resistance occur naturally
at a lower frequency in subtype B (less than 1%).
The M434I mutation, which is associated with a four-
fold increase in resistance, was more common in
subtype A (36.59%, P , 0.0001) and C (17.05%,
P , 0.0001). This is reflected in the median EC50
reported for these subtypes: 243 nM in subtype C and
1132 nM in subtype A compared with subtype B
(61.5 nM) [4]. Furthermore, within subtype C, two
(P ¼ 0.0463) of the 217 sequences analysed also con-
tained the double mutation M434I, I595F, which is
reported to result in a 498-fold increase in resistance to
BMS-378806. The naturally occurring existence of this
double mutant may indicate the absence of a significant
fitness disadvantage in such viruses. Both subtypes A
and C also contained the D185N mutation at a high
frequency (53.46%, P , 0.0001 and 54.88%, P ,
0.0001, respectively).
Subtype D showed relatively low background genoty-
pic resistance to BMS-378806, an observation that is
not in accord with the relatively high EC50 of
2183 nM [4]. Mutations observed included M475I
(3.32%, P ¼ 0.0863, resulting in 40-fold increased
resistance), M434I (4.84%, P ¼ 0.0225) and S440R
(4.84%, P, 0.0001). A number of other mutations
were observed singly in sequence data but have not
been reported in vitro. These include M426L (8.06%),
which has been associated with a 116-fold increase in
resistance.
Sequences of CRF01_AE suggested extremely high
resistance to BMS-378806, again confirming the effi-
cacy data available for this subtype (a range of . 2000
to . 10 000 nM). A total of 83.33% (P, 0.0001) of
sequences contained the M475I mutation that confers
40-fold resistance, with 77.08% (P , 0.0001) of these
changes occurring in conjunction with R350K and
12.5% (P , 0.0001) also with D185N.
Sequences of subtypes F and G were unusual as none
of the mutation combinations observed in vitro were
present (although few sequences were analysed). This
result is surprising in view of the low efficacy observed
in vitro (estimated EC50 for these subtypes ranging from
214 to . 5000 nM) [4]. Subtype G showed evidence
of the M426L mutation (15.38%, P ¼ 0.1795). Both
subtypes also contained a high incidence of the D185N
mutation (42.86%, P ¼ 0.002 and 53.85%, P , 0.0001,
respectively) and the R350K mutation (71.43%,
P , 0.0001 and 15.38%, P ¼ 0.6516, respectively). It
may be that the presence of these mutations in isolation
is sufficient for reduced drug efficacy.
Isolates of subtypes other than B have previously been
shown to be less sensitive to BMS-378806 [4].
Although it is not always possible to infer the pheno-
type from genotypic data, these results suggest that
reduced efficacy in non-B viruses may be caused by
high levels of genotypic resistance within the drug-
naive population. These high levels of background
genotypic resistance to BMS-378806 suggest that these
resistance mutations do not confer a fitness disadvan-
tage that is characteristic of viruses resistant to the
reverse transcriptase and protease inhibitors and possibly
also enfuvirtide [5,6].
BMS-378806 is a prototype drug likely to be followed
by derivatives that may have broader specificity.
Nevertheless, the high genotypic resistance to BMS-
378806 may limit its usefulness in non-B populations,
particularly in subtype C and CRF01_AE viruses.
Future drugs based on BMS-378806 will need to be
designed with these results in mind in order to expand
the subtype range of this drug.
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Viral load and CD4 cell response to protease
inhibitor-containing regimens in subtype B versus
non-B treatment-naive HIV-1 patients
Ste´phane De Wita, Ronan Boulme´b, Be´ne´dicte Polla,
Jean-Claude Schmitb and Nathan Clumecka
We compared the response to protease inhibitor-
containing highly active antiretroviral therapy in
175 HIV-1 treatment-naive patients harbouring
subtype B versus non-B. No difference in the
proportion of patients with viral loads below 400
copies/ml was observed at month 24. However,
there was a significant difference in the median
CD4 cell increase at month 24. Whether this is
caused by viral or immune factors warrants
further investigation.
Studies on highly active antiretroviral therapy
(HAART) in individuals infected with non-B subtypes
are needed to identify potential subtype-specific differ-
ences in the response to therapy. We compared the
efficacy of a protease inhibitor-containing regimen
(with two nucleoside analogues) in treatment-naive
patients harbouring either B or non-B subtypes. Re-
verse transcriptase and protease sequencing was per-
formed using the Viroseq version 2.0 method (Celera
Diagnostics, USA) and the TruGene HIV-1 sequencing
kit (Bayer Diagnostics, Berkeley, CA, USA), and viral
subtyping was done using I-subtyping, the HIV-SEQ
program from Stanford University and was confirmed
by the subtyping tool from the National Center for
Bioinformatics.
To evaluate the response to HAART, the proportion
of patients achieving a plasma HIV viral load below
400 copies/ml and the absolute CD4 cell count after 6,
12 and 24 months were computed. Baseline demo-
graphic and laboratory characteristics were compared
between B and non-B groups using chi-square and
Fisher exact tests. Wilcoxon/Kruskall–Wallis tests were
used for univariate analyses. A multiple linear regression
was performed for the CD4 cell count evolution from
baseline to month 24. As a result of the non-normality
of CD4 cell count variation, this value was square root
transformed. The following variables were included in
the model: subtype, sex, baseline parameters [viral load,
total lymphocyte count (absolute and percentage), CD4
cell count (absolute and percentage), Centers for
Disease Control and Prevention stage and drug regi-
mens at treatment initiation].
We identified 175 patients, of whom 56 (32%) were
infected by subtype B and 119 (68%) by non-B subtype
virus, including subtypes A (21), C (25), D (eight), G
(eight), H (two), J (one), recombinant forms (AE
seven, AG 22) and mosaics (22). Most B patients were
Caucasians (90%) and homosexual (71%), whereas most
non-B patients were Africans (89%) and heterosexual
(100%). The median baseline viral load (4.9 versus
4.8 log) and CD4 cell count (264 versus 225 cells/mm3)
were comparable in both groups. There was no
statistical difference in the use of any antiretroviral drug
between both groups. There was no difference be-
tween the groups in median follow-up (1536 versus
1617 patient-days; P ¼ 0.42). The proportion of pa-
tients who achieved undetectable viral load at month
24 was 52% for the B subtype and 64% for the non-B
subtype (intent to treat analysis; missing equals failure).
The CD4 cell increase at month 24 was significantly
lower in the non-B group: +161 versus +235 cells/
mm3 (P, 0.02). Among the different non-B subtypes,
differences were noted in the CD4 cell response,
although none was significant: subtype A: +140; C:
+158; circulating recombinant forms (CRF): +165;
mosaics: +148; and others +185 cells/mm3. As subtype
A had the lowest CD4 cell increase, we compared the
CD4 cell response between group B and group AA
patients, i.e. 66 patients, harbouring group A, CRF-
AG, CRF-AE and mosaics containing at least a part of
subtype A. There was a statistically significant differ-
ence between B and AA patients in terms of CD4 cell
increase at month 24: +235 versus +162 (P, 0.03). At
treatment initiation, the viral load was lower in the AA
group (4.7 log versus 4.9 log; P, 0.02) and the CD4
cell count was lower, although not statistically signifi-
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cant (211 versus 264 cells/mm3). In multiple linear
regression, baseline viral load and the percentage of
total lymphocytes were the only variables associated
with the CD4 cell variation.
Most of the available data on the clinical outcome of
HAART in non-B HIV-1 subtypes suggest that pa-
tients respond equally well regardless of the subtype.
One report [1] has, however, suggested that the
subtype may affect the clinical response in the long
term but factors such as adherence and psychosocial
conditions should be taken into account. Other studies
did not confirm these findings [1–4]. Our study,
performed in a single centre providing the same
therapeutic attitude as well as similar psychosocial
support to both B and non-B patients, argues against a
role for viral subtypes in treatment responses in terms
of viral load. However, the CD4 cell increase at month
24 was significantly lower in the non-B group. Larger
CD4 cell increase after HAART initiation have been
shown to be associated with higher baseline HIV-1
viral loads [5]. Baseline CD4 cell count also play a role
in CD4 cell response, higher baseline CD4 cell count
being associated with higher CD4 cell increases [6,7].
In our study, the median viral load at treatment
initiation was equivalent in both groups, and baseline
CD4 cell level was slightly lower, although not
statistically significant, in the non-B patients.
Moreover, in multiple linear regression, baseline CD4
cell level was not predictive of CD4 cell response at
month 24. We explored the hypothesis that the
difference in CD4 cell response could be caused by
some specific non-B subtypes. We could not find any
statistically significant differences in CD4 cell response
among the different non-B subtypes, but showed that
patients harbouring subtype A were responsible for all
the difference in CD4 cell increase at month 24,
although the viral load response did not differ. The
same baseline parameters as the global analysis were
evaluated and did not influence the CD4 cell re-
sponse.
Differences in CD4 cell response could be caused by
viral or host characteristics, which should be further
explored. A more rapid depletion of CD4 lymphocytes
and higher levels of plasma HIV-1 RNA has been
observed in human peripheral blood lymphocyte of
severe combined immunodeficient mice infected with
A and C-clade HIV-1 isolates in comparison with B-
clade-infected mice [8]. However, in a study evaluating
viral fitness in vitro in peripheral blood mononuclear
cell culture [9], primary CD4 T cells and macrophages
from different human donors, decreased fitness of
subtype C compared with subtype B was observed.
These apparently contradictory findings together with
our observations underline the need for robust prospec-
tive trials on greater numbers of patients infected with
non-B subtypes to establish whether such differences
should be taken into account in the clinical setting.
aSt Pierre University Hospital, Brussels, Belgium; and
bABL Advanced Biological Laboratories and CRP-Sante´,
Luxembourg.
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First-line efavirenz versus lopinavir–ritonavir-based
highly active antiretroviral therapy for naı¨ve
patients
Roberto Manfredi, Leonardo Calza and Francesco
Chiodo
Ninety-seven consecutive patients started anti-
HIV therapy based on efavirenz (46) or lopina-
vir–ritonavir (51) in an observational study.
Despite the significantly more compromised im-
munological-clinical baseline conditions of
patients starting lopinavir–ritonavir, a mean
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clinical-laboratory follow-up of 17 months
showed a comparable laboratory response and
therapy interruption or change rate, although the
toxicity profile of the two compounds proved
significantly different. Randomized studies com-
paring these two recommended first-line treat-
ments are warranted, particularly from a
pharmacoeconomic viewpoint.
The 2002–2004 international guidelines for antiretro-
viral management consider lopinavir–ritonavir highly
active antiretroviral therapy (HAART) or efavirenz-
based HAART to be the two alternative first-line
choices for HIV-infected antiretroviral drug-naive pa-
tients [1,2]. However, no randomized comparative
study has been performed until now, dealing with these
two profoundly different therapeutic strategies (the first
based on a boosterized protease inhibitor, and the
second on a non-nucleoside reverse transcriptase inhi-
bitor), with regard to both efficacy and tolerability
issues [3–5].
The most important variables conditioning both the
efficacy and safety parameters of lopinavir–ritonavir
and efavirenz-based HAART were assessed in 97 con-
secutive antiretroviral-naive patients followed since the
year 2002 in an open-label observational study con-
ducted at our outpatient reference centre in Bologna,
Italy. After giving their written informed consent, 51
consecutive patients treated with lopinavir–ritonavir
plus two nucleoside analogues were compared with 46
patients who received efavirenz plus two nucleoside
derivatives, selected by the physician in charge from all
available molecules (including zidovudine, didanosine,
zalcitabine, stavudine, lamivudine, abacavir, and teno-
fovir). At baseline, the two patient groups under
consideration were statistically comparable with regard
to all demographic and epidemiological features, as well
as the mean plasma HIV viraemia (4.5  1.4 versus
4.3  1.6 log10 HIV-RNA copies/ml, for the lopina-
vir–ritonavir and efavirenz groups, respectively; Table
1). However, a previous or concurrent diagnosis of
AIDS (P , 0.0001), or a significantly lower mean CD4
lymphocyte count (P ¼ 0.002), were found among
patients who received lopinavir–ritonavir as opposed
to efavirenz-treated subjects. During the subsequent
follow-up period, which until now ranged from 10 to
33 months (mean 16.8  6.9 months), the laboratory
workout showed a comparable virological response
(with regard to the time and rate of both viral decay
and the rate of viral suppression) in the presence of
only one case of virological failure in the efavirenz
group (explained by the appearance of a mutation at
codons 103 and 181, at genotyping assay), versus no
failed patient found in the lopinavir–ritonavir group
(ns) (Table 1). Notwithstanding the significantly lower
mean initial CD4 lymphocyte count, lopinavir–ritona-
vir-treated individuals achieved a more rapid and
elevated immune recovery (P ¼ 0.011 and P ¼ 0.005,
respectively), compared with those who received an
efavirenz-based combination. Early (first month) inter-
ruptions as a result of a poor tolerability rate proved
similar: eight patients were recorded in the lopinavir–
ritonavir group, compared with six episodes among
efavirenz-treated patients, although short-term unto-
ward events predominanly involved the entire gastro-
intestinal tract for lopinavir–ritonavir, compared with
the central nervous system for efavirenz-containing
regimens (P ¼ 0.0011). The overall need for regimen
interruption or substitution attributable to toxicity,
untoward events, insufficient patient adherence, or
laboratory-clinical failure, as measured throughout the
entire study period, tested quite low and was compar-
able between the two study groups (21.6% on the
whole), as was the mean time to treatment interrup-
tion, but the observed mid-term toxicity rate proved
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1. A comparison of selected features of efavirenz versus lopinavir–ritonavir-treated patients in our open-label clinical-laboratory
experience.
Patient features Efavirenz (n ¼ 46) Lopinavir–ritonavir (n ¼ 51) P value
Male : female ratio 31 : 15 35 : 16 ns
Age in years (mean  SD and range) 37.2  11.4 (21–62) 38.3  13.8 (33–68) ns
Type of risk for HIV disease (IVDU, heterosexuals, MSM) 15/18/13 15/21/15 ns
Mean baseline viraemia (log10 HIV-RNA copies/ml) 4.3  1.6 4.5  1.4 ns
Mean baseline CD4 lymphocyte count (cells  SD) 293.4  96.5 196.8  111.4 P ¼ 0.002
No. with full-blown AIDS disease 10 35 P, 0.0001
No. who reached undetectable viral load (, 50 copies/ml) in study
period
45 51 ns
Mean time to complete viral suppression (months  SD) 6.8  1.1 6.3  1.5 ns
Mean time to peak CD4 lymphocyte count (months  SD) 12.1  6.5 9.4  3.5 P ¼ 0.011
Mean peak CD4 lymphocyte count (mean  SD) reached in study
period
556.5  102.4 612.2  88.7 P ¼ 0.005
Early (ﬁrst month) treatment interruption caused by poor tolerability 6 8 ns
Overall treatment interruptions throughout the entire study period 10 11 ns
Mean time to interruption (months  SD) 8.9  2.1 9.2  3.1 ns
No. developing hyperlipidemia 24 5 P ¼ 0.0016
IVDU, intravenous drug users; MSM, men who have sex with men.
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significantly different from a qualitative point of view.
Lopinavir–ritonavir-treated patients experienced dysli-
pidemia in more than 50% of overall cases (serum
triglycerides . 200 mg/dl, or cholesterolemia . 220
mg/dl), versus nearly 10% of individuals belonging to
the efavirenz group (P ¼ 0.0016; Table 1).
Our experience conducted on 97 consecutive antiretro-
viral-naive patients treated with lopinavir–ritonavir
versus efavirenz-based HAART, although limited by its
open-label observational design, showed a comparable
virological response, although an apparently more po-
tent and rapid immunological recovery was attained in
the lopinavir–ritonavir group, even taking into account
the more severe initial immunodeficiency and AIDS
rate in the latter patient group. On the other hand,
although efavirenz-treated patients experienced more
infrequent adverse events, and benefited from a low pill
burden and an expected improved adherence (three
capsules once a day at bedtime for efavirenz, versus three
capsules twice a day for lopinavir–ritonavir) [3–5], the
rate of early treatment interruptions tested similarly in
the two study groups. The last update of international
guidelines for antiretroviral treatment proposed either
lopinavir–ritonavir or efavirenz-based HAART as
equivalent first-line treatments for HIV disease in anti-
retroviral-naive patients [1,2], but in the absence of
randomized comparative studies, the selection of lopina-
vir–ritonavir or efavirenz-based regimens should take
into careful account the initial immunological and
disease status of the patient, because lopinavir–ritonavir-
based combinations seem to offer a better recovery in
this last (more compromised) patient group, although
efavirenz is better accepted and is more easy to admin-
ister. Further data are strongly warranted on long-term
outcomes, the viral resistance burden, and tolerability
issues on these two very different antiretroviral regimens
proposed as first-line combinations for naive HIV-
infected patients [1,2]. Given also the profoundly differ-
ent expenditures associated with the administration of
these two therapeutic strategies [6] (an efavirenz-based
combination costs nearly 30% less than a lopinavir–
ritonavir regimen in Italy), an appropriate pharmaco-
economic assessment of these two first-line selected
regimens also seems highly desirable.
Department of Clinical and Experimental Medicine, Divi-
sion of Infectious Diseases, University of Bologna ‘Alma
Mater Studiorum’, S. Orsola Hospital, Bologna, Italy.
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Causes of death in HIV infection: the key
determinant to deﬁne the clinical response to anti-
HIV therapy
Amanda Mocrofta, Jose Gatellb, Peter Reissc, Bruno
Ledergerberd, Ole Kirke, Stefano Vellaf, Anders Blaxhultg,
Andrew N. Phillipsa, Jens Lundgrene for the EuroSIDA
study group
Studies have shown an increased risk of new
AIDS/death among injecting drug users (IDU)
starting highly active antiretroviral therapy
(HAART). Of 3872 patients starting HAART in
the EuroSIDA study, 819 were IDU (21.2%).
During 14 769 person-years of follow-up, 499
patients progressed to new AIDS/death. Com-
pared with homosexual individuals, IDU had an
increased incidence of new AIDS/death, but only
for non-HIV deaths. There is an urgent need to
define and standardize causes of death in observa-
tional studies.
Since the introduction of highly active antiretroviral
therapy (HAART), morbidity and mortality has fallen
to one-fifteenth of the level seen before HAART [1].
In an early study of 6645 patients from the EuroSIDA
study, after adjustment there were no differences in the
risk of death according to the exposure group [2]. The
Antiretroviral Treatment Cohort Collaboration studied
approximately 12 000 treatment-naive patients starting
HAART, of whom 17% were injecting drug users
(IDU). Recent findings demonstrated an increased risk
of new AIDS/death or death among IDU after starting
HAART [3,4], although the study was not able to
differentiate between HIV-related and other causes of
death. It is therefore unclear to what extent this finding
is the result of a poor response to HAART in IDU
compared with other patient groups.
EuroSIDA is a longitudinal pan-European (including
sites in Israel and Argentina) observational study of
9802 patients with HIV, which has been described
elsewhere [1]. The cause of death has been recorded
since the beginning of the study (www.chip.dk). We
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sought to describe differences in clinical progression
after starting HAART according to exposure group
and for different events (new AIDS/death, HIV-related
death or non-HIV-related death). Patients were classi-
fied as dying from an HIV-related event when the
cause of death was indicated as HIV related, resulting
from an AIDS-defining event or caused by invasive
bacterial infection. All other causes of death were
classified as non-HIV deaths. A sensitivity analysis
categorized deaths from invasive bacterial infections as
non-HIV related.
Patients included in this analysis had started HAART
(two or more nucleoside reverse transcriptase inhibitors
plus at least one protease inhibitor, non-nucleoside
reverse transcriptase inhibitor or abacavir), had a CD4
cell count and viral load measured in the 6 months
before starting HAART and some prospective follow-
up. Patients may have received non-HAART antire-
troviral treatment before starting HAART. Those who
were treatment naive at starting HAART were in-
cluded in the Antiretroviral Treatment Cohort Collab-
oration. Patients were followed to their first event or
their last follow-up, at latest December 2003. Poisson
regression was used to determine the incidence rate
ratio (IRR) of clinical progression after adjustment for
confounding variables. These included age, previous
AIDS diagnosis, previous antiretroviral treatment,
HAART regimen started, hepatitis C status, date
started HAART, and both CD4 cell count and viral
load as time-updated variables.
A total of 3872 patients were included; 1767 were
homosexual (45.6%), 819 were IDU (21.2%), 991 were
heterosexual (25.6%) and 295 (7.6%) belonged to other
exposure groups. A total of 1514 patients were treat-
ment naive (39.1%), and the most common HAART
regimen was a single-protease inhibitor-containing
regimen (n ¼ 2758, 71.2%). The median CD4 cell
count at starting HAART was 220 [interquartile range
(IQR) 104–341/mm3] and viral load was 4.52 (IQR
3.70–5.15 log10 copies/ml). The median date of start-
ing HAART was June 1997 (IQR 2/97–3/99).
During 14 769 person-years of follow-up 499 patients
progressed to new AIDS/death; 296 patients died, and
of these, 194 (66.5%) were non-HIV related. Com-
pared with homosexual individuals (Fig. 1), after
adjustment, there was a significantly increased inci-
dence of new AIDS/deaths among IDU [IRR 1.36;
95% confidence interval (CI) 1.02–1.82, P ¼ 0.039].
However, there was no increased incidence of AIDS
(IRR 0.86, P ¼ 0.45) or HIV-related death (IRR
1.01, P ¼ 0.99). The increase was confined to non-
HIV deaths, in which IDU had over a twofold in-
creased incidence (IRR 2.53; 95% CI 1.64–3.92,
P , 0.0001). The increased incidence in IDU was
more pronounced when deaths from invasive bacterial
infections were not included as HIV-related deaths
(IRR 3.03; 95% CI 1.88–4.87, P , 0.0001). A sig-
nificantly lower proportion of IDU were known to
have died from HIV-related causes (24.0% versus
39.1% in all other exposure groups combined,
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Fig. 1. Adjusted incidence rate ratios of new AIDS/death, AIDS, HIV or non-HIV death after starting highly active
antiretroviral therapy. Adjusted for age, AIDS, previous antiretroviral treatment, highly active antiretroviral therapy (HAART)
regimen started, hepatitis C status, date started HAART and both CD4 cell count and viral load as time-updated variables. Het,
Heterosexual individuals; Hom, homosexual individuals; IDU, injecting drug users; PYFU, person-years of follow-up.
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P ¼ 0.010, chi-squared test), and a significantly higher
proportion were reported to have died from liver-
related events (20.8 versus 4.0% in all other exposure
groups combined, P , 0.0001, chi-squared test). There
were no significant differences between IDU and all
other exposure groups combined in the proportion of
patients who died from suicide or drug overdose, after
a cardiovascular event, unknown cause or any other
cause (P . 0.3 all comparisons, chi-squared test).
The EuroSIDA study has demonstrated an increased
clinical progression among IDU after starting HAART.
IDU are known to have an increased risk of chronic
liver disease, bacterial infections, sepsis, drug overdoses
and suicides [5], particularly among active IDU. The
increased incidence was only found for non-HIV
deaths, and was significant after adjustment for relevant
confounding variables. In particular, the increased
incidence could not be explained by co-infection with
hepatitis C, although a higher proportion of IDU died
from liver-related disease. We do not have data on
current injecting drug use and were not able to adjust
for this, but it is unlikely to explain completely the
increased incidence. The introduction of HAART,
more specific information on the cause of death and
longer follow-up are likely explanations for the differ-
ences compared with earlier findings [2] in which we
did not find an increased risk of death in IDU.
IDU had no increased incidence of AIDS or HIV-
related death. This suggests, on average, that IDU who
participated in EuroSIDA and started HAART had a
comparable response to other exposure groups, were
able to adhere to complex regimens, and benefited
from a similar reduction in the risk of AIDS or HIV-
related death. EuroSIDA patients may not be wholly
representative of those with HIV across Europe, but do
represent a heterogeneous population who have been
treated according to local guidelines, which will differ
between centres and over time.
In summary, these results show the importance of
collecting data on the precise cause of death. Without
this information results could have been misinterpreted
as IDU having an inferior response to HAART com-
pared with other exposure groups. As the proportion
of non-HIV-related deaths increases in observational
cohorts, there is a need to define and standardize causes
of death more effectively, particularly as observational
studies will increasingly be used for pharmacovigilance
and the monitoring of serious adverse events.
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Increased risk of adverse pregnancy outcomes in
HIV-infected women treated with highly active
antiretroviral therapy in Europe
European Collaborative study prepared by Claire
Thorne, Deven Patel and Marie-Louise Newell
Highly active antiretroviral therapy (HAART)
may be associated with adverse pregnancy out-
comes. Among 4372 live births in the European
Collaborative Study, the prematurity rate in-
creased to 24.9% in 2000–2004. Antenatal
HAART use initiated pre-pregnancy was strongly
associated with prematurity (AOR 2.05, 95% CI
1.43, 2.95), particularly severe prematurity. The
implication of increased prematurity is evidenced
in high neonatal mortality in these groups (0.66%
for infants at 34–36 weeks and 7.37% at < 34
weeks’ gestation).
HIV-infected women taking highly active antiretroviral
therapy (HAART) could face possible adverse events in
pregnancy. Although we and other European observa-
tional studies have shown a substantially increased risk
of premature delivery associated with antenatal combi-
nation antiretroviral therapy [1–3], which was not seen
in a study in the USA [4], this was generally felt to be
clinically manageable. There is no information docu-
menting the consequences of premature delivery for
the infants. Increasing numbers of infected women in
Europe are taking highly potent, complex combina-
tions of drugs throughout pregnancy, often initiated
before or in early pregnancy. The impact of these
changes in HIV treatment on pregnancy outcome is
unclear, but we recently noted a worrying increase in
severe pregnancy-related adverse events, including neo-
natal deaths, which are described here.
Since 1986 HIV-infected women identified before or
during pregnancy and their infants are followed accord-
ing to standard clinical and laboratory protocols, in the
ongoing European Collaborative Study [2,3]. We
define prematurity and severe prematurity as delivery
before 37 and 34 weeks’ gestation, respectively, neona-
tal death as death within the first 28 days of life, and
perinatal mortality as stillbirths and deaths of live born
infants within the first week of life. Data entry was
carried out using MS Access 2000 and analyses using
SAS statistical software (v8.02, SAS Institute, Cary,
NC, USA).
There were 4372 live births to women enrolled be-
tween 1986 and the end of April 2004, of whom 3131
(74%) were white, 914 (22%) were black and 171 (4%)
were of other ethnicity. The median maternal age at
the time of delivery was 28.3 years (range 10–47). The
overall crude prematurity rate was 18.9% (828/4372),
with a significant recent increase from 16.4% (136/832)
in 1985–1989, 15.7% (187/1192) in 1990–1994, and
18.0% (205/1142) in 1995–1999 to 24.9% (300/1206)
in 2000–2004 (2 ¼ 30.1, P , 0.002). Similar trends
were observed in the prevalence of low birthweight
and very low birthweight. The rate of elective caesar-
ean section in the European Collaborative Study was
high (65.4%, 783/1198, in 2000–2004), reflecting its
use in the prevention of mother-to-child transmission
[5]. The median gestational age among infants delivered
by elective caesarean section was 38 weeks, although
some centres had a policy of scheduling elective
caesarean section at 36 weeks [5]. The increase in
prematurity among women delivering by emergency
caesarean section or vaginally (thus with a ‘sponta-
neous’ delivery with rupture of the membranes or
initiation of labour) was from 16.1% (108/670) in
1985–1989, 15.0% (147/982) in 1990–1994, to 20.0%
(118/591) in 1995–1999 and 37.1% (154/415) in
2000–2004 (2 ¼ 66.4, P , 0.002).
The prematurity rate among women taking monother-
apy (predominantly zidovudine) in pregnancy was
16.8% (118/704), 13.4% (34/254) for dual therapy, and
25.5% (274/1075) for HAART (2 ¼ 26.6, P,
0.002). In univariable and multivariable logistic regres-
sion analysis, HAART in pregnancy, particularly when
initiated before pregnancy, was strongly predictive of
prematurity (Table 1). Taking severe prematurity as the
outcome gave adjusted odds ratios (AOR) of a similar
size for most explanatory variables, but a stronger
association with HAART [AOR 2.50, 95% confidence
interval (CI) 1.19–5.24, P ¼ 0.016 when initiated
during pregnancy, and AOR 4.41, 95% CI 2.06–9.41,
P , 0.002 when inititated pre-pregnancy]. Although
adjusting for unaccounted centre-associated variation
through a variable for random effect at the centre level
improved the model’s goodness of fit, the AOR for the
variables of interest here remained at a similar magni-
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Research Letters 2337
tude. A sub-analysis limited to 1275 women with
emergency caesarean section or vaginal deliveries iden-
tified the same risk factors for premature delivery as
above, although the HAART-associated risk was more
pronounced (HAART started antenatally: AOR 3.25,
95% CI 1.99–5.31, and pre-pregnancy: AOR 4.00,
95% CI 2.26–7.08).
To assess the clinical consequences of this increase in
prematurity and low birthweight we investigated neo-
natal and perinatal deaths. There were 28 neonatal
deaths (eight in the most recent period); with a median
gestation of 31 weeks (range 22–40) and median
birthweight of 1213 g (range 500–3940). The neonatal
mortality rate was 73.7 per 1000 (16/217) for infants
born before 34 weeks, 65.5 per 1000 (4/611) for those
born at 34–36 weeks, and 2.26 per 1000 (8/3544) for
term infants (2trend ¼ 110.0, P , 0.002). The few
deaths preclude multivariable analysis, but univariably
there was a strong relationship between gestational age
and neonatal mortality: 71% of the neonates who died
(20/28) were premature versus 18% of surviving infants
(808/4344, P , 0.002). Other univariable associations
(ethnicity, mode of delivery, maternal age) disappeared
when controlling for gestational age. The overall
neonatal mortality rate fluctuated at approximately six
to seven per 1000 between 1985 and 2003, compared
with three to four per 1000 in the general population
in Europe. The perinatal mortality rate was 18 per
1000 (95% CI 12.2–25.4; 31/1725) in 1998–2003,
reaching 21.7 per 1000 (95% CI 5.95–54.7) in 2003,
substantially higher than the five to nine per 1000 in
the general European population.
Our findings of a substantially increased risk of severely
curtailed pregnancy duration among women taking
HAART antenatally, particularly when initiated pre-
pregnancy, coupled with the very high neonatal mor-
tality rate associated with delivery at these early gesta-
tions, are very concerning. Although not denying its
prevention of mother-to-child transmission benefit, we
would suggest that these data are taken into considera-
tion when making therapeutic decisions for HIV-
infected women of childbearing ages whose clinical,
immunological and virological status does not indicate
a need for the early initiation of HAART.
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Table 1. Risk factors for delivery before 37 weeks’ gestation in 2279 mother–child pairs.
N OR P value AOR (95% CI) P value
Maternal age (years)
, 25 501 1.00 1.00
26–34 1463 1.15 0.32 1.05 (0.78–1.41) 0.75
> 35 315 1.82 , 0.002 1.45 (0.98–2.13) 0.06
Maternal ethnic group
White 1572 1.00 1.00
Black 628 0.93 0.54 0.73 (0.55–0.96) 0.02
Other 79 1.22 0.48 1.01 (0.56–1.81) 0.97
Maternal IDU in pregnancy
No 2073 1.00 1.00
Yes 206 1.75 , 0.002 2.15 (1.48–3.12) , 0.002
Maternal CD4 cell count
> 500 cells/mm3 847 1.00 1.00
200–499 1117 1.13 0.33 1.00 (0.77–1.29) 1.00
, 200 315 2.02 , 0.002 1.95 (1.40–2.72) , 0.002
Mode of delivery
Vaginal 975 1.00 1.00
Emergency caesarean section 300 5.87 , 0.002 5.23 (3.80–7.20) , 0.002
Elective caesarean section 1004 1.62 , 0.002 1.37 (1.02–1.82) 0.03
Antenatal antiretroviral use
None 944 1.07 0.62 1.01 (0.71–1.41) 0.95
Mono/dual therapy 1.00 1.00
HAART started antenatally 446 2.03 , 0.002 1.88 (1.34–2.65) , 0.002
HAART started prepregnancy 321 2.19 , 0.002 2.05 (1.43–2.95) , 0.002
AOR, Adjusted odds ratio; CI, conﬁdence interval; HAART, highly active antiretroviral therapy; IDU, injection
drug use; OR, odds ratio.
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Changes in HIV prevalence among young Thai men
as deﬁned by hepatitis C co-infection as a marker
for mode of transmission
Penprapa Chanbancherda, Robert M. Parisb, Kalyanee
Torugsac, Khin S. Myintb, Suebpong Sangkharomyac and
Arthur E. Brownb
To obtain a better understanding of the evolving
HIV-1 epidemic in Thailand, we utilized anti-
body to hepatitis C virus (HCV) to indicate the
mode of HIV-1 transmission. Although the pro-
portion of men with HCV co-infection increased
between 1995 and 2000, the prevalence was simi-
lar, whereas the prevalence of men not co-
infected decreased (1.93–0.46%). This suggests
that HIV-1 infection associated with parenteral
transmission has been stable despite a dramatic
reduction in the sexual transmission of HIV-1.
When the Royal Thai Army Medical Department
noticed a high prevalence of HIV-1 infection among
northern recruits in 1989, it established a screening and
prevention programme for HIV infection in conjunc-
tion with biennial military induction. This programme
has provided critical surveillance data for the country,
has been instrumental in the development of policy,
and informative for monitoring trends in HIV risk
behaviour [1]. HIV-1 in Thailand was initially de-
scribed as two epidemics; one of subtype B among
injection drug users (IDU) occurring predominantly in
Bangkok, and a second with the circulating recombi-
nant form, 01_AE (formerly subtype E), among female
sex workers and their clients in the north. More
recently, concurrent with the reduction in high-risk
sexual behaviour, it has been demonstrated that the
proportion of HIV infections attributable to injection
drug use has increased among young Thai men from
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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the north in the period from 1991 to 1998 [2]. As
hepatitis C virus (HCV) is often associated with
parenterally acquired HIV infection as a result of a
common mode of transmission, it may be useful to use
co-infection as an indicator of risk behaviour associated
with injection drug use when this information is either
unavailable or unreliable and there is a high prevalence
of HCV infection among IDU [3]. In a study of IDU
in Bangkok, 96% of those with HIV infection were
co-infected with HCV [4]. In a community vaccine
preparatory cohort study on the eastern seaboard of
Thailand, more than 90% of those participants who
reported previous injection drug use were HCV in-
fected [3]. Therefore, HCV serology in this setting may
facilitate the evaluation of differing trends in the mode
of HIV transmission. We previously reported the high
proportion of HIV/HCV co-infection among young
Thai men in 2000 [5]. This current analysis builds on
this information to characterize the epidemic in terms
of the mode of transmission at two timepoints separated
by 5 years.
Sera were tested for HIV-1 by two different sequential
HIV enzyme immunoassays (EIA) [6], and by a third-
generation hepatitis C EIA (UBI Biomedical, Beijing,
China). Samples were considered HIV-1 positive if
both assays were reactive and confirmed by western
blot (HIV 2.2 Blot, GeneLab, Singapore), and HCV
positive if the HCV EIA was repeatedly reactive.
Confirmatory testing for HCV was not performed
because of the low rate of false positives previously
obtained on a subset of samples with low HCV EIA
reactivity that were tested by recombinant immunoblot
assay (RIBA HCV 3.0; Chiron, Emeryville, CA, USA;
P. Chanbancherd, unpublished data) and the high
proportion of HCV antibody reactivity in the HIV-
infected population tested. Subjects with HIV infection
were referred for counselling, care, and management at
military hospitals or Thai Ministry of Public Health
facilities. All samples tested for HCV were unlinked to
any personal identifiers.
Among recruits whose residence location was known,
HIV prevalence decreased from 2.4% (1243 out of
51 131 screened) in 1995 to 1.1% (711 out of 62 296
screened) in 2000 (P , 0.0001 by chi-square statistic).
Within this overall decline in HIV prevalence, there
are two trends that differ considerably based on the
presence or absence of HCV co-infection. The overall
proportion of HCV co-infection increased from 20.8%
(249 out of 1196) in 1995 to 49.5% (282 out of 570) in
2000, using available sera from HIV-infected men. The
regions with the highest proportion and largest in-
creases in HCV co-infection in 2000 were the south
(75.0% compared with 31.8% in 1995) and Bangkok
(63.0% compared with 22.1%). The overall prevalence
of HIV-infected recruits with HCV co-infection did
not change significantly (from 0.5 to 0.4%, Fig. 1a),
whereas the prevalence of HIV-infected recruits with-
out HCV infection decreased nearly fourfold, from 1.9
to 0.5% over this time period (Fig. 1b). There was an
increase in the prevalence of HCV-infected men in
Bangkok and southern Thailand in 2000 compared
with 1995 (P ¼ 0.005 by chi-square statistic).
These distinct trends in the Thai HIV epidemic, when
assessed using a marker to provide information about
different routes of transmission, reaffirms the known
success in reducing sexually transmitted HIV-1. In
contrast, the data strongly suggest that IDU-related
transmission has not decreased in the 5-year period.
These data are consistent with a previous study of risk
factors for HIV-1 infection in a study of young men
tested during military recruitment in northern Thailand
[2], in which the percentage of HIV-infected men who
indicated previous injecting drug use increased from
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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15% in 1995 to 25% in 1998. The proportion of men
with HCV co-infection in this study increased from
13.9% in 1995 to 41.0% in 2000 in the same region.
Notably, the highest prevalence of HIV/HCV co-
infection was observed among men from southern
Thailand. The epidemiology of HIV in this region may
more closely resemble that of bordering Malaysia,
where the majority of HIV transmissions are thought
to occur among IDU [7,8]. This study highlights the
importance of dissecting HIV-1 national epidemics
despite objective evidence of successful prevention
efforts. Successful public health interventions in Thai-
land have reduced the impact of commercial sex work
and mother-to-child transmission on the epidemic;
however, this analysis, which utilizes a surrogate mar-
ker for parenteral transmission, reinforces the recent
assessment by the Joint UN Programme on HIV/AIDS
(UNAIDS) that IDU will continue to fuel the HIV-1
epidemic in Thailand [9].
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Received: 10 NovObjectives: To carry out an epidemiological analysis of the emerging epidemic in an
Eastern European country and to compare the approach to prevention of mother-
to-child transmission (MTCT) with that in Western Europe.
Design: Prospective cohort study established in 1985 in Western Europe and extended
to Ukraine in 2000.
Methods: Data on 5967 HIV-infected pregnant women and their infants (1251 from
Ukraine and 4716 from Western/Central Europe) was analysed. Factors associated with
transmission were identified with logistic regression.
Results: HIV-infection among pregnant women enrolled in Western European centres
has shifted from being largely injecting drug use (IDU)-related to heterosexually-
acquired; in Ukraine IDU also gradually declined with women increasingly identified
without specific risk factors. In Ukraine in 2000–2004 most (80%) women received
single dose nevirapine (sdNVP) and/or short-course zidovudine prophylaxis [MTCT rate
4.2%; 95% confidence interval (CI), 1.8–8.0 for sdNVP with short-course zidovudine];
2% (n ¼ 27) received antenatal HAART and 33% (n ¼ 418) delivered by elective
caesarean section (CS); in Western European centres 72% of women received HAART
(MTCT rate 1.0%; 95% CI, 0.4–1.9) and 66% delivered by elective CS during the same
period.
Conclusions: Our findings indicate distinct differences in the epidemics in pregnant
women across Europe. The evolution of the MTCT epidemic in Ukraine does not appear
to be following the same pattern as that in Western Europe in the 1980s and 1990s.
Although uptake of preventive MTCT prophylaxis has been rapid in both Western
Europe and Ukraine, substantial challenges remain in the more resource-constrained
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An estimated 580 000 HIV-infected people live in
Western Europe and 1.3 million in Eastern Europe and
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heterosexual transmission prevails, accounting for 58% of
new infections in 2003, largely associated with origin
from sub-Saharan Africa [2,3]. It was not until the mid- to
late-1990s that the HIV epidemic fully emerged in
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1420 AIDS 2006, Vol 20 No 10Federation and Ukraine) bear the brunt of the epidemic
[2,4,5], and although initially focused among IDUs,
new HIV infections among non-IDU heterosexuals are
now rapidly increasing [2]. HIV seroprevalence in Central
Europe is substantially lower than that elsewhere in
Europe, with most HIV diagnoses concentrated in
Romania and Poland [5].
Use of antenatal HAART, elective caesarean section (CS)
delivery and no breastfeeding is highly effective in
reducing mother-to-child transmission (MTCT) of HIV
[6–8]. Prevention of MTCT (PMTCT) programmes
have resulted in only around 250 vertically-acquired HIV
infections in Western Europe annually, despite increasing
numbers of HIV-infected women [9]. In Eastern Europe,
there is a higher prevalence of HIV infection (1.0 versus
0.3% in the West), more infected women of childbearing
age (34% of total HIV-infected population versus 26% in
the West) and health care systems have only limited
capacity to cope with the worsening HIV epidemic
[1,10]. In Ukraine, 2115 infants were born to women
with identified HIV-infection in 2004, a 40% increase
since 2003 (Dr N Zhilka, personal communication,
2005). The approach to PMTCT in Ukraine currently
follows models used in other resource-limited settings:
single dose nevirapine (sdNVP) to mothers intrapartum
and to the neonate and/or short course antenatal
zidovudine (ZDV) prophylaxis, with formula feeding
[11–13]. Similar approaches are being used in other
Eastern European countries with high HIV prevalence
and/or incidence [14].
The European Collaborative Study (ECS) is an ongoing
cohort study which started nearly 20 years ago in Western
Europe and extended to Ukraine in 2000. This provided
the opportunity for an epidemiological analysis of the
situation in Ukraine, comparison with Western Europe
and assessment of whether the experience in the West has
relevance for the younger epidemic in the East.Methods
HIV-1 infected pregnant women were enrolled and their
infants prospectively observed in accordance with
standard protocols [6,15]. Pregnant women are screened
for HIV infection within standard antenatal care, with all
but one centre having a universal antenatal HIV
screening policy [16] and those infected invited to
enrol; pregnant women identified as HIV-infected from
before pregnancy were also invited to participate.
Informed consent was obtained before enrolment,
according to local guidelines and ethics approval was
granted. The ECS was set up in 1985. Centres from
Spain, Italy, the United Kingdom, Germany and
Belgium have participated since the study started, with
centres from Sweden (1986), the Netherlands (1987),pyright © Lippincott Williams & Wilkins. UnauthoPoland (1989), Denmark (1995) and Ukraine (2000)
joining subsequently.
Information collected included maternal CD4 cell count
(since 1992), most likely maternal mode of HIV acquisi-
tion and antiretroviral prophylaxis/treatment. In the
Ukraine centres, CD4 cell counts were available for a
small, selected group only [n ¼ 71, of which 69 were
receiving antiretroviral therapy (ART), two-thirds from
one centre]. Delivery and infant characteristics recorded
included mode of delivery, sex, birthweight, gestational
age and infection status. Maternal CD4 cell counts nearest
the time of delivery were used here.
Infants with persistence of antibody beyond 18 months of
age and/or a positive virological marker of infection on
two separate blood samples regardless of age were
included as infected [6,15]. If a child from a Western/
Central European centre was HIVantibody-negative and
no virus or antigen had ever been detected, (s)he was
classified as uninfected, regardless of age. In the centres in
Ukraine, due to a lack of virological diagnostic laboratory
facilities, dried blood spot filter papers were collected and
sent to Amsterdam for testing (RetinaTM Rainbow HIV-1
RNA assay; Primagen, Amsterdam, The Netherlands). As
diagnosis of HIV infection based on clinical symptoms
may occur earlier than exclusion of infection in settings
with limited access to virological tests [17], only children
born 18 months or more before the time of the analysis
were included in the estimation of MTCT rates in the
Ukraine centres to reduce likelihood of bias; definition of
HIV infection here was based on the development of
AIDS and HIV-associated mortality (n ¼ 12), persistence
of antibody beyond 18 months (n ¼ 24) or detectable
virus in two or more blood samples taken on different
occasions (n ¼ 6).
Elective CS was defined as delivery before rupture of
membranes and onset of labour, premature delivery as
occurring before 37 weeks of gestation, with gestational
age confirmed by ultrasound and reported to the nearest
completed week, and IDU in pregnancy according to
self-report, clinical report or neonatal drug withdrawal
symptoms. Women with CD4 cell counts < 200 cells/ml
were classified as severely immunosuppressed. Multiple
births (32 twin pairs, one triplet) were treated as separate
mother–child pairs.
Univariable comparisons for categorized variables were
tested with the x2 test or x2 test for trend. Univariable
and multivariable logistic regression analysis was used to
obtain odds ratios (OR), adjusted odds ratios (AOR)
and 95% confidence intervals (95% CI). All probability
values were two-tailed. Data entry was carried out
using MS Access 2000 (Microsoft Corp., Redmond,
Washington, USA) and analyses using SAS statistical
software (v8.02; SAS Institute, Cary, North Carolina,
USA).rized reproduction of this article is prohibited.
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HIV-infected pregnant women
Of the 5967 mother–child pairs enrolled by December
2004, 1251 (21%) were from Ukraine, 179 (3%) from
Poland and 4537 (76%) from Western European centres.
Poland was the only country included without a universal
antenatal HIV testing policy at this time [18] and most
(136; 76%) of the pregnant women enrolled here had an
IDU history; all the women were white, all but one had
been born in Poland and they had a median age at delivery
of 26.5 years (range, 17–43 years).
Maternal and delivery characteristics of women enrolling
in the eight Western European countries and in Ukraine
are presented in Table 1. Western European centres were
ethnically heterogeneous, reflecting recent migration
from Africa: 84% (863/1025) of black women came from
sub-Saharan Africa, increasing from 4% (35/838) in
1985–1989 to 37% (478/1309) in 2000–2004 (P <
0.002). Women from sub-Saharan Africa enrolling in
2000–2004 were older (median age 30.3 versus 27.8
years), less likely to be married or cohabiting [71% (326/
457) versus 78% (574/733); x2 ¼ 7.42; P ¼ 0.006] and
more likely to be identified as HIV-infected throughopyright © Lippincott Williams & Wilkins. Unauth
Table 1. Maternal and delivery characteristics.
Whole period
Ethnicity n ¼ 4
Black 1025 (
White 3158 (
Other 181 (
Timing of first positive HIV test n ¼ 4
Before pregnancy 2582 (
During pregnancy 1535 (
At delivery 420 (
Parity at enrolment n ¼ 4
0 2191 (
1 1155 (
2 492 (
 3 290 (
History of pregnancy termination n ¼ 4
No 2565 (
Yes 1625 (
Living outside country of birth n ¼ 4
No 2935 (
Yes 1334 (
Reported risk factors for acquisition of HIV infection n ¼ 4
IDU 1062 (
Sexual 2320 (
IDU and sexual 928 (
Other 51 (
No risk factors specified 176 (
Gestational age n ¼ 4
< 34 weeks 235 (
34–36 634 (
 37 3587 (
Birth weight (g) n ¼ 4
Median (range) 2932 (420
IDU, injection drug user.antenatal testing [44% (211/267) versus 26% (220/831);
x2 ¼ 42.9; P < 0.0001] than other women enrolling in
Western European centres at this time. Overall, women
enrolling in the Western European centres in 2000–2004
were more likely to know their HIV diagnosis before
pregnancy, independent of ethnicity, mode of acquisition
and parity, with an AOR of pre-pregnancy diagnosis of
10.1 (95% CI, 7.95–12.8) in 2000–2004 with 1985–
1989 as baseline. Women from Ukraine were 83% less
likely to be diagnosed before pregnancy than women
in Western Europe (AOR, 0.17; 95% CI, 0.15–0.21)
overall.
Women enrolling in the Ukraine centres were more
similar to those enrolling in Western European centres in
the first 5 years of the study than those enrolling more
recently. In the Western centres in 1985–1989, 93%
(783/846) of women were white, 35% (294/846) aware
of their infection before pregnancy and 79% (668/846)
IDUs. Median age in the Western European centres was
28.5 years (range, 10–47 years) overall, 25.1 years (range,
10–41 years) in 1985–1989 and 31.7 (range, 15–47
years) in 2000–2004, compared with 25.4 years (range,
14–43 years) in Ukraine. Prevalence of very young
maternal age was higher in Ukraine than in Westernorized reproduction of this article is prohibited.
Western Europe Ukraine
n ¼ 4537 2000–2004 n ¼ 1384 2000–2004 n ¼ 1251
364 n ¼ 1326 n ¼ 1234
23) 559 (42) 1
72) 702 (53) 1212 (98)
4) 65 (5) 21 (2)
537 n ¼ 1384 n ¼ 1251
57) 916 (66) 248 (20)
34) 419 (30) 759 (61)
9) 49 (4) 244 (19)
128 n ¼ 1294 n ¼ 1219
53) 571 (44) 710 (58)
28) 412 (32) 381 (31)
12) 210 (16) 90 (7)
7) 101 (8) 38 (3)
190 n ¼ 1313 n ¼ 1220
61) 805 (61) 692 (57)
39) 508 (39) 528 (43)
269 n ¼ 1309 n ¼ 1243
69) 611 (47) 1024 (99)
31) 698 (53) 9 (1)
537 n ¼ 1384 n ¼ 1251
23) 135 (10) 111 (9)
51) 1031 (74) 318 (25)
20) 139 (10) 239 (19)
1) 15 (1) 8 (1)
4) 64 (5) 575 (46)
456 n ¼ 1350 n ¼ 1251
5) 91 (7) 32 (3)
14) 240 (18) 89 (7)
81) 1019 (75) 1130 (90)
459 n ¼ 1262 n ¼ 1251
–5190) 2900 (420–5190) 3085 (1200–5000)
Co
1422 AIDS 2006, Vol 20 No 10Europe [9% (114/1250) were aged < 20 years compared
with 4% (150/4209); x2 ¼ 64.7; P < 0.0001] and
Ukrainian young women were more likely to be married
[39% (43/110) versus 19% (19/100); x2 ¼ 10.1; P ¼
0.001], less likely to have had a pregnancy termination
[10% (11/113) versus 16% (29/140); x2 ¼ 4.87;
P ¼ 0.027] and less likely to report any IDU [13%
(14/104) versus 26% (53/149); x2 ¼ 14.3; P ¼ 0.0002].
Temporal trends in maternal mode of acquisition of HIV
are presented in Figs 1a and 1b. In Western Europe this
has shifted from IDU-related to heterosexual trans-
mission. Since 2000, IDU has gradually declined in
Ukraine, with an increase in women reporting no risk
factors; that is, this latter group did not report current or
past use of injecting drugs, having an IDU or other high-
risk sexual partner, blood transfusions or any other high-
risk sexual behaviour (e.g. multiple sex partners).
Women not reporting specific risk factors in Ukraine
were largely married or cohabiting (87%; 479/553), of
similar age to those reporting heterosexual risk factors
(respective medians, 24.7 and 25.6 years, with 52 and
45% aged < 25 years) and were significantly younger
than IDUs (median age 27.2 years; 12% aged< 25 years;
x2 ¼ 370.5; P < 0.0001). Prevalence of current IDU was
17% (757/4537) in Western European centres and 10%pyright © Lippincott Williams & Wilkins. Unautho
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Fig. 1. Trends over time in mode of acquisition of HIV
infection: (a) Western European centres and (b) Ukraine.
IDU, injection drug user.(125/1251) in Ukraine; in the West this prevalence
decreased from 30% (257/846) in 1985–1989 to 5% (71/
1384) in 2000–2004 (x2trend ¼ 316.5; P < 0.0001).
Although in Ukraine, former or current IDUs were
older than other women (see above), in Western Europe
women without an IDU history were older than those
with (median age 29.1 versus 27.9 years, respectively),
reflecting the proportional increase in older African
women in recent years [19].
Median maternal CD4 cell count was 420 cells/ml (range,
0–2350 cells/ml) (n ¼ 3009, including 71 from Ukraine).
In 1135 (38%) women CD4 cell count was 500 cells/ml,
in 1471 (49%) it was 200–499 cells/ml and in 403 (13%)
< 200 cells/ml. Black women were more likely to be
severely immunosuppressed than white (141/787 (18%)
versus 240/2016 (12%); x2 ¼ 16.9, P < 0.0001). Limiting
a multivariable logistic regression to data on 2205
Western European women from the period when CD4
cell count measurements were routinely recorded and
allowing for ethnicity and time period (the latter used to
assess maturity of the epidemic and as a proxy for trends in
therapeutic management), black women remained at
increased risk of severe immunosuppression than white
women (AOR, 1.47; 95% CI, 1.13–1.91); women
delivering in 2000–2004 were significantly less likely to
be severely immunosuppressed than women delivering in
1992–1995 (AOR, 0.66; 95% CI, 0.48–0.89), indepen-
dent of ethnicity.
Mother-to-child transmission
In the following analyses, data from the Polish centres
were combined with those from the Western European
centres, due to small numbers in the former and very
similar access to PMTCT interventions. Overall MTCT
rates were 6.7% (95% CI, 4.9–8.9) (42/628) in Ukraine
and 9.1% (95% CI, 8.3–10.0) (373/4092) in Western/
Central Europe. The MTCTrate declined significantly in
the latter centres from 16.1% in 1992–1993 to 1.7% in
2002–2003 (x2 ¼ 70.6; P < 0.0001), with no significant
trend in Ukraine over 2000–2004 (P ¼ 0.76).
Of the 2441 (52%) women in Western/Central European
centres receiving no antenatal ART, most enrolled before
1994; 1021 (22%) women received monotherapy or dual
therapy and 1252 (26%) received HAART, in 610 (49%)
cases initiated before pregnancy. The 739 women in
Western/Central Europe on ZDV monotherapy started
this at a median of 26 gestational weeks, with most
delivering before 1997. In Ukraine, two-thirds (n ¼ 793)
of women received sdNVP, of whom 63% (n ¼ 503) also
received ZDV monotherapy, as a short-course regimen,
initiated at a median 35 gestational weeks; a further fifth
of women received either ZDV monotherapy (n ¼ 208)
or HAART (n ¼ 27). Table 2 includes the crude MTCT
rates in Western/Central Europe and in Ukraine,
stratified by ART. Although no adjustment was made
for other variables, the MTCT rate in Western/Centralrized reproduction of this article is prohibited.
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.Europe in the IDU-driven era (1985–1994) among
women not receiving antenatal ARTwas not significantly
different from that in the same group in Ukraine currently
(15.4 versus 19.8%; x2 ¼ 1.02; P ¼ 0.31).
In Western/Central Europe the elective CS rate increased
from 17% (204/1220) in 1990–1994 to 47% (543/1156)
in 1995–1999 and 63% (909/1438) in 2000–2004
(x2 ¼ 589.2; P < 0.0001), whereas in Ukraine the
elective CS rate was 33% (418/1251), with no trends
over the 5 years of data collection.
Logistic regression analyses of MTCT risk were carried
out separately for Western Europe and Ukraine (Table 3).
As only 71 mother–child pairs from Ukraine had CD4
cell counts, we were unable to include CD4 cell count in
the analysis for this area. In Ukraine, only 170 women in
the analysis had an elective CS, and although the AOR
indicated a reduced transmission risk versus vaginal
delivery, this did not reach statistical significance
(Table 3). Overall, use of abbreviated regimens in
Ukraine was associated with a 70% reduced MTCTrisk.
Use of sdNVP alone was associated with a 66% reduced
MTCT risk after adjusting for prematurity and mode of
delivery compared with no antiretroviral prophylaxis
(AOR, 0.34; 95% CI, 0.15–0.82), with a similar AOR
for ZDV monotherapy only (AOR, 0.44; 95% CI, 0.16–
1.22), although this did not reach statistical significance
probably owing to small numbers; sdNVP-boosted
short-course ZDV was associated with the greatest
reduction in risk (AOR, 0.23; 95% CI, 0.09–0.63)
compared with no prophylaxis; however, this combi-
nation was not statistically significantly more effective
compared with sdNVP alone or short-course zidovudine
alone. In Western/Central Europe, maternal CD4 cell
count was an important risk factor, with severe maternal
immunosuppression independently associated with a
doubled risk and elective CS with a two-thirds reduced
risk. Women taking HAART were more than 90% less
likely to transmit infection than those untreated (Table 3)
and 75% less likely than women on mono or dual therapy
(AOR, 0.25; 95% CI, 0.12–0.54).Discussion
We present findings from the first epidemiological study of
HIV-infected pregnant women in Ukraine. The Ukrainian
HIV epidemic has been dominated by IDU [5,13], with
high IDU prevalence, young age at IDU initiation, high-
risk behaviours (drug use-related and sexual), low HIV
prevention awareness and the intersecting epidemics of
IDU and commercial sex work accelerating the epidemic
[4,20,21]. By 2004, 50% of women enrolled in our
Ukraine centres were IDU or reported an IDU sexual
partner. Although nearly 80% women in Western
European centres enrolling in 1985–1989 were IDUsorized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unautho
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e.this had declined to 20% in 2000–2004. The relatively low
prevalence of IDU history (less than 30%) reported among
pregnant women in Ukraine may reflect under-reporting
due to social desirability bias or alternatively, pregnant IDU
women may not have been enrolled due to a lack of
antenatal care. However, these biases are likely to have
remained constant over time, suggesting that the decline in
IDU seen is real.
Our findings regarding mode of acquisition in Ukraine
are consistent with reports of the evolving epidemic
there, with evidence that HIV is spreading to bridging
populations (sexual partners of IDU and sex workers) and
beyond to the general population, with one-third of new
HIV diagnoses in Ukraine heterosexually acquired in
2003 [1,13,21,22]. Most women not reporting any risk
factors in our Ukraine centres probably acquired HIV
heterosexually through unprotected sexual intercourse
with casual or regular partners, including their husbands
(87% were married or cohabiting), but were unaware of
their exposure to HIV. Similarly, 48% of new HIV
infections in women in Eastern Europe in 2004 reported
to the European HIV/AIDS Monitoring Centre were in
the ‘other/undetermined’ category [9]. Our finding of
more very young women in Ukrainian versus Western
European centres probably reflects their tendency to start
child-bearing at younger ages, but also suggests that
Ukrainian women may acquire HIV infection at younger
ages [23].
The overall MTCT rate in the Ukrainian centres was
6.7% during 2000–2004. The Ukraine government
implemented the use of short-course ZDVand/or sdNVP
for mother and infant with formula feeding in 2001 [22].
We lacked statistical power to show a significant
difference between either short-course ZDV boosted
with sdNVP compared to sdNVP alone or to short-
course ZDV alone, although the crude MTCT rates
suggest that there might be a benefit in combining sdNVP
and short-course ZDV in this population, consistent with
trial findings elsewhere and WHO guidelines [11]. The
overall MTCT rate in the ZDV monotherapy group in
Western Europe was marginally less than that in Ukraine
(6.4 versus 7.8%), despite shorter ZDV duration in
Ukraine, starting at 35 weeks. The Ukrainian govern-
ment recently updated its national policy, which now
recommends that short-course ZDV is started at 28 weeks
gestation. The in utero/intrapartum MTCT rate in the
sdNVP only group here was similar to that in the
HIVNET 012 trial (6.9 versus 8.1%) [24]. However,
the rate at which short-course ZDV was boosted by
sdNVP was somewhat higher in our non-trial situation
than in the Thai PHPT2 trial [11] with longer antenatal
ZDV, but lower than in the West African Ditrame Plus
study where just over half were breastfed [25].
National guidelines in Western Europe now recommend
HAART in pregnancy as prophylaxis for PMTCT, withrized reproduction of this article is prohibited.
CMother-to-child HIV transmission in Europe Thorne et al. 1425continuation post-partum determined by maternal
virological and immunological status, although there is
still a place for ZDV monotherapy combined with
elective CS for some pregnant women (e.g. those with
low viral loads not requiring HAART for their own
health) [26,27]. The upper 95% CI of the 1% MTCTrate
among women on HAART in the Western European
centres was 1.9%, just overlapping with the lower 95% CI
of the 4.2% MTCT rate among Ukrainian women
receiving sdNVP and short-course ZDV, at 1.8%. This
highlights that a reduction in MTCT rates to very low
levels without widespread access to HAART is possible in
non-breastfeeding, non-trial settings.
However, access to HAART for eligible HIV-infected
mothers should be prioritized, and is not only important
for maternal health, but also for the children’s future
health and social care, regardless of infection status
[28,29]. Although expanding access to antiretroviral
drugs in Ukraine is underway, only an estimated 13% of
HIV-infected people eligible for ART are currently
treated [13]. As we only had limited CD4 cell count data
in Ukraine and no viral load information, we cannot
make any conclusions regarding the need for HAART in
our study population.
In terms of generalizability of our results to elsewhere in
Ukraine, an estimated 20% of all pregnant HIV-infected
women delivering nationally in 2001–2004 were
enrolled in the ECS (Ukrainian AIDS Center, 2005
unpublished data). The ECS centres were in Southern
Ukraine, the national epicenter [30], in Odessa,
Micolaiev and Simferopol and include those at the
forefront of the PMTCT programme in Ukraine [31].
Uptake of and access to prophylactic interventions in
these centres may be somewhat greater than in areas with
lower prevalence and/or less experience. In particular,
the 33% elective CS rate in the Ukrainian centres here
was higher than that reported for HIV-infected women
in Ukraine overall, at around 14% (Dr N Zhilka, personal
communication, 2005). Furthermore, our findings re-
garding mode of acquisition of HIV may be specific to
Southern Ukraine, as the first affected region of Ukraine,
particularly regarding the trends over time. With regard to
generalizability to other Eastern European countries,
although IDU remains a driving force in many countries’
epidemics, an increasing proportion (up to 45% or more)
of new reported HIV infections are due to unprotected
sex in Russia, Belarus, Moldova and Kazakhstan [32].
There are similarities between the early HIVepidemics in
Western Europe and Ukraine, notably the importance of
IDU and sexual contact with IDUs.Access to and uptake of
PMTCT prophylaxis was rapid in Western Europe [33,34],
and antenatal HAARTuse has contributed to the very low
rates of MTCT there [35–37]. Although knowledge of
effective PMTCT interventions pre-dated the Ukraine
epidemic, application of these is an enormous challengeopyright © Lippincott Williams & Wilkins. Unauthhere, as in all low-income settings [38–40]. These
challenges include transforming national PMTCT strat-
egies from a medically-focused vertical approach towards a
horizontal approach and integrating prevention activities
into maternal and child health services [41]. The Ukraine
government has addressed PMTCT with substantial
success, with a decreasing MTCT rate from over 25%
prior to 2000 to 8% in 2002 [22] (Dr N Zhilka, personal
communication, 2005). However, increasing HIV inci-
dence and lack of widespread access to HAART is likely to
result in an increasing burden of paediatric HIV infection
in Ukraine. The juxtaposition between this situation and
the discussion in Western Europe of the potential
elimination of vertically-acquired HIV infection under-
scores the urgent need to scale-up the response to the
epidemic in the most affected regions of Eastern Europe,
including Ukraine, remembering that PMTCT not only
includes application of antenatal and perinatal prophylaxis
and prevention of unwanted pregnancies in HIV-infected
women, but also primary prevention.Acknowledgments
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H I V / A I D SM A J O R A R T I C L E
Time to Undetectable Viral Load after Highly Active
Antiretroviral Therapy Initiation among HIV-Infected
Pregnant Women
European Collaborative Studya
Background. There have been no clinical trials in resource-rich regions that have addressed the question of
which highly active antiretroviral therapy (HAART) regimens are more effective for optimal viral response in
antiretroviral-naive, human immunodeficiency virus (HIV)–infected pregnant women.
Methods. Data on 240 HIV-1–infected women starting HAART during pregnancy who were enrolled in the
prospective European Collaborative Study from 1997 through 2004 were analyzed. An interval-censored survival
model was used to assess whether factors, including type of HAART regimen, race, region of birth, and baseline
immunological and virological status, were associated with the duration of time necessary to suppress viral load
below undetectable levels before delivery of a newborn.
Results. Protease inhibitor–based HAART was initiated in 156 women (65%), 125 (80%) of whom received
nelfinavir, and a nevirapine-based regimen was initiated in the remaining 84 women (35%). Undetectable viral
loads were achieved by 73% of the women by the time of delivery. Relative hazards of time to achieving viral
suppression were 1.54 (95% confidence interval, 1.05–2.26) for nevirapine-based HAART versus PI-based regimens
and 1.90 (95% confidence interval, 1.16–3.12) for western African versus non-African women. The median duration
of time from HAART initiation to achievement of an undetectable viral load was estimated to be 1.4 times greater
in women receiving PI-based HAART, compared with women receiving nevirapine-based HAART. Baseline HIV
RNA load was also a significant predictor of the rapidity of achieving viral suppression by delivery, but baseline
immune status was not.
Conclusions. In this study, nevirapine-based HAART (compared with PI [mainly nelfinavir]-based HAART),
western African origin, and lower baseline viral load were associated with shorter time to achieving viral suppression.
Plasma HIV RNA load is the preeminent risk factor for
mother-to-child transmission (MTCT) of HIV infec-
tion [1, 2]. In resource-rich regions, HAART (typically
composed of 3 antiretroviral agents from 2 drug classes)
has substantially reduced MTCT rates through suc-
cessful suppression of HIV RNA load [2, 3]. Although
an increasing proportion of HIV-infected pregnant
women in these regions are identified and treated before
pregnancy, a substantial minority receive a diagnosis
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antenatally and start antiretroviral therapy (ART) for
the first time during pregnancy to delay disease pro-
gression and/or to prevent MTCT [2]. In many Western
European countries, these women are increasingly likely
to have acquired HIV infection through heterosexual
contact and to be from countries with generalized ep-
idemics (mainly countries in sub-Saharan Africa) [4].
No clinical trials in resource-rich regions have ad-
dressed the question of which regimens are more ef-
fective for optimal viral response in ART-naive, HIV-
infected pregnant women. Using data from a
multicenter prospective cohort, this study was con-
ducted to determine whether choice of initial HAART
regimen for HIV-infected pregnant women is associated
with the duration of time that is necessary to achieve
undetectable viral load by delivery.
METHODS
The European Collaborative Study is an ongoing ob-
servational cohort study that was established in 1985,
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in which HIV-1–infected pregnant women are enrolled and
their infants are prospectively observed according to standard
protocols [2]. Informed consent was obtained, and local ethics
committee approval was granted. Information collected in-
cluded timing and type of ART, maternal CD4 cell count, HIV
RNA load, and sociodemographic characteristics.
Laboratory tests were performed locally in laboratories lo-
cated in tertiary care centers and university hospitals. For HIV
RNA load quantification, Amplicor HIV-1 Monitor Test, ver-
sions 1.5 and ultrasensitive (Roche Diagnostic Systems); Quan-
tiplex HIV-1 RNA (b-DNA) assay, version 3.0 (Chiron Diag-
nostics); or nucleic acid sequence–based amplification/
nuclisens (Organon Teknika) were used. Classification of
undetectable viral load (viral suppression) was based on the
lower limit of quantification of the assay. Of the 759 antenatal
HIV RNA load measurements available, 561 (74%) were mea-
sured with ultrasensitive assays (quantification limit,50 cop-
ies/mL). HAART was defined as a regimen of 3 antiretroviral
drugs, including a nucleoside reverse-transcriptase inhibitor
backbone and nevirapine (NVP)—a nonnucleoside reverse-
transcriptase inhibitor (NNRTI)—or a protease inhibitor (PI).
We restricted the analysis to HIV-infected women who were
ART-naive at conception; 153 women were first identified as
having HIV-infection during pregnancy, and 87 women were
known to have HIV infection before pregnancy (46 of these
women were known not to have previously received prophylaxis
for prevention of MTCT, either because of no prior pregnancies
or documented nonreceipt of ART during previous pregnancies
that occurred while enrolled in European Collaborative Studies,
and 41 were not receiving ART at conception and had no
documented prior ART use). Other eligibility criteria were a
detectable HIV RNA load measurement within 6 weeks before
initiation in the study and at least 1 subsequent measurement.
Statistical methods. To determine the association of ma-
ternal factors and initial HAART regimen with viral suppres-
sion, we examined the duration of time from treatment initi-
ation to the achievement of undetectable HIV RNA load until
the time of delivery. For women not achieving an undetectable
HIV RNA load, the time was right-censored at the last mea-
surement at or before delivery. For those achieving an unde-
tectable HIV RNA load, the end point was known only to have
occurred between initiation and the first measurement (left-
censoring) or between any 2 measurements following initiation
(interval-censoring).
A parametric survival model based on the Weibull distri-
bution, incorporating left-, right-, and interval-censoring, was
used [5]. Estimates from Weibull models can be represented
either as relative hazards (RHs) or as the acceleration factor
between 2 levels of a covariate. Because most women reached
viral suppression, the RH reflects the rapidity with (rate at)
which viral suppression occurred, rather than solely the prob-
ability of the event occurring; larger RHs are associated with
more rapid attainment of viral suppression.
After adjusting for baseline viral load, race, type of HAART,
baseline CD4 cell count, maternal age, trimester at initiation
of HAART, timing of HIV diagnosis, history of injection drug
use, and year of delivery were considered in the Weibull model.
A stepwise model selection procedure was used to choose salient
prognostic variables, with a variable retained if its inclusion
resulted in a significantly improved log likelihood. The pro-
pensity of being treated with NVP-based HAART was estimated
by a logistic regression model that included the covariates men-
tioned above; the propensity score was then included in all
adjusted models after stratification into quintiles [6].
Stratified survival curves and associated survival probabilities
were obtained with Turnbull’s generalization of the Kaplan
Meier estimate, allowing for interval-censored data [5, 7], with
95% CIs calculated using the adjusted bootstrap percentile
method with 1000 replications. Turnbull estimates of the pro-
portion of women achieving undetectable viral loads, by treat-
ment group and race, were calculated separately for women
with baseline viral loads 4 log10 copies/mL or !4 log10 copies/
mL. Skewed continuous variables were compared using the
Mann-Whitney U test, and categorical variables were compared
using the x2 test. Analyses were performed using Stata software,
version 9.1 (StataCorp), and R, version 2.2.0 (R Development
Core Team).
RESULTS
Of 1346 women receiving antenatal HAART who delivered a
newborn from 1997 through 2004, 240 pregnant, HIV-infected
women met our inclusion criteria. The characteristics of these
women are shown in table 1. Most women (59%) were black,
90% of whom were born in sub-Saharan Africa (table 1). PI-
based HAART was initiated in 156 women (65%), with the
remaining 84 women (35%) receiving an NNRTI-based regi-
men (all including NVP). Most regimens had a zidovudine and
lamivudine combination nucleoside reverse-transcriptase in-
hibitor backbone (table 2). One hundred twenty-five PI-based
regimens (80%) included nelfinavir (NFV), with the remaining
containing a lopinavir and ritonavir combination (4 regimens),
ritonavir (13 regimens), indinavir (8 regimens), or saquinavir
(6 regimens). The proportion of women receiving NVP-based
HAART increased from 16 (25%) of 64 women during 1997–
2000 to 37 (35%) of 105 women and 31 (44%) of 71 women
during 2001–2002 and 2003–2004, respectively ( ).Pp .02
There were no differences between black and non-black women
with respect to type of HAART received (48 [34%] of 141 black
women vs. 34 [35%] of 96 non-black women received an NVP-
based HAART regimen; ), the distribution of baselinePp .94
median HIV RNA load (4.13 log10 copies/mL [interquartile
range (IQR), 3.54–4.60] vs. 4.20 log10 copies/mL [IQR, 3.76–
Table 1. Characteristics of 240 treatment-naive, HIV-infected pregnant
women at initiation of HAART and the number of women acheiving the end
point of an undetectable HIV RNA load by delivery.
Characteristic All women
Women
acheiving an
undetectable
viral load
Race
Non-black 96 (41) 63 (66)
Black 141 (59) 110 (78)
Unknown 3 2
Region of birtha
Europe 75 (32) 46 (61)
The Americas 23 (10) 18 (78)
Asia 8 (3) 7 (88)
Northern Africa 6 (2) 5 (83)
Eastern Africa 44 (19) 33 (75)
Southern Africa 2 (1) 1 (50)
Central Africa 40 (17) 31 (78)
Western Africa 39 (16) 32 (82)
Unknown 3 2
Age at delivery
Median years (IQR) 29 (25–33)
15–19 years 10 (4) 6 (60)
20–29 years 113 (48) 86 (76)
30–39 years 107 (45) 74 (69)
40 years 8 (3) 7 (88)
Unknown 2 2
History of IDU
Non-IDU 215 (91) 159 (74)
IDU 21 (9) 12 (57)
Unknown 4 4
Timing of diagnosis of HIV infection
Antenatal 153 (64) 113 (74)
Prepregnancy 87 (36) 62 (71)
Stage of pregnancy at initiation of HAART
Median weeks of gestation (IQR) 23 (18–27)
First trimester 14 (6) 12 (86)
Second trimester 168 (70) 129 (77)
Third trimester 58 (24) 34 (59)
HIV RNA viral load, log10 copies/mL
Median (IQR) 4.16 (3.62–4.58)
5 20 (8) 10 (50)
4–4.99 125 (52) 88 (70)
3–3.99 74 (31) 58 (78)
!3 21 (9) 19 (90)
CD4 cell count
Median cells/mL (IQR) 328 (210–480)
!200 cells/mL 48 (22) 29 (60)
200–499 cells/mL 124 (56) 95 (77)
500 cells/mL 48 (22) 38 (79)
Unknown 20 13
NOTE. Data are no. (%) of patients, unless otherwise indicated. IDU, injection drug
user.
a Regions of Africa were defined according to the United Nations groupings.
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Table 2. Characteristics of study patients by HAART category.
Characteristic
PI-based
HAART
(n p 156)
NVP-based
HAART
(n p 84) P a
Received NRTI backbone
No. of patients receiving zidovudine and lamivudine (%) 139 (89) 72 (86)
No. of patients receiving another dual combination (%) 17 (11) 12 (14) .58
Median time of initiation of HAART, weeks of gestation (IQR) 23 (18–27) 21.5 (16–28) .57
Median baseline HIV RNA load, log10 copies/mL (IQR) 4.18 (3.60–4.58) 4.08 (3.71–4.54) .58
Median baseline CD4 cell count, cells/mm3 (IQR) 305 (190–452) 355 (277–506) .02
Median no. of viral load measurements (IQR) 3 (2–3) 3 (2–3) .77
Median interval between successive HIV RNA load tests, weeks (IQR) 7.5 (4–10) 6 (4–10) .07
Median duration of gestation at delivery, weeks (range) 38 (25–42) 37 (23–41) !.01
NOTE. NRTI, nucleoside reverse-trascriptase inhibitor; NVP, nevirapine; PI, protease inhibitor.
a P values were calculated with the x2 test or Mann-Whitney U test, as appropriate.
4.56]; ), and baseline median CD4 cell count (313 cells/Pp .18
mm3 [IQR, 210–449] vs. 370 cells/mm3 [IQR, 231–528]; Pp
). However, black women tended to start treatment later.12
than non-black women (median of 24 weeks of gestation [IQR,
20–28] vs. median of 20.5 weeks of gestation [IQR, 15–27];
).P .01
The median number of virological measurements per woman
was 3 (range, 2–7 measurements), with a similar interval be-
tween successive tests for the 2 treatment groups (table 2).
Figure 1 shows the distribution of HIV RNA load measure-
ments at initiation, by weeks of gestation, together with baseline
median viral load and baseline median CD4 cell count. Thirty-
nine (24%) of 165 women starting HAART during the first or
second trimester had a CD4 cell count !200 cells/mm3, com-
pared with 9 (16%) of 55 women starting HAART during the
third trimester ( ).Pp .35
Although time of HAART initiation and baseline HIV RNA
loads were similar between treatment groups, the PI-based
group had significantly lower baseline CD4 cell counts (table
2). Among the NVP group, 61 women (73%) had a CD4 cell
count 1250 cells/mm3 at initiation; of these women, 57 (93%)
delivered a newborn before February 2004 (when NVP pre-
scribing information changed [8]).
The median gestational age at delivery was 38 weeks (range,
23–42 weeks), and 175 (73%) of 240 women had undetectable
viral loads by this time; table 1 shows the number of women
reaching this outcome, by maternal characteristics. The pro-
portion of women achieving an undetectable viral load did not
differ between treatment groups ( 111 [71%] of 156 women
receiving PI-based regimens and 64 [76%] of 84 women re-
ceiving NVP-based HAART regimens; ). Figure 2 dis-Pp .49
plays estimated proportions of women achieving undetectable
viral loads—beginning at the time of initiation of therapy—
stratified by HAART category and baseline viral load. For
women with a baseline HIV RNA load 4 log10 copies/mL,
35.2% (95% CI, 20%–51.1%) of the PI group and 53.0% (95%
CI, 20%–94%) of the NVP group achieved an undetectable
HIV RNA load by 5 weeks, 56.4% (95% CI, 45%–71%) of the
PI group and 76.4% (95% CI, 56%–94%) of the NVP group
achieved an undetectable viral load by 10 weeks, and 59.4%
(95% CI, 43%–755) in the PI group and 93.4% (95% CI, 66%–
99.0%) of the NVP group achieved an undetectable viral load
by 15 weeks, indicating a differing response by treatment cat-
egory (figure 2B). Stratifying by race and baseline viral load,
58.7% (95% CI, 44%–75%) of non-black women and 66.3%
(95% CI, 53%–79%) of black women with baseline HIV RNA
loads 4 log10 copies/mL achieved an undetectable viral load
at 10 weeks, and 64.1% (95% CI, 38%–85%) of non-black
women and 79.3% (95% CI, 65%–93%) of black women
achieved an undetectable viral load at 15 weeks, suggesting
possible race-associated differences.
RHs from univariable survival analyses adjusting for baseline
viral load confirmed the race differences described above (RH
for black women vs. non-black women, 1.40; 95% CI, 1.00–
1.97) and were explored in further models through examination
of region of birth. Table 3 shows the RHs for time from ini-
tiation of HAART to achievement of an undetectable viral load
for the full-adjusted model. Twenty-three women with infor-
mation missing on race or CD4 cell count were excluded from
the model; these women had characteristics that were similar
to those of women who were included (data not shown). In-
cluding 2-way interaction terms between any of the variables
in the final model did not significantly improve the fit. The
rate of women achieving an undetectable viral load in the NVP
group was estimated to be almost 1.5 times than that in the
PI group (table 3). Baseline viral load and being of Western
African origin were also significant factors affecting the rate of
achieving undetectable viral load by delivery. A sensitivity anal-
ysis including women receiving a PI-based regimen including
NFV only revealed similar RHs among women receiving NVP-
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Figure 1. Distribution of baseline HIV RNA load measurements, median baseline HIV RNA load, and median CD4 cell count, by timing of initiation
of HAART during pregnancy. IQR, interquartile range.
based HAART (RH, 1.56; 95% CI, 1.05–2.32), as did including
only women initiating therapy in the first and second trimesters
(RH, 1.82; 95% CI, 1.18–2.84).
Using the acceleration factor format, the median time to
achievement of an undetectable viral load for a woman re-
ceiving PI-containing HAART was estimated to be 1.38 times
(95% CI, 1.04–1.83 times) that for a woman receiving NVP-
containing HAART. The predicted median time to achievement
of an undetectable viral load for non-African women with base-
line CD4 cell counts of 200–499 cells/mm3 and HIV RNA viral
loads of 3.81–4.39 log10 copies/mL who initiated treatment dur-
ing the second trimester was 7.1 weeks (95% CI, 3.60–10.53
weeks) for the NVP group and 9.8 weeks (95% CI, 5.38–14.16
weeks) for the PI group; for Western African women with sim-
ilar characteristics, these times were 4.4 weeks (95% CI, 2.1–
6.7 weeks) and 6 weeks (95% CI, 3.2–8.9 weeks), respectively.
Viral response in 70 women eligible for NVP, according to
current prescribing advice [8] (i.e., with baseline CD4 cell
counts !250 cells/mm3) was explored; the median baseline viral
load was 4.35 log10 copies/mL (IQR, 4.05–4.69), the median
duration of gestation at initiation of HAART was 22 weeks,
and 16 women (24%) received NVP. The percentage of women
reaching an undetectable viral load at 5 weeks was 34.8% (95%
CI, 20.4%–46.7%) for those receiving PI-based regimens and
52.9% (95% CI, 22.1%–71.6%) for those receiving NVP reg-
imens; the percentages increased to 50.4% (95% CI, 34.0%–
62.8%) and 82.4% (95% CI, 50.7%–93.7%), respectively, at 8.5
weeks. In adjusted analyses, these treatment group differences
were not statistically significant (RH for NVP-containing
HAART, 1.89; 95% CI, 0.87–4.12).
The 65 women (27%) who delivered with a detectable viral
load were similar to those achieving undetectable viral loads
with regard to regard to race and type and timing of HAART
(data not shown). However, more of the women with detectable
viral loads at delivery were severely immunosuppressed (defined
as a CD4 cell count !200 cells/mm3; 19 [33%] of 58 women
with a detectable viral load vs. 29 [18%] of 162 women with
an undetectable viral load; ), and more of these womenPp .03
had baseline viral loads 15 log10 copies/mL (10 [15%] of 65
women with a detectable viral load vs. 10 [6%] of 175 with an
undetectable viral load; ); the median viral load at de-Pp .03
livery for women with a detectable viral load was 2.48 log10
copies/mL (IQR, 2.26–3.11), and only 20 of these women (31%)
had a viral load 11000 copies/mL.
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Figure 2. Survival curves for the time from initiation of HAART to achievement of an undetectable viral load, by initial treatment category: (A),
women with a baseline viral load !4 log10 copies/mL, and (B), women with a baseline viral load 4 log10 copies/mL. NVP, nevirapine; PI, protease
inhibitor.
DISCUSSION
Suppressing plasma HIV RNA load below detectable limits is
one of the goals for effective treatment of HIV-infected women
during pregnancy and for prevention of MTCT [9, 10]. In our
study, most pregnant women (73%) initiating HAART anten-
atally delivered with an undetectable viral load, and the re-
maining women delivered with a detectable but generally very
low viral load. Less than one-quarter of the women had im-
munological indications for treatment [9, 10]. Most women
were prescribed PI-containing HAART, with a highly homog-
enous approach, with 76% of these women receiving a com-
bination of NFV, zidovudine, and lamiduvine. NFV has the
most extensive data on pharmacokinetics and safety during
pregnancy among all of the PIs and is currently preferred for
use in antenatal HAART, especially in patients in whom there
are no maternal indications for treatment [11]. One-third of
women received NVP-containing HAART, with increasing use
over time; this trend is unlikely to continue because of updated
NVP prescribing advice [8]. The predominance of zidovudine-
and lamiduvine-containing regimens in our study reflects cur-
rent recommendations for this nucleoside reverse-transcriptase
inhibitor combination to be the backbone treatment for preg-
nant women [10, 11] and is consistent with prescribing patterns
in Europe for nonpregnant individuals [12].
To our knowledge, this study is the first to suggest that choice
of initial HAART regimen has implications for timely achieve-
ment of undetectable viral load during pregnancy. Adjusting
for baseline prognostic factors, the hazard of achieving an un-
detectable viral load was greater for women receiving NVP-
containing HAART, with women in the PI group requiring an
average of 1.4 times longer to achieve viral suppression. Find-
ings conflict with regard to the relative effectiveness of PI-
containing versus NNRTI-containing HAART regimens in non-
pregnant adults. A recent direct meta-analysis of
“head-to-head” randomized trials suggested that NNRTI-based
HAART (predominated by efavirenz) was 60% more effective
for virological suppression than was PI-based HAART (50%
boosted PIs), although no difference in clinical outcomes was
reported [13]. However, an indirect meta-analysis yielded con-
tradictory results (i.e., NNRTI-based HAART was less effective
than PI-based HAART for virological suppression [13]); these
discordant results may be a result of differences in population,
study design, or type of nucleoside reverse-transcriptase inhib-
itor backbone, highlighting the difficulties of translating trial
findings into clinical recommendations and the importance of
direct comparisons [13].
Therapeutic decision-making during pregnancy is compli-
cated by unique factors, including the need to consider pre-
vention of MTCT, safety and toxicity, and physiological
changes, which may affect pharmacokinetics [8, 14]. Accu-
mulating data on NFV pharmacokinetics suggest that drug lev-
els during the third trimester may frequently be subtherapeutic
[15–17]. This may explain why we found a superior virologic
response with NVP-containing versus PI-containing (mostly
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Table 3. Factors associated with time to achieving undetectable HIV RNA load after initiation of HAART
during pregnancy among 217 study women.
Variable
No. of
patients
Univariate analysis Multivariable analysis
RH (95% CI) P RH (95% CI) P
Region of birth
Non-African 96 1.00 1.00
Eastern Africa 42 1.15 (0.73–1.83) .55 1.61 (0.84–3.11) .15
Central Africa 33 1.58 (0.96–2.60) .07 1.24 (0.70–2.21) .46
Northern or southern Africa 7 0.82 (0.31–2.13) .68 1.25 (0.38–4.07) .72
Western Africa 39 1.58 (1.0–2.50) .05 1.90 (1.16–3.12) .01
HAART regimen
PI-based 141 1.00 1.00
NVP-based 76 1.62 (1.14–2.31) !.01 1.54 (1.05–2.26) .02
Baseline HIV RNA load, log10 copies/mL
a
4.40 72 1.00 1.00
3.81–4.39 73 1.75 (1.15–2.66) !.01 1.70 (1.08–2.68) .02
!3.81 72 2.54 (1.69–3.80) !.001 2.76 (1.68–4.52) !.001
Baseline CD4 cell count, cells/mm3
!200 47 1.00 1.00
200–499 123 1.39 (0.89–2.15) .14 1.25 (0.69–2.24) .46
500 47 1.42 (0.83–2.43) .20 1.40 (0.71–2.76) .33
NOTE. Univariate and multivariable estimates were adjusted for baseline viral load. Multivariable estimates were adjusted
for all covariates listed in the table, with the addition of the treatment propensity score and trimester of initiation during
pregnancy. NVP, nevirapine; PI, protease inhibitor; RH, relative hazard.
a Baseline HIV RNA load was categorized according to their tertiles.
NFV) HAART—in contrast to the Combine Study, in which
an equivalent response was reported among ART-naive non-
pregnant individuals randomized to a zidovudine and lami-
duvine backbone with NVP or NFV [18].
African and non-African pregnant women had similar base-
line immune and virological status—in contrast to previous
findings based on the whole cohort [4]—probably reflecting
eligibility criteria for this analysis. The median baseline CD4
cell count among black women in our study was marginally
lower than those reported in African prevention of MTCT trials
(335–363 cells/mm3 among ART-naive pregnant women) [19,
20]. Univariably, black women in our study responded to
HAART more favorably than did non-black women; further
investigation, stratifying by region of birth, revealed that this
effect was limited to women of western African origin. Limited
information is available regarding response to HAART among
African populations, and even less is available for pregnant
African women. In the Drug Resource Enhancement against
AIDS and Malnutrition pilot in Mozambique, 26 (65%) of 40
pregnant women starting HAART, with a median baseline HIV
RNA load of 4.2 log10 copies/mL, achieved viral suppression
(viral load, !400 copies/mL) by delivery after an average of 12
weeks [21]; these data are consistent with our results. An impact
of race on disease progression or response to HAART has been
suggested by several studies of pregnant and nonpregnant in-
dividuals, which generally revealed poorer virological responses
among black and/or African groups; these findings were sug-
gested to be a result of coinfections or adherence [22–24]. We
did not have adherence data available, but it seems unlikely
that differing adherence levels could explain our findings, be-
cause the better virological response to HAART was limited to
the western African group only. Little is known about the im-
pact of different HIV subtypes on the effectiveness of HAART
[25, 26]. Differences in underlying maternal subtype may pos-
sibly explain our findings, although host biological and genetic
differences may also play a part [27].
We found no significant difference in time to attaining un-
detectable viral load between severely immunosuppressed
women and those with greater immunocompetence. This is
consistent with other studies that have found a significant as-
sociation between baseline viral load and subsequent virological
response after HAART initiation but not an association between
baseline CD4 cell count and virological response [28, 29]. Few
studies have examined the latter association among ART-naive
pregnant women, in whom treatment effect and the relationship
between baseline CD4 cell count and viral load may differ from
that in nonpregnant adults [30, 31].
Our data are limited by their observational nature [32]; how-
ever, we allowed for interval-censoring [5], adjusted for timing
of initiation of therapy during pregnancy, and minimized con-
founding by ART experience through our selection criteria.
Additionally, we used a treatment propensity score to reduce
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bias in the comparison of a treatment group to a nonrandom-
ized control group [6]. We could not account for additional
factors potentially influencing response to HAART, such as ad-
herence, biological differences in drug activity arising from var-
iations in body weight and pharmacokinetics between groups,
HIV subtypes, and other genetic factors [14, 33, 34]. A dis-
advantage of cohort data is their limited contemporary rele-
vance when therapeutic practices have changed over time. A
case-in-point is the NVP prescribing changes after the asso-
ciation of the drug with hepatotoxicity in women with mod-
erate to high CD4 cell counts [8]. If clinicians comply with
prescribing advice, one would expect the future group of ART-
naive women starting NVP-containing HAART to have lower
CD4 cell counts than the women in our study. However, our
subanalysis of women with CD4 cell counts !250 cells/mm3
indicates that our results may be generalizable but had limited
statistical power.
Although guidelines state that pregnancy should not preclude
use of optimal ART regimens [11], in reality, there are limited
options. For nonpregnant adults, NNRTI-containing HAART
is recommended as a first-line regimen, preserving PI-contain-
ing HAART for later treatment, with efavirenz as the preferred
agent. Because efavirenz is contraindicated during the first tri-
mester of pregnancy, NVP-containing HAART has been in-
creasingly used for ART-naive pregnant women in Europe, but
this is no longer recommended for women with relatively good
immune functioning. The potential option of initiating efavi-
renz-based HAART during the second or third trimester, if
contraception can be assured after delivery, has been suggested
in current World Health Organization recommendations for
resource-limited countries [35], but whether this approach will
be used in Europe is uncertain.
To date, NFV has been the overwhelming choice to accom-
pany zidovudine and lamivudine in the treatment of ART-naive
women in our study, but was less effective with regard to vi-
rological suppression than NVP-containing HAART. Boosted
PI regimens appear to offer superior virological suppression in
ART-naive adults, compared with PI alone [36], and lopinavir
and ritonavir combination therapy is identified as a preferred
PI regimen for initial HAART during pregnancy in current US
guidelines—albeit, with limited pharmacokinetic and safety
data [11, 37]. As more information becomes available, includ-
ing boosted PIs in initial HAART regimens during pregnancy
may become increasingly common, and the question of the
equivalence of such regimens to other HAART regimens war-
rants investigation (in addition to research of new agents, such
as integrase inhibitors). In the absence of clinical trials of
HAART among pregnant women, our findings add to the evi-
dence base to assist therapeutic decision-making for ART-naive,
HIV-infected pregnant women. Our results strongly suggest
that an ART-naive pregnant woman with a CD4 cell count
!250 cells/mm3 should begin receiving NVP-containing
HAART rather than NFV-containing HAART. In addition, our
results highlight the urgent need for further research of the
pharmacokinetics, efficacy, and safety of ART during pregnancy.
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Abstract
Globally the HIV epidemic mainly affects young people, particularly young females who are vulnera-
ble to acquisition of HIV as a result of their biological and social susceptibility. Women represent an
increasing proportion of newly diagnosed HIV cases in Western and Eastern Europe, reaching 35%
and 40%, respectively, in 2004. In the European Collaborative Study (ECS), HIV-infected pregnant
women are enrolled and their infants followed-up prospectively. By the end of 2005, 5956 women
had enrolled, of whom 1912 (32%) were aged<25 years at delivery. Enrolments of youth declined in
Western European centres from 59% in 1985 to 18% in 2005. In Ukraine, youth enrolments
declined from 52% in 2001 to 43% in 2005. Median ages of the young and older sub-cohorts were
22.3 and 29.9 years, respectively. Injecting drug use (IDU) was more common in the older than
younger sub-cohorts [42% (n=1684) vs. 35% (n=675), p<0.001]. However, young IDUs were more
likely to be currently using injecting drugs than older IDUs (59% vs. 38%, p<0.001), to report cur-
rent sharing of injecting equipment (22% vs. 13%, p=0.001) and to report an IDU sex partner (59%
vs. 48%, p<0.02). Young HIV-infected pregnant women in Europe are a heterogeneous group, pos-
sibly less identifiable as being at risk of HIV infection. They will have diverse needs for services dur-
ing and after pregnancy, including harm reduction services and psychosocial support, in addition to a
universal need for prevention of mother-to-child transmission services.
Keywords: HIV, youth, injecting drug use, hetero sexual transmission, pregnancy
Introduction
Nearly half the world’s population are aged less than 25 years, and young people between
the ages of 15 and 24 years account for half of the new cases of HIV infection each year
(UNAIDS, 2006). An estimated 10 million youth (15–24 years) were living with HIV
infection by the end of 2003, of whom two-thirds lived in sub-Saharan Africa. In contrast,
an estimated 6% (or 600,000) were living in Eastern Europe and Central Asia and less than
1% in Western Europe.
Women are both biologically and socially more susceptible to acquisition of HIV than
men ( Johnson & Laga, 1988). Young women are especially vulnerable, due not only to
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their increased biological susceptibility to acquisition of infection as a result of an immature
genital tract, but also because, in many settings, the patterns of sexual networking (for
example, with young women commonly having older sexual partners) and gender inequali-
ties also put them at increased risk (UNAIDS, 2006). It is estimated that young women
worldwide aged 15–24 years are 1.6 times more likely than young men to be HIV-infected
(UNFPA, 2005).
In Western Europe, 3.5% of the 55,103 female cases of HIV infection reported to date
have been in women aged 15–19 years and 42% in those aged 20–29 years. In Eastern
Europe the HIV epidemic is more recent but has accelerated rapidly, particularly in the
Russian Federation and Ukraine (Hamers & Downs, 2003). In these settings, 19% of the
112,500 HIV infections to date in women have been in those aged 15–19 and 61% in those
aged 20–29 years (EuroHIV, 2005).
The European Collaborative Study is an ongoing prospective study of HIV-infected
women and their children. In this paper we describe the sub-group of young, pregnant
HIV-infected women aged<25 years enrolling in the study, noting trends over time and
geographic patterns with regard to their sociodemographic, obstetric and HIV-disease
related characteristics.
Methods
The European Collaborative Study (ECS) is a cohort study, in which HIV-infected women
are identified during pregnancy and their infants followed prospectively according to stand-
ard clinical and laboratory protocols (European Collaborative Study, 2005). The ECS was
set up in 1985 and includes 33 centres from 10 European countries (Spain, Italy, the
United Kingdom, Germany, Belgium, Sweden, the Netherlands, Poland, Denmark and
Ukraine).
HIV-infected women identified in pregnancy are invited to participate in the study, with
informed consent obtained; pregnant women already known to be HIV infected as the res-
ult of earlier testing are also invited to take part. Local ethical approval has been granted.
Information collected at enrolment and during pregnancy includes sociodemographic char-
acteristics, obstetric history, mode of acquisition of HIV infection and injecting drug use
(IDU) history.
Women aged less than 25 years by the time of delivery of their infant were considered as
‘youth’, according to the current UNAIDS definition of youth as those people falling
between the ages of 15 and 24 years inclusive (www.unaids.org/youth). The small number of
pregnant adolescents enrolled in the study aged<15 years were considered together with the
youth sub-group. All other women (i.e. those aged 25 years or more at delivery of their
infants) were classified as the older sub-cohort, and used in specific comparative analyses.
IDU was determined by self-report, the presence of drug withdrawal symptoms in the
neonate and clinical observation; toxicology screening was not carried out. Women enrolling
in Ukraine were classed as living in Eastern Europe and the remaining women were classified
as living in Western Europe (including the 2% of women enrolled in the Polish centres).
Statistical analysis
Univariable comparisons were assessed with the χ2 test for categorical variables. Univaria-
ble and multivariable logistic regression analysis was used to obtain unadjusted and
adjusted odds ratios (OR) and 95% confidence intervals (CI). Data entry was carried out
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using Microsoft Access 2000 and analyses using SAS statistical software (version 9.01, SAS
Institute, Cary, NC, USA).
Results
Trends in enrolment of youth over time
By the end of December 2005, 5956 HIV-infected women had enrolled in the ECS, 1912
(32%) of whom were aged<25 years at the time of delivery. Median ages of the young and
older sub-cohorts were 22.3 years and 29.9 years, respectively. The proportion of young
women aged<25 years enrolling in the study declined substantially in the Western Euro-
pean centres over the study period (Figure 1), from nearly 60% in 1985 to a plateau of 12–
14% in 1999–2002; however, since then the proportion of young women enrolling began to
increase, reaching just under a fifth of enrolments in 2005. In the centres in Ukraine, the
rate of youth enrolments gradually declined since enrolments began in 2000, but the abso-
lute level was substantially higher than that in the Western European centres, at around
40–50% of total enrolments.
Characteristics of young sub-cohort
Most (1646, 86%) of the younger cohort were white, 209 (11%) were black (186 of whom
were born in Africa) and 29 (3%) of other ethnic groups. Just over half the youth sub-
cohort (1111, 58%) were living in Western Europe and 801 (42%) in Ukraine, whereas a
greater proportion of the older sub-cohort lived in Western Europe 78% (n=3078,
χ2=211.6, p<0.001). Figure 2 shows the most likely mode of acquisition of HIV infection
of 1481 women with identified transmission risk factors. The remaining 431 women
Figure 1. Trends over time in enrolment of youth (as a percentage of total new enrolments in the cohort), by geo-
graphic area.
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reported no specific risk factors for acquisition of HIV infection – they did not report cur-
rent or past use of injecting drugs, having an IDU or other high-risk sexual partner, blood
transfusions or any other sexual risk (e.g. multiple sex partners or origin from an area where
heterosexual transmission is common); most (95%, 409) of this group of young women
were living in Ukraine, were married or cohabiting (88%, 395) and had never been preg-
nant previously (59%, 255).
Injecting drug use
There were 675 (35%) women with a history of or current IDU in the young sub-cohort
(540 in Western Europe and 135 in Ukraine), significantly fewer than in the older sub-
cohort (42%, n=1684, χ2=21.8, p<0.001). However, young IDUs had substantially more
risky behaviours than older IDUs, with a higher proportion injecting illicit drugs in the cur-
rent pregnancy [59% (273/460) vs. 38% (476/1251), χ2=62.0, p<0.001] and reporting an
IDU sex partner [59% (354/605) vs. 48% (736/1525), χ2=18.2, p<0.001]. Of those cur-
rently using injecting drugs at enrolment, younger women were significantly more likely to
report sharing injecting equipment than older women [22% (59/273) vs. 13% (64/467),
p=0.001]. Among 288 young IDUs who were using injecting drugs at enrolment, having
an IDU sex partner and not being married or cohabiting were significantly associated with
an increased likelihood of sharing injecting equipment in the current pregnancy, while
knowledge of HIV status before the current pregnancy was protective against this high-risk
behaviour with borderline significance (Table I).
The proportion of young women with current or past IDU has declined significantly over
the study period in the Western European centres, from 74% (245/396) in 1985–1989, to
48% (162/336) in 1990–1994, 26% (48/188) in 1995–1999 and 14% (37/257) in 2000–
2005 (p<0.05). The prevalence of risky sexual behaviour among young IDU women in
Western Europe was relatively stable over the study period, with 58% (142/245) reporting
an IDU sex partner in 1985–1989 and 54% (20/37) in 2000–2005. However, the preva-
lence of sharing injecting equipment declined from 30% (34/113) to 11% (1/9) in the same
time period among the sub-group with current use in pregnancy and information available.
In the Ukraine centres, where enrolment started in 2000, 20 (43%) of the 47 young women
currently using injecting drugs reported sharing injecting equipment.
Figure 2. Most likely mode of acquisition of HIV infection in 1481 young women with identified risk factors.
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Non-IDU youth with identified sexual risk factors
There were 789 young women without a history of IDU who had sexual risk factors for
acquisition of HIV infection (Figure 2). A total of 185 (23%) were refugees or migrants
from Africa (primarily sub-Saharan Africa); origin in Africa was considered a risk factor for
acquisition of HIV infection, although no information was available on when these women
arrived in Europe from Africa. Of the remaining 604 women, the most common risk factor
was having an IDU sexual partner (399, 66%).
Identification in relation to pregnancy
Overall, young women were less likely to know of their HIV infection status before preg-
nancy than older women [31% (599/1912) vs. 53% (2143/4044), χ2=244.6, p<0.001],
with the majority of youth identified through testing during pregnancy (n=1083) or intra-
partum (n=230). This age-related finding applied within risk groups; for example, 46%
(308/675) of IDU youth had been diagnosed before pregnancy compared with 78% (1097/
1683) of older drug-using women (χ2=76.4, p<0.001) and among the African-born
women, 28% (52/184) of the young women knew of their infection before pregnancy vs.
48% (336/707) of those older (χ2=22.0, p<0.001). However, in the case of IDUs, this
association was confounded by the increasing trend towards earlier diagnosis over time,
and since 2000, 84% (36/43) of young IDUs in Western Europe have been aware of their
infection before becoming pregnant.
Within the youth sub-cohort, IDUs were nearly twice as likely to have received their HIV
diagnosis before their pregnancy as non-IDUs [46% (308/675) vs. 24% (284/1191),
χ2=94.3, p<0.001]. However, this association was only of borderline significance among
the sub-group of Ukrainian women [24% (32/135) vs. 17% (107/638), χ2=3.63,
p=0.057]. Among the young women without an IDU history, the likelihood of knowledge
of HIV status before the current pregnancy varied between groups. For example, 34%
(125/371) of non-African women living in Western Europe knew of their HIV status before
their pregnancy compared with only 17% (107/638) of non-IDU women in Ukraine.
Discussion
The proportion of young HIV-infected women enrolling in the Western European centres
of the ECS has declined over time. As only pregnant women are eligible to enrol, this may
partly reflect the ageing of the antenatal population in Europe over the study duration
Table I. Risk factors for sharing injecting equipment in young IDU women.
% Sharing OR (95% CI) AOR [95% CI], p value
Timing of HIV diagnosis
During pregnancy/at delivery 24% (41/173) 1.00 1.00
Before pregnancy 14% (16/115) 0.54 (0.29–10.01) 0.53 (0.27–10.1), 0.054
IDU sex partner
Never 9% (7/75) 1.00 1.00
Ever 23% (50/213) 3.00 (1.30–6.95) 2.73 (1.16–6.38), 0.02
Marital status
Married or cohabiting 15% (27/178) 1.00 1.00
Single or divorced 27% (30/110) 2.20 (1.23–3.93) 2.12 (1.16–3.87), 0.01
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(Goldstein et al., 2003). In Ukraine, the proportion of youth enrolments is substantially
higher than in study centres in Western Europe, at just under a half of total enrolments;
this is due most probably to the HIV epidemic in Ukraine predominantly affecting youth,
with 80% of reported HIV infections among individuals aged less than 30 years, twice that
in Western Europe (UNAIDS 2004), in addition to the younger age at initiation of child-
bearing in Ukraine (Goldberg et al., 2001).
In our cohort, just over a third of young HIV-infected women enrolling were past or cur-
rent IDUs, with most of these women enrolled in the earlier years of the study. Our finding
that young IDUs were more likely to report risky behaviours than older IDUs appears to
reflect partly their timing of enrolment, as more young IDUs were enrolled at a time when
such behaviours were more prevalent, prior to the implementation of harm reduction activ-
ities in Western Europe, including needle and syringe exchanges, voluntary counselling and
testing (VCT), drug substitution programmes and outreach education (Des Jarlais &
Friedman, 1988; Hunter et al., 2000; Amundsen et al., 2003). However, other studies have
identified youth as being particularly vulnerable to risk-taking behaviours in relation to
both sex and injecting drug use (Fennema et al., 1997; Herlitz & Ramstedt, 2005; Krall
et al., 2000; Smith et al., 2005). O’Connell and colleagues reported that being female,
being young and having fewer years experience of injecting drugs were significantly associ-
ated with requiring help with injecting, which itself was an independent predictor of HIV
seroconversion (O’Connell et al., 2005). Among the IDU youth here, sharing of injecting
equipment has declined substantially over time in Western Europe, indicating that harm
reduction messages have reached at least some of this group of young women and their
injecting partners. It was more difficult to investigate trends in Ukraine, as enrolment has
been over a shorter period.
Among the young IDUs in this study, those most vulnerable to risky injecting behaviour,
as indicated by current injecting equipment sharing, were those unaware of their HIV
infection status before pregnancy, those having sex with other IDUs and those who were
single. There is evidence from elsewhere that IDUs who are aware of their HIV status have
less risky injecting behaviours than other IDUs, which is consistent with our finding (Wood
et al., 2001). There is increasing evidence of gender differences with regard to risk behav-
iours among IDUs, for example, with women more likely to share injecting equipment than
men, more likely to need help injecting and more likely to have multiple sexual partners as
a result of exchanging sex for drugs or money to buy drugs (Kyrychenko & Polonets, 2005;
Montgomery et al., 2002; O’Connell et al., 2005); these findings indicated that gender-
specific strategies for harm reduction may be appropriate and possibly more effective than
other approaches.
Being the sexual partner of an IDU and not consistently using condoms are well-recog-
nized risk factors for sexual acquisition of HIV, and compounds the existing risk of
parenteral acquisition in women who themselves inject drugs (Estebanez et al., 2000; Wilson
et al., 1999). Here, the proportion of young IDU women who had sexual partners who also
injected drugs remained relatively stable over time. We did not collect information on sex-
ual practices, including condom use, but the fact that this is a cohort of pregnant women
indicates that unprotected sexual intercourse has occurred. Other research has indicated
that sexual risk-taking among IDUs is often more resistant to change than injecting behav-
iours (White et al., 1993) and given the reported reductions in injection equipment-sharing
here, it could be hypothesized that young IDUs in the more recent years of the study were
more likely to have acquired infection sexually than parenterally. These findings reiterate
the importance of delivering harm reduction messages to young IDUs that encompass both
sexual and injecting behaviours.
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The role and impact of ‘bridging populations’ between high-risk groups such as IDUs
and sex workers and the general population is critical in the evolution of HIV epidemics
(WHO/UNAIDS, 2000). In our study population, the impact of IDU on the acquisition of
HIV was considerable among young women with no IDU history as a result of sexual con-
tact with male IDU; for example, two-thirds of non-African, non-IDU women here
reported having an IDU partner. We found that young women who were sexual partners of
IDUs but who did not inject drugs themselves were no more likely to know of their HIV
status before pregnancy than non-IDU women who did not report an IDU sex partner.
This could be interpreted in a number of ways – for example, the former group may not
have known that having sexual intercourse with an IDU put them at risk of HIV infection
and had therefore not sought HIV testing previously; alternatively, they may not have
accessed VCT services, despite an appreciation of the risk, for a variety of personal and/or
structural reasons.
There is evidence to show that consistent condom use by IDUs is usually less common
with their primary sexual partners than with casual sexual partners (Rosengard et al.,
2004), and thus women with IDU sex partners are at risk from IDUs’ risk behaviour with
both sexual and injecting partners. In a nested study within the ECS, investigating the
prevalence of and risk factors for sexually transmitted infections, HIV-infected pregnant
women who reported having had an IDU sex partner were at a three-times increased risk of
bacterial sexually transmitted infections (STIs) than those with no previous sexual contact
with an IDU (European Collaborative Study, 2006).
Nearly a quarter of young women in our study did not report any specific risk factors for
HIV acquisition, most of whom were living in Ukraine. Most women probably acquired
infection heterosexually through unprotected sexual intercourse with casual or regular part-
ners, including their husbands (88% were married or cohabiting), but were unaware that
they had been exposed to HIV. Although social desirability bias may have resulted in some
under-reporting of risk factors, our finding is consistent with the rapidly evolving epidemic
in Ukraine and the shift towards a generalized epidemic with at least 1% of the population
estimated to be HIV infected, with most infections concentrated in the youngest age groups
(UNAIDS, 2004); furthermore, 48% of new HIV infections in women in Eastern Europe
in 2004 reported to the European Centre for the Epidemiological Monitoring of HIV/
AIDS were in the ‘other/undetermined’ category (EuroHIV, 2005).
Regarding the timing of identification of HIV infection, our results are reassuring with
regard to young IDUs enrolling in Western Europe. Although initial findings indicated that
young IDUs were less likely to know their HIV status than older IDUs, over time there was
an improvement in ascertainment of infection status among all IDUs regardless of age.
This suggests that access to VCT in the group of drug-using young women is relatively
good (although the observation is limited by a relatively small sample size). Knowledge of
HIV infection status prior to pregnancy among IDU youth in Ukraine was substantially
lower than in the Western European centres, with only 25% of IDUs enrolling since 2000
diagnosed prior to pregnancy; scaling-up VCT in Ukraine, particularly among vulnerable
groups, is a priority of the Ukraine HIV programme.
UNAIDS has called for an intensification of HIV prevention worldwide, with a focus on
prevention among young people one of the essential programmatic actions required
(UNAIDS, 2005). This is in line with the UN General Assembly Special Session on HIV/
AIDS youth-specific targets, including to ensure that by 2005 at least 90% by 2005, and by
2010 at least 95% of young men and women aged 15–24 have access to the information,
education and services necessary to develop the life skills required to reduce their vulnera-
bility to HIV infection. Our results not only highlight the need for primary prevention and
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harm reduction services targeted at youth already using injecting drugs and those at risk at
initiating IDU, but also at other groups with high-risk sexual behaviours. Young HIV-
infected pregnant women in Europe, and those vulnerable to acquisition of HIV as a result
of their own behaviour and that of their partners, are a relatively heterogeneous group and
will have diverse needs for services during and after pregnancy, including harm reduction
services and psychosocial support, in addition to a universal need for services for preven-
tion of mother-to-child transmission of HIV infection.
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CHAPTER 3. 
TOXOPLASMA GONDII INFECTION 
3.1. Scientific background: toxoplasmosis in pregnancy 
Toxoplasma gondii is a common parasitic infection acquired by ingesting 
oocysts excreted by cats and contaminating soil or water, or by eating tissue 
cysts which remain viable in undercooked meat of infected animals (1). The 
life cycle of T. gondii cysts consists of two stages asexual and sexual: the asex-
ual takes place in the intermediate hosts (mammals and birds), the sexual stage 
takes place in the intestine of the definitive host (members of feline family, 
predominantly domestic cats).  
T. gondii has been shown to migrate over long distances in the host’s body; 
crossing biological barriers, actively enter the blood stream, invade cells and 
cross substrates and non-permissive biological sites such as the placenta.  
Clinical manifestations and severity of illness following infection are af-
fected by features of the interaction between the parasite and the host and in-
clude strain virulence, inoculum size, route of infections, competence of the of 
the host’s immune response, integrity of the host’s mucosal and epithelial bar-
riers, host’s age and genetic background. In particular genetic background 
plays a significant role in increasing susceptibility to T. gondii in humans: for 
example HLA-DQ3 appears to be more frequently associated with toxoplasma-
dependent encephalitis. Thus in this area, further research is mandatory to clear 
the role of genes on foetal susceptibility to intrauterine infection (2).  
The rates of positive seroprevalence in women at child-bearing age in the pe-
riod 1990-2000 were 58% in Central European countries, 51-72% in several 
Latin-American countries and 54-77% in West  African countries (3). Low se-
roprevalence, 4-39%, was reported in southwest Asia, Chine and Korea as well 
as in cold climate areas as Scandinavian countries. It should be noted that sero-
positive prevalence in the same country may differ among populations or geo-
graphical regions. 
Congenital toxoplasmosis 
Congenital infection occurs only when a woman becomes infected during 
pregnancy. The prevalence of T. gondii and its incidence of human infection 
vary widely amongst various countries. Worldwide, 3-8 infants per 1000 live 
births are infected in utero. Multiple factors are associated with the occurrence 
of congenital toxoplasmosis (CT) infection, including route of transmission, 
climate, cultural behaviour, eating habits and hygienic standards. This combi-
nation leads to marked differences even among developed nations.  
Only a few cases of CT transmitted by mother who were infected prior to 
conception have actually been reported (4-6). Such cases could be attributed to 
re-infection with a different, more virulent strain or by reactivation of a chronic 
disease.  
Chronically infected women, who are immunodeficient, may also transmit 
the infection to their foetuses; the risk of this occurrence is difficult to quantify, 
but it is probably low. Latent T. gondii infection may be reactivated in immu-
nodeficient individuals (such as HIV-infected women) and result in MTFT of 
the parasite.  
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The risk of foetal infection is multifactorial, depending on the time of mater-
nal infection, immunological competence of the mother during parasitemia, 
parasite load and strain’s virulence (3). The probability of foetal infection is 
only 1% when primary maternal infection occurs during the preconception pe-
riod but increases as pregnancy progresses; infection acquired during the first 
trimester by women not treated with anti-T. gondii drugs results in congenital 
infection in 10 to 25% of cases. For infections occurring during the second and 
third trimesters, the incidence of foetal infection ranges between 30–54% and 
60–65%, respectively (7). The consequences are more severe when foetal in-
fection occurs in early stages of pregnancy, when it can cause miscarriage 
(natural abortion or death occurs in 10% of pregnancies infected with T. gondii 
(8), severe disease, intra-uterine growth retardation or premature birth. The 
likelihood of clinical symptoms in the newborn is reduced when infection oc-
curs later. Clinical manifestations in newborns with congenital toxoplasmosis 
vary and can develop at different times before and after birth. Most newborns 
infected with T. gondii are asymptomatic at birth (70–90%). When clinical 
manifestations are present they are mainly non-specific and may include: a 
maculopapular rash, generalized lymphadenopathy, hepatomegaly, 
splenomegaly, hyperbilirubinemia, anemia and thrombocytopenia (9). The clas-
sic triad of chorioretinitis, intracranial calcifications and hydrocephalus is 
found in fewer than10% of infected infants. The most prevalent consequence of 
congenital toxoplasmosis is chorioretinitis. Late-onset retinal lesions and re-
lapse can occur many years after birth (8), but the overall ocular prognosis of 
congenital toxoplasmosis seems satisfactory, when infection is identified early 
and appropriately treated. Early diagnosis and treatment are believed to reduce 
the risk of visual impairment.  
Overall most children with CT are developmentally normal but up to four per 
cent die or have evidence of permanent neurological damage or bilateral visual 
impairment during the first years of age with a wide spectrum of clinical dis-
eases (8,10).  
Maternal serology 
Toxoplasma infection in immunocompetent adults is usually asymptomatic. 
Consequently, infected mothers can only be detected by serological testing. 
Prenatal testing for toxoplasmosis involves testing of women with undetectable 
antibodies at their first visit. To detect infection early in pregnancy, women 
who are IgG and IgM positive at their first prenatal test undergo further tests 
(e.g. for high or rising IgG or low IgG Avidity). None of these tests reliably de-
termines the timing of infection and most women identified will have acquired 
infection prior to conception and hence are unlikely to transmit the infection to 
the foetus. When serology alone is insufficient, other evidence for toxoplasma 
infection should be sought. Replacing foetal blood analysis, which is a high 
risk procedure for the foetus, with molecular evaluation of amniotic fluid has 
provided a low risk diagnosis of congenital toxoplasmosis. Polymerase chain 
reaction (PCR) is currently the most common molecular technique routinely 
used for diagnosis of toxoplasmosis, although, it has not yet been standardized. 
The most popular target gene for PCR diagnosis of T. gondii is the 35-fold re-
petitive gene B1. Different protocols influence the sensitivity and specificity of 
PCR assays. The specificity and positive predictive value of PCR tests on am-
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niotic fluid samples is close to 100% (11,12). However, the sensitivity of these 
PCR tests varies and estimated, based on a large number of studies, to be 70–
80%. One report showed that the sensitivity of PCR from amniotic fluid is af-
fected by the stage of pregnancy in which maternal infection occurs: best sensi-
tivity was detected when maternal infection occurred between 17 and 21 weeks 
of pregnancy (11-14). In addition, treatment with anti-toxoplasma drugs may 
also affect the sensitivity. However, the reliability of a PCR test performed on 
amniotic fluid prior to the 18th week of pregnancy requires further evaluation. 
It should also be noted, that testing amniotic fluid for T. gondii was found to be 
effective about 4 weeks following infection, which is already during the para-
sitemic stage in the infected mother. Therefore, PCR test should not be per-
formed in the absence of serologic or other clinical/sonographic data indicative 
of infection. 
Treatment 
Anti T. gondii treatment initiation generally requires confirmatory laboratory 
tests in a reference centre, followed by consultation with experts. 
Once maternal infection has been confirmed, treatment with spiramycin is 
prescribed to reduce the risk of MTCT, the woman is referred for amniocente-
sis for foetal diagnosis and, if foetal infection has occurred, treatment with 
pyrimethamine-sulfadiazine combination is prescribed to reduce impairment in 
the child.  
Spiramycin is used to prevent placental infection; it is used in many Euro-
pean countries as Italy but in the US it is currently not approved by the FDA. 
The combination of pyrimethamine, (adult dosage 25–100 mg/d×3–4 weeks), 
sulfadiazine adult dosage 1–1.5 g qid×3–4 weeks) and folinic acid (leucovorin, 
10–25 mg with each dose of pyrimethamine, to avoid bone marrow suppres-
sion) is the basic treatment protocol recommended by the WHO (15) and CDC 
(16). 
Treatment with pyrimethamine and sulfadiazine to prevent foetal infection is 
contraindicated during the first trimester of pregnancy due to concerns regard-
ing teratogenicity, except when the mother’s health is seriously endangered. 
During the first trimester sulfadiazine can be used alone. 
As recently reviewed by Montoya and Liesenfeld (14), treatment protocols 
vary among different centres. The effectively of anti-T. gondii treatment is 
evaluated based on two criteria: rate of mother to child transmission and preva-
lence and severity of sequel. The majority of the studies are retrospective or 
cohort studies of various populations and case definitions. The difference in 
study patterns and methodologies affects the reliability and validity of the re-
sults and thus prevents issuing further recommendations. 
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3.2. Our Experience: Materials and methods  
• Type of study: This is a prospective cohort study; 
• Inclusion criteria: pregnant women with suspected infection by 
Toxoplasma gondii are enrolled and followed up; 
• Data collection for pregnant women: Each pregnant woman enrolled in 
the study is assigned a unique coded serial number and this number is used 
to follow her and her child anonymously. Clinical and laboratory informa-
tion is collected from enrolled women and during pregnancy; the amount of 
follow-up information depending on the trimester at which the women were 
enrolled and the number of routine visits they underwent during pregnancy. 
Initial information collected includes mother’s full obstetric history, marital 
status, ethnic group, likely route Toxoplasma infection (eating raw or under-
cooked meat, contact with soil etc. ), treatment details. Clinical and ultra-
sonographyc information (biometry, Doppler velocimentry, nuchal translu-
cency) information is collected during pregnancy as well as every complica-
tion during pregnancy or after delivery. Serum samples from all pregnant 
women referred to our Department for suspected toxoplasma infection were 
submitted for confirmatory testing from outside sources to our laboratory. 
Confirmatory serologic testing includes IgG and IgM enxyme-linked immu-
nosorbent assay (ELISA) and IgG Avidity test. Results of the toxoplasma 
serologic profile help to distinguish recently acquired infections, termed re-
cent infection, from those acquired in the more distant past, termed distant 
infection. Toxoplasma serologic profile results, the gestational age of the pa-
tient and the results of previous serologic testing, when available, are rou-
tinely used to assess whether infection was acquired during pregnancy. 
When the toxoplasma serologic profile suggests an infection acquired during 
pregnancy, treatment with spiramycin is recommended. To establish 
whether the foetus is infected we recommended PCR examination of amni-
otic fluid at 18 weeks gestation or more and always after at least 4 weeks 
form maternal infection. When amniocentesis is positive for T. gondii or the 
parents refuses the invasive prenatal diagnosis, we recommend 
pyrimethamine -sulfadiazine treatment. Delivery information includes gesta-
tional age in completed weeks, birthweight in grams, the administration of 
therapy during pregnancy including type of therapy and dose, mode of de-
livery and perinatal problems. Each child is followed-up by a specific team 
of paediatricians up to 12 months of age and documents the child’s care and 
treatment as well as their clinical status and evidence of disease progression. 
If the foetus is judged infected, he will be followed up as long as possible 
according to parents compliance. 
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3.3. The effectiveness of the screening 
There are two principal motivations for maternal screening and diagnosis of 
foetal infection with toxoplasmosis. The first objective is to provide clinicians 
with information that would allow them to make optimal decisions regarding 
treatment. Specifically, repeated screening of pregnant women has been used as 
a strategy to allow early diagnosis of maternal infection. An early detection of 
maternal infection and prenatal diagnosis of congenital infection is also advo-
cated for making a more optimal choice of the medications.  
The second objective of prenatal testing is to provide women with the oppor-
tunity for making an informed decision regarding their pregnancy. Women can 
make informed decision with respect to pregnancy termination if foetal infec-
tion is confirmed and/or the foetus is found to have significant anomalies on ul-
trasound scan. 
However there is no consensus about the most effective screening strategy or 
the best type of treatment. Uncertainty about the benefits of prenatal treatment  
(17-18) and concerns about adverse treatment effects and costs required to pre-
natal screening have led to diverse policies including no screening (19-20) neo-
natal screening and prenatal screening with monthly or 3-monthly re-testing 
scheduled. 
So far, some authors have evaluated the effected of prenatal treatment on 
mother to child transmission. Wallon et al.(17) reviewed studies comparing 
treated and untreated concurrent groups of pregnant women with proved or 
likely acute toxoplasma infection. The results showed treatment to be effective 
in five studies but ineffective in four. Gras et al.(21) reported that the effect of 
prenatal pyrimethamine–sulfadiazine combination treatment on the cerebral 
and ocular sequelae of intrauterine infection with T. gondii was not beneficial. 
Neto et al. (22) suggest that for patients with sequelae, because of the delay in 
anti-toxoplasma treatment (6–14 months post diagnosis), the disease was not 
prevented. Gilbert et al. (23) reported the effect of prenatal treatment in 554 in-
fected women and their offspring. In this study comparison of early versus late 
treatment and of combination treatment (pyrimethamine, sulfadiazine) with spi-
ramycin or no-treatment, were all statistically insignificant. Another European 
multicenter study comparing transmission rates and clinical outcomes in 856 
mother–infant pairs, found no significant association between the outcome and 
the intensity of treatment protocol in pregnancy (24). In the same way a sys-
tematic review of cohort studies based on universal screening for congenital 
toxoplasmosis found that among 1438 mothers and 550 infected infants there 
was no evidence that prenatal treatment significantly reduced the risk of clini-
cal manifestations (25). 
Bessieres et al (26) found that cases could be identified during pregnancy as 
well as during the neonatal period. Foulon et al (27) reviewed the measures of 
prevention of congenital toxoplasmosis and concluded that treatment during 
pregnancy significantly reduces sequelae and treatment of infected children has 
a beneficial effect when therapy is begun soon after birth. 
In conclusion, the efficacy of anti-T. gondii treatment in pregnancy is still an 
unsettled matter. It is difficult to find the effect of treatment when comparing 
the different studies because of: different treatment regimes and timing (for 
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small groups of patients), the pharmacokinetics patterns of drugs (concentration 
in amniotic fluid and foetal CSF), patient compliance with treatment and differ-
ent methodologies of follow-up in each study. 
Notwithstanding these uncertainties, there are many potential risks and psy-
chological costs associated with prenatal screening and diagnosis for CT. The 
possible psychological consequences include parental anxiety due to both false 
positive results and the uncertainties related to the prognosis of children with 
prenatal diagnosis of CT. False positive results are likely to have negative psy-
chological repercussions even after the birth of an unaffected child. Moreover, 
true positive results in unaffected or mildly affected children may also consti-
tute a source of long-term anxiety and parental concern. 
Whatever may be the benefits of screening for maternal toxoplasmosis is dis-
cussed in the above letter published in an international journal. 
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Author’s reply
Although many of the panellists in 
our study have extensive experience 
with older patients in many diﬀ erent 
settings (eg, emergency, surgery, 
medicine, oncology, rehabilitation, and 
physical therapy), none was speciﬁ cally 
a geriatrician, as Marianne Falconer 
and Desmond O’Neill point out.
The issue of assigning priority in 
terms of support for activities of daily 
living was discussed in great detail. 
Although perhaps more pervasive 
among older people, this issue, of 
course, is not restricted to them. It is of 
similar concern to almost all acutely ill 
patients, irrespective of baseline health 
or abilities. Thus the need to consider 
debility and provision of support for 
activities of daily living outside the 
hospital setting in the event of early 
discharge is independent of age.
Certainly, the panellists did not 
imply that support for activities of 
daily living is not important. However, 
one of the underlying assumptions, as 
detailed in our report, was that basic 
care would exist for those discharged 
to the community, and that such 
support would therefore be met in 
other settings. This tempered the 
assigned priority, since withdrawal of 
hospital-based support for activities 
of daily living was not, in itself, felt to 
result in an adverse medical outcome 
requiring a critical intervention.
In the next phase of the study, we 
will have the ability to determine 
whether the panellists’ assigned 
priorities for all critical interventions 
were reasonably accurate, by means of 
empirically derived data.
I declare that I have no conﬂ ict of interest.
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Patient safety and 
patient error: the carer’s 
perspective
In their Viewpoint on patient safety and 
patient error (Jan 13, p 158),1 Stephen 
Buetow and Glyn Elwyn mention 
carers (caregivers) only in their opening 
paragraph. Although patient error has 
received some attention in published 
studies, the relevant activities and 
experiences of carers have almost 
totally been ignored. The contribution 
of carers to health care in the UK has 
been valued at £57·4 million annually2 
and medicine-related tasks have 
been shown to be an integral part of 
the wider caring role with their own 
associated carer-burden.3 
Carers can undertake a wide range 
of medicine-related activities, each 
of which presents its own potential 
for error:4 monitoring supplies 
and ordering repeat prescriptions; 
assisting with administration of 
complex regimens, frequent dosing, 
and multiple forms of dosage and 
administration; and “clinical roles”, 
including advising on as-needed and 
regular medicines and management 
of side-eﬀ ects, for which they might 
have limited access to, and problems 
interpreting, information. 
Carers operate in a partnership 
with their care-recipient5 and oft-
en other carers. When diﬀ ering 
perspectives regarding the risks, 
beneﬁ ts, and value of medicines 
arise, this will aﬀ ect the medicine-
related behaviours of carers and care-
recipients—eg, dilemmas relating 
to the sharing or concealment of 
information or their control. The 
relationship between the patient and 
health professional, and issues of 
conﬁ dentiality and autonomy, take 
on a further dimension when carers 
are included, since patients and 
carers have their own independent 
needs and agendas.
A conceptually valid model or tax-
onomy of patient error must embody 
the dimensions and eﬀ ect of caring.
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Screening for 
toxoplasmosis in 
pregnancy
The Syrocot Study Group (Jan 13, 
p 115)1 states that it is unclear whether 
prenatal antitoxoplasma treatment 
has any beneﬁ t. This result needs 
urgent conﬁ rmation since it poses the 
basis for a radical change in prenatal 
management.
Although some researchers have 
raised doubts about the eﬀ ect of 
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prenatal treatment for toxoplasma 
infection,2 there has never been a 
deﬁ nitive consensus. Nevertheless, 
mass screening for toxoplasmosis 
is mandatory in some European 
countries, including Italy, with a 
consequent “cost” to both the public 
and patients. In theory, screening can 
only be done if there is a reliable and 
valid test to detect the disease in its 
preclinical stage and if advantages of 
interventions are clear.3 But there is 
evidence that serological screening in 
pregnancy is not reliable.4,5 
Between 1995 and 2006, 
542 mother-child pairs were counselled 
in our department for suspected 
toxoplasmosis. Repetition of serology 
and reinterpretation of the serological 
proﬁ le (of all previous results) revealed 
a false-positive rate of 90% obtained in 
previous IgM tests and a seroconversion 
rate of 12% (63/542). 
The rationale behind the decision 
to continue screening was that 
beneﬁ ts to the fetus outweigh the 
consequences of a false-positive 
result (anxiety, invasive prenatal 
diagnosis, treatment of uninfected 
women). However, given the 
uncertainty about the beneﬁ ts of 
prenatal treatment, is it ethically 
correct to carry on?
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Early child development 
in developing countries
“Finally I have data to convince 
my Minister of Finance to invest 
in early child development” repor-
ted the Minister of Women and 
Child Development, Malawi, at a 
meeting held at the Institute of
Child Health, London, UK, to 
mark The Lancet’s series on child 
development in developing countries 
(Jan 6–Jan 20).1–3
At the meeting, hosted by the 
Centre for International Health and 
Development, presenters explained 
that more than 200 million children 
younger than 5 years are not 
developing to their potential owing 
to poverty, poor health, and nutrition. 
Although eﬀ ective interventions 
are available, coverage is low. Repre-
sentatives from WHO, UNICEF, and 
the World Bank expressed a strong 
commitment to strengthening pro-
grammes and research to move the 
Lancet recommendations forward. 
Other agencies including UNESCO, 
the Bernard van Leer and Aga Khan 
Foundations, and many non-gov-
ernmental organisations explained 
how they are putting the recom-
mendations into practice.
The Lancet steering group will 
become the International Child 
Development Committee. This 
year, we plan to advocate for early 
child development programmes 
through presentations at meetings 
in Turkey, India, Spain, Venezuela, 
and Bangladesh and at the Society 
for Research in Child Development 
and the Pediatric Academic Societies. 
We will meet at the Rockefeller 
Foundation’s Bellagio Study and 
Conference Center to develop 
implementation strategies and 
establish priorities in collaboration 
with the Child Health and Nutrition 
Research Initiative. We will provide 
guidance in assessment of existing 
programmes, development of new 
models for delivering services, and 
integration of child development 
activities into health and nutrition 
services. In 2 years, we will report 
on global progress in early child 
development programmes.
The International Child Development Committee 
comprises S Grantham-McGregor, P Engle, M Black, 
M Cabral de Mello, J Meeks Gardner, B Lozoﬀ , 
N Ulkuer, T Wachs, S Walker, and M Young. I declare 
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Risk factors for adverse 
outcomes in developing 
countries
In their child development series 
article, Susan Walker and colleagues 
(Jan 13, p 145)1 cite two of our recent 
pub lications:2,3 “Two small Brazilian 
stud ies suggest an association 
between incidence of diarrhoea in 
the first 2 years of life and impaired 
cognitive performance in later 
childhood.89,90 However, a larger 
cohort study in Peru with control for 
4 Liesenfeld O, Press G, Montoya JC, et al. False-
positive results in immunoglobulin M (IgM) 
Toxoplasma antibody tests and importance of 
conﬁ rmatory testing: the Platelia Toxo IgM 
test. J Clin Microbiol 1997; 35: 174–78.
5 Roberts A, Hedman K, Luyasu V, et al. 
Multicenter evaluation of strategies for 
serodiagnosis of primary infection with 
Toxoplasma gondii. Eur J Clin Microbiol Infect Dis 
2001; 20: 467–74.
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3.5. The diagnostic procedures 
The diagnostic evaluation of T. gondii is part of routine pregnancy follow-up 
and differential diagnosis of intrauterine infection. Intrauterine ultrasono-
graphic findings of T. gondii infection are usually non-specific and in most 
cases no pathological evidences are revealed. In certain cases the ultrasono-
graphic findings may include: intracranial calcifications, echogenic streaks, mi-
crocephalus, ventricular dilatation and hydrocephalus (1). Gay-Andrieu et al 
(2) described two cases of intrauterine infection in which the diagnosis was 
based upon hydrocephalus in foetal ultrasound, even though PCR of amniotic 
fluid was negative in both cases. Additional ultrasonographic findings may in-
clude hepatomegaly, splenomegaly, ascitic fluid, cardiomegaly and placental 
abnormalities (3).  
Safadi et al (4) followed 43 children with congenital toxoplasmosis for a pe-
riod of at least 5 years. Most of them (88%) had sub-clinical presentation at 
birth. The most common neurological manifestation was a delay in neuropsy-
chomotor development. Half of the children developed neurological manifesta-
tions, 7 children had neuroradiologic alterations in skull radiography, and 33 
children in tomography. Notably, cerebral calcifications were not associated 
with an increased incidence of neurological sequelae. Chorioretinitis was the 
main ocular sequelae, found in almost all children and noted years after birth, 
despite specific therapy in the first year of life. 
Starting from our experience in foetal ultrasound, we have analysed the effi-
cacy of targeted ultrasonographic examinations to predict the effect of foetal 
infection by T. gondii. As reported above, this paper was presented as an oral 
communication at the World Congress on Ultrasound in Obstetrics and Gyne-
cology. 
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The role of targeted fetal ultrasound in women with acute toxoplasmosis in pregnancy 
Agangi, A.; Napolitano, R.; Mallia Milanes , G.; Mazzarelli, L.L.; Quaglia, F.; Paladini, D.; Martinelli, P. 
University of Naples, Federico II, Italy, Italy 
Objective: To assess the role of targeted fetal ultrasound in pregnant women with acute toxoplasmosis.  
Methods: 187 pregnant women with seroconversion or fourfold increase of IgG antibody titer for Toxoplasma 
gondii in 2 weeks represent the study population. All women underwent monthly ultrasound monitoring; 
amniocentisis was proposed for the PCR test, treatment with spiramicin or pirimetamine/sulfadiazine according to 
the risk was planned, unless the development of adverse effects of therapy. Ultrasound examinations were carried 
out by expert operators looking for lesions/ signs possibly related to fetal infection. In all cases, gestational age at 
referral, at seroconversion and at the ultrasound evidence of fetal lesions, type of maternal treatment, result of 
PCR, feto-neonatal outcome were analysed.  
Results: Prenatal ultrasound showed one or more pathological features in 7/187 (3%) cases (ventriculomegaly 
4/7; splenomegaly 2/7, intracranial calcifications 2/7). Median time to evidence of the first abnormal finding was 15 
weeks (range 2-29). In no case, was termination of pregnancy considered because of the advanced gestational age 
at ultrasonographic diagnosis. At birth, 18/187 neonates resulted infected (10%). As for the outcome, there were 
186 livebirths (1 twin), 1 intrauterine death and 1 neonatal death. In both deaths, ultrasonography had shown 
more than one sign of infection. All neonates with negative prenatal ultrasound had a normal development, all the 
remaining 5 neonates with abnormal fetal ultrasound were infected (median follow-up time 58 months, range 5 
months - 11 years).  
Conclusion: Our results demonstrate that, in fetuses at high risk of congenital infection (CT), ultrasound may have 
higher prognostic significance than amniocentesis. In fact, in this series a negative PCR could not rule out CT. In 
addition, we have confirmed the high specificity of ultrasound though the small numbers relatively reduce the 
significance of this finding.  
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CHAPTER 4 
FOETAL MALFORMATIONS: DIFFERENTIAL DIAGNOSIS 
4.1 Introduction 
Major congenital malformations occur in 2–4% of all live births. Up to 15% 
of all diagnosed pregnancies will result in foetal loss. The cause of these ad-
verse pregnancy outcomes is understood in only a minority of the incidents. In 
particular, ultrasound is commonly used during pregnancy to recognise find-
ings that may be indicative of foetal infection. If foetal infection is suspected, 
suggestive sonographic findings should be sought. Although not specific, 
common sonographic findings of foetal infection include ventriculomegaly, in-
tracranial calcification, hydranencephaly, microcephaly, cardiac anomalies, 
hepatosplenomegaly, echogenic bowel, intraabdominal calcifications, hydrops, 
placentomegaly, IUGR and abnormal amniotic fluid volume. It is important to 
note that most affected foetuses with infection appear sonographically normal. 
Although a normal anatomic survey can be reassuring, it cannot predict a nor-
mal anatomic outcome. Findings also change or resolve over time so serial 
scanning can be very important.  
The recognition of minor or major foetal anomalies is of crucial importance 
in the prenatal era because it may lead to one of the subsequent scenarios: 
1. The couple opt for pregnancy termination, 
2. The baby is delivered in a high specialized centre with specific ability for 
the disease, 
3. The baby takes advantage of intrauterine therapy or surgery, 
4. The couple go on with the pregnancy and is prepared to welcome a baby 
affected by a health problem. 
In ancient times congenital abnormalities were only apparent at birth, on the 
contrary with the advent of obstetric ultrasound the full range of foetal disease 
could be diagnosed and this led to the concept of the foetus as a patient. Over 
the last 20 years obstetric ultrasound has revolutionised the clinician’s ap-
proach to the foetus and we have learnt an enormous amount about foetal 
physiology and also the natural history of foetal malformations and foetal dis-
ease. Using this information an accurate prenatal diagnosis can be made and 
this diagnosis together with the likely prognosis can be conveyed to the par-
ents. 
For the parents the diagnosis of a foetal abnormalities is usually an unex-
pected and shattering experience. The approach to the parents is now truly mul-
tidisciplinary involving many different clinicians including obstetricians, radi-
ologists, paediatricians, paediatric surgeons and clinical geneticists. In this way 
each expert in his or her field can help to give the parents as much information 
as possible. 
It is clear therefore that obstetric ultrasound has come a long way from the 
early days of static scanners and has also introduced the possibility of foetal 
therapy. 
During the years we observed many cases of different foetal malformations. 
Some of these were not related to foetal infection but, because of their atypical 
features, were considered for publications. 
Above a select list of papers published in international journals is reported. 
 
PRENATAL DIAGNOSIS
Prenat Diagn 2006; 26: 67–70.
Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pd.1356
SHORT COMMUNICATION
Early prenatal diagnosis of concordant posterior urethral
valves in male monochorionic twins
G. M. Maruotti, A. Agangi, P. Martinelli and D. Paladini*
Prenatal Diagnosis Unit, Department of Gynecology and Obstetrics, University Federico II of Naples, Naples, Italy
The association between monozygotic twins and posterior urethral valves (PUV) in postnatal life has been
thoroughly described. In the fetus, the prenatal recognition of PUV is feasible. However, it has been repeatedly
reported in singletons but never in monochorionic twins. We describe two cases of early prenatal diagnosis of
concordant PUVs in monochorionic twins. In one of the sets, the expression of the disease was different for
each twin. Copyright  2006 John Wiley & Sons, Ltd.
KEY WORDS: posterior urethral valves; prenatal diagnosis; monochorionic twins; prune-belly syndrome
INTRODUCTION
The association between posterior urethral valves (PUV)
and monozygotic twins is well established in the pedi-
atric literature, with at least 13 cases reported so far
(Morini et al., 2002). In the fetus, both the complete
and the incomplete form of PUV can be diagnosed pre-
natally by ultrasound on the basis of a distended bladder,
severe hydronephrosis and oligohydramnios. Although
the ultrasound diagnosis of PUV has been reported as
early as the 13th week of gestation in singletons (Oga
et al., 1994), the prenatal recognition of PUV in twins
has yet to be described.
We report the early prenatal diagnosis of concordant
PUV in two sets of male monochorionic twins.
CASE REPORTS
Case 1
A 31-year-old Caucasian woman, in her first pregnancy,
was referred to our unit at 14 weeks’ gestation owing to
a suspected case of PUV in one twin of a monochorionic
diamniotic pregnancy. Family history was negative for
congenital anomalies and for twinning. On ultrasound,
we confirmed the monochorionicity of the pregnancy,
but detected anomalies in the urinary tracts of both
twins. In particular, one twin showed complete PUV: an
extremely distended and ruptured bladder with urinary
ascites (Figure 1A) and severe bilateral hydronephrosis
with hyperechoic dysplastic kidneys. In addition, the uri-
nary ascites acted as a contrast medium, enabling us to
detect the extremely reduced thickness of the abdominal
wall. The other twin was diagnosed with an apparently
*Correspondence to: D. Paladini, Via Petrarca, 72, 80122
Naples, Italy. E-mail: paladini@unina.it
less severe form of PUV: moderately distended blad-
der with evidence of the bladder neck, bladder wall
thickening, severely dysplastic hydronephrotic kidneys
(Figure 1B), and distended distal urethra (Figure 1C).
The amount of amniotic fluid was only moderately
reduced in both sacs owing to the early gestational age.
No other malformations were detected. Karyotyping by
CVS was proposed but was declined by the patient.
During the prenatal counseling session, the couple was
informed of the type of malformation and of its differ-
ent manifestation in each twin. An assessment of fetal
renal function by repeated cystocentesis was proposed
to be carried out in the least affected twin in order to
assess the renal function (Evans et al., 1991; Nicolini
and Spelzini, 2001), but the couple refused the procedure
and opted for termination of pregnancy. The pathology
report confirmed the prenatal diagnosis of PUV in both
twins (Figure 3A,B). The twin with the severest form
had developed prune-belly syndrome (PBS) (Figure 3A).
Case 2
A 35-year-old woman, gravida 2,1,0,0, was referred to
our unit at 15 weeks of gestation with a suspected case
of megacystis in both fetuses of a monochorionic di-
amniotic pregnancy. On ultrasound, both fetuses showed
signs of complete PUVs: both had severely distended
bladders with evidence of the bladder neck (Figure 2)
and hyperechoic dysplastic kidneys. These findings led
us to suspect the development of secondary PBS in
both twins. The karyotype, obtained by CVS, showed
a 46,XY complement. In this case as well, after a
thorough prenatal counseling session, the couple opted
for termination of pregnancy. The necropsy confirmed
the prenatal diagnosis of PUVs. Both the specimens at
birth showed secondary PBS (Figure 3C).
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Figure 1—Case 1. (A) shows a longitudinal view of the twin with an extreme form of posterior urethral valves: an extremely distended bladder
(Bl) and urinary ascites (Asc); note also the thin abdominal wall, consistent with the diagnosis of secondary prune-belly syndrome; (B) shows
that the other twin had severely dysplastic and hyperechoic kidneys (arrows), a moderately enlarged bladder (Bl) and (C) a distended urethra
(arrow)
Figure 2—Case 2. Three-dimensional ultrasound—VCI-C rendering.
The image shows a coronal view of both fetuses with severely dilated
bladders (Bl1 and Bl2) and severe oligohydramnios. In the upper fetus,
the lungs (L) and the heart in between are visible. In the lower fetus,
the arrow indicates a hyperechoic dysplastic kidney
DISCUSSION
PUVs represent the most common cause of severe
obstructive uropathy in children, with an incidence of
approximately 1 in 1500 to 1 in 8000 boys (Cendron
et al., 1994), and they appear to be the cause of about
9% of cases of urinary obstruction in fetuses (Elder,
1997). PUV is a sporadic disorder whose etiology
is unknown, though its association with twinning has
suggested a genetic cause. It may be related to failure of
the complete disintegration of the urogenital membrane,
which leaves membranous tissue within the posterior
urethra responsible for the obstruction of the bladder
outlet (Dinneen et al., 1993).
The prenatal ultrasound diagnosis of PUV is feasible
and has already been reported as early as the 13th
week of gestation (Sweeney et al., 1981; Dibbins et al.,
1985; Turner, 1985; Helin and Persson, 1986; Silver
et al., 1990; Oga et al., 1994; Cochat et al., 1996;
Rani et al., 1997; Cohen et al., 1998; Yerkes et al.,
2001); since the urethral obstruction is not directly
detectable through an ultrasound, the diagnosis of PUV
depends, in most instances, upon the recognition of
sonographic signs of the lower urinary tract obstruction
in a male fetus (dilated bladder, hydronephrosis and
renal dysplasia (Figures 1 and 2). Additional inconstant
findings are represented by a dilated posterior urethra
and bladder wall hypertrophy (Glazer et al., 1982;
Hayden et al., 1988). The most important prognostic
indicator is represented by the presence of a hyperechoic
kidney with cortical cysts, which is indicative of severe
renal dysplasia (Romero, 1988). The occurrence of
renal dysplasia was formerly believed to be uniquely
dependent upon the degree and length of the urinary
tract obstruction due to misexpression of the Pax-
2 gene (Edouga et al., 2001); however, this concept
has recently been partially revised and the onset of
renal dysplasia is currently considered, at least in some
instances, to be primary and synchronous with the
Copyright  2006 John Wiley & Sons, Ltd. Prenat Diagn 2006; 26: 67–70.
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Figure 3—Postmortem examination of the specimens. (A) Case 1, same twin of Figure 1A: the extreme abdominal distention is evident; in
the upper left insert, the specimen of the kidneys and the urinary tract with the extremely dilated bladder is shown; (B) Case 1, same twin of
Figure 1B: note the lesser abdominal distention in comparison with (A) and the dilated distal urethra (arrow) on the excised specimen (upper
right insert); (C) the set of twins of case 2, both showing massive abdominal distention
urinary tract obstruction owing to the misexpression of
not only the Pax-2 but also of other genes such as
Bcl2 and the transforming growth factor b1 (Winyard
et al., 1996; Yoo et al., 2000). Another prognostic factor
worth considering is certainly the amount of amnionic
fluid: an early onset and severe oligohydramnios is
a reliable indicator of impaired renal function and,
therefore, such a finding should be part of the prenatal
prognostic evaluation. However, it should be underlined
that the oligohydramnios sequence starts developing
only after 16 weeks of gestation, since until this time the
amniotic fluid is mainly produced by filtration through
the membranes, and therefore during the first 16 weeks
of pregnancy it cannot be considered as a reliable
indicator of normal renal function.
The ultrasound differential diagnosis includes other
causes of lower urinary tract dilatation, such as massive
vesico-ureteral reflux and the megacystis, microcolon
intestinal hypoperistalsis (MMIHS) syndrome (Kohler
et al., 2004). However, the amount of amniotic fluid
is severely decreased in complete PUV, normal or
moderately reduced in severe vesico-ureteral reflux and
increased in the MMH syndrome. As for the differential
diagnosis between PUV and urethral atresia, this is often
impossible though the latter instance is a great deal rarer
than PUV (Hurwitz et al., 1984).
Whether complete PUV has led to the development
of PBS, cryptorchidism and abdominal wall hypoplasia
should be detected. In fact, the triad identifying the PBS
is represented by the megacystis, cryptorchidism and
hypoplastic abdominal wall. However, cryptorchidism
can be detected only after the 32nd week of gesta-
tion when the testicles are expected to descend in the
scrotum in 97% of male fetuses (Achiron et al., 1998),
whereas the laxity and thinning of the abdominal wall
musculature are much more difficult to detect; in this
case, we could detect it in one fetus of the first set of
twins owing to the presence of the urinary ascites which
acted as a natural contrast medium (Figure 1A). There-
fore, the prenatal diagnosis of PBS may be confidently
hypothesized only in the third trimester of pregnancy.
The overall prognosis of the condition remains guarded
despite the possibility of in utero intervention by vesico-
amniotic shunting (Gnirs et al., 1988; Perez-Brayfield
et al., 2001).
The overall prevalence of structural defects is 1.2–2
times higher in fetuses from twin pregnancies compared
to singletons, with most of the excess risk due to
increased rates in monochorionic twins (Baldwin, 1994).
This is true also for PUV, whose association with
twins has repeatedly been reported in postnatal life
(Kroovand et al., 1977; Grajewski and Glassberg, 1983;
Livne et al., 1983; Romero, 1988). However, despite
this association, we were not able to find any case
of concordant PUV diagnosed prenatally in twins in
a MEDLINE search from 1966 using the key words
‘posterior urethral valve, fetus, and twins’. Hence, to
our knowledge, the present cases represent the first two
cases of concordant PUV in monochorionic twins to
be reported prenatally. Of interest is also the different
manifestation of the anomaly in each twin of the first
set: one presented with a classic PBS secondary to a full-
blown form of PUV, whereas the second one presented
with an apparently less severe form.
In conclusion, we have documented the early prenatal
diagnosis of PUV in two sets of monochorionic twins
and described the various manifestations of the disease
in the first set of twins. This latter finding should be
considered when assessing monochorionic twins with
one affected fetus, for the involvement of the other
Copyright  2006 John Wiley & Sons, Ltd. Prenat Diagn 2006; 26: 67–70.
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twin may be subtle and escape ultrasound diagnosis if a
detailed examination is not performed.
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CASE REPORT
Split notochord syndrome variant: prenatal findings and
neonatal management
A. Agangi1, D. Paladini1*, P. Bagolan2, G. M. Maruotti1 and P. Martinelli1
1Prenatal Diagnosis Unit, Department of Gynecology and Obstetrics, University Federico II of Naples, Naples, Italy
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Spilt notochord syndrome is an extremely rare form of spinal dysraphism characterized by a complete cleft
of the spine and a persistent communication between endoderm and ectoderm. A variant of split notochord
syndrome was diagnosed in a 25-week-old fetus showing a prolapsed congenital colostomy and a spinal cystic
lesion. The final diagnosis included protruding colon segment, imperforate anus with a rectourethral fistula and
lipomyelomeningocele. The ultrasound features of the condition and the post-natal management are discussed.
The neonate was successfully treated with a posterior sagittal anorectoplasty, while the lipomyelomeningocele
was resected at a later stage. Copyright  2005 John Wiley & Sons, Ltd.
KEY WORDS: split notochord syndrome; prenatal diagnosis; congenital colostomy; dorsal enteric fistula;
lipomyelomeningocele
INTRODUCTION
Split notochord syndrome (SNS) represents an extremely
rare and pleomorphic form of spinal dysraphism charac-
terized by a wide spinal defect and a persistent com-
munication between endoderm and ectoderm (Almog
et al., 2001, Gilbert-Barness and Luise, 1997). In its
basic form, it consists of a neural tube defect with an
endoectodermal fistula opening in the dorsal area, but
several variants differing for the type and the site of
the associated anomalies, which involve the gastroin-
testinal tract, the central nervous system (CNS) and,
less often, the urogenital tract have been described
by pediatric surgeons and neonatologist (Faris and
Crowe, 1975; Flower, 1998). Owing to its pleomor-
phism, this condition has rarely been identified prena-
tally, with only two cases reported in the last 20 years
(Almog et al., 2001). We present here the prenatal
findings leading to the putative diagnosis of SNS
and the post-natal surgical management of this condi-
tion.
CASE REPORT
A 29-year-old obese woman, gravida 2 para 0, was
referred to our centre at 25 weeks of gestation with
a suspicion of a neural tube defect involving the dis-
tal part of the sacrum. The family history was unre-
markable, with no consanguinity reported. The trans-
abdominal ultrasound examination showed a small round
hypoechoic apparently cystic mass involving the lower
*Correspondence to: D. Paladini, Via Petrarca, 72 80122—
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part of the sacrum and an oblongated perineal structure
closely resembling an intestinal loop, possibly originat-
ing from the lateral perineal region. None of the cere-
bellar and ventricular abnormalities usually associated
with an open spinal defect were present. Since the fetus
was in breech presentation and the patient significantly
overweight, trans-vaginal ultrasound was performed. A
much clearer view of the spinal mass, the intestinal fluid-
filled structure and their relationship was achieved, the
intestinal structure originating from the lateral aspect of
the gluteal region (Figure 1A). The patient was informed
about the likely presence of a combined defect of the
caudal embryonal area involving both the spine and the
lower intestinal tract, consistent with the split notochord
spectrum of anomalies. Karyotyping was offered, but
was declined by the patient. Two subsequent scans did
not reveal any change in the volume of the masses or any
other abnormality possibly overlooked at the first scan.
At term, a male neonate weighing 3400 g was delivered
by caesarean section.
Post-natal physical examination showed an intestinal
loop originating in the lateral perineal area, with the
serosa on its external surface (Figure1B,C and Figure2),
a dorsal enteric fistula opening at the base of the loop, an
imperforate anus and a skin-covered lump in the sacral
area (Figure1B and Figure2). The left thigh was mildly
hypoplastic and the right testicle was undescended. An
X ray of the abdomen and spine showed the rectum
ending blindly 3 cm from the perineal surface and the
splitting of the sacrum and the coccyx with a scimitar-
shaped sacral defect. A decompressive colostomy and
a partial resection of the protruding colon segment
were performed as initial treatment. Histology confirmed
that the protruding structure was of intestinal origin
and that the external layer was the serosa. The post-
operative course was uneventful. Magnetic resonance
imaging (MRI) and computed tomography (CT) of the
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Figure 1—(A) At trans-vaginal ultrasound, the relationships between the protruding intestinal segment (arrows) and the sacrococcygeal
lipomyelomeningocele (L) are demonstrated (Sp, spine). (B) For comparison, a lateral view of the lower trunk after the excision of the protruding
intestinal segment and creation of the colostomy (arrow) is shown. Note the lumbar mass represented by the lipomyelomeningocele (L). (C) A
frontal view of the neonate at birth showing the relationships between the intestinal segment (arrows) still in place and the scrotum (S)
brain and spine confirmed the normality of the former
and the presence of a complete cleft below L4 with a
tethered cord associated with a lipomyelomeningocele.
After counselling with neurosurgeons, it was decided to
give priority to the repair the gastrointestinal malforma-
tion, and to untether the conus at a later stage. At the
age of two months, the baby underwent posterior sagit-
tal anorectoplasty via a combined dorsal and anterior
approach. The double route approach was needed for
the difficulties in locating the exact branching point of
the protruding intestinal segment from the colon. Dur-
ing the intervention, a rectourethral fistula, demonstrated
by the pre-operative distal colostogram, was also identi-
fied and closed. The protruding loop was then removed
and the anoplasty completed in the standard way. The
post-operative course was uneventful. The colostomy
was closed at six months of age and the baby was dis-
charged with a well-functioning anus. The colon was
of normal length and size, whereas the ectopic sphinc-
ter showed a reduced para-sagittal muscular component,
especially on the left side. The intestinal function was
relatively good, with moderate constipation. As for the
bladder function, the neurogenic bladder was managed
by intermittent catheterization. At three years of age,
the baby underwent the neurosurgical excision of the
lipomyelomeningocele, in the hope that hopefully an
improvement of bladder and intestinal function would
ensue, but the situation remained basically unchanged
after the operation.
DISCUSSION
Spinal dysraphisms consist of a wide spectrum of con-
genital anomalies resulting from defective embryogen-
esis of the spinal cord and vertebrae (Gilbert-Barness
and Luise, 1997). The pathogenesis of the condition is
unknown. One hypothesis refers to the persistence or
partial obliteration of an accessory neuroenteric canal
that connects the yolk sac and the amniotic cavity in the
third post-conceptional week (Rosselet, 1995). However,
the most recepted theory suggests that an anomalous
splitting or duplication of the notochord would allow
the endoderm or primitive gut to stick in and adhere
to the dorsal ectoderm (Saundres, 1943). As for the
lipomyelomeningocele, it is considered to be the result
of the premature dysjunction of neuroectoderm and ecto-
derm (Sigh and Sigh, 1982).
The malformations featuring spinal dysraphisms can
occur as isolated lesions or in combination with a wide
range of anomalies of the spinal canal, the CNS and/or of
other systems, most often the gastrointestinal tract. There
are two varieties of spinal dysraphism, open and closed.
In the former type (spina bifida cystica), the membrane
and/or the cord may be exposed; in the latter type (occult
spinal dysraphism), the spinal defect is covered with
skin and can be associated or not with a skin-covered
backmass (Byrd et al., 1991). The SNS, together with
the caudal regression syndrome, belongs to the group of
complex occult spinal dysraphism (Tortoli-Donati et al.,
2000). Therefore, SNS represents an exceedingly rare
Copyright  2005 John Wiley & Sons, Ltd. Prenat Diagn 2005; 25: 23–27.
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Figure 2—The dorsal view of the neonate shows the relation-
ship between the protruding intestinal segment (arrowhead), the
lipomyelomeningocele (L) and the scrotum (S)
malformation characterized by a persistent connection
between the endoderm and ectoderm, resulting, in its
most severe form, in a midline communication between
the intestinal cavity and dorsal skin. In the most severe
form, the so-called dorsal enteric fistula, the newborn
has a bowel ostium on the back. Of note, SNS most
commonly occurs in the lower cervical or upper thoracic
spine, much less frequently in the lumbosacral region
(Meller et al., 1989), as in the index case.
The difficulties encountered in the effort to correctly
classify the SNS variant of the index case are easily
understood if a MEDLINE search is attempted. We
performed a search in the English language literature
(1966–2004) for the terms ‘split notochord syndrome’
and ‘dorsal enteric fistula’ and retrieved only nine
affected children. However, the lesions are so different
from each other with such a wide range of associated
anomalies that each one might be considered a unique
variant (Table 1).
With respect to prenatal diagnosis of SNS, there are
only two such reports, and both describe SNS with
thoracic openings (Almog et al., 2001). To the best of
our knowledge, this represents the first case of prenatal
recognition of an SNS located in the lower spinal area.
In our case, at ultrasound the occult spinal dysraphism
(OSD) appeared as a sacro-coccygeal skin-covered cys-
tic mass, thought to represent a simple spinal defect,
but post-natally recognized as a lipomyelomeningocele,
while the perineal mass showed all the features of an
intestinal loop, hence the putative diagnosis of a com-
plex malformation involving tissues of ectodermal and
endodermal origin.
The differential diagnosis of lipomyelomeningoceles
includes the cystic variant of sacrococcygeal teratomas
and spina bifida. However, the latter is associated in
the majority of cases with secondary modifications
of the central nervous system, and, in addition, the
bony vertebral defect is almost always detectable. As
for sacrococcygeal teratomas, they are generally much
larger and are not associated with other perineal or
gluteal anomalies. Isolated lipomyelomeningoceles can
be detected prenatally (Seeds and Powers, 1988), but
not in the context of spinal dysraphisms. Since SNS
is often associated with tethered cord, neurological
deterioration may ensue, even in asymptomatic children,
if prophylactic surgery is not performed. Although
the anomaly is grossly evident at birth, the prenatal
recognition of the condition allows in utero transport to
tertiary referral centres. Whenever unusually appearing
structures of intestinal origin are detected in association
with cystic lesions of the lower spine, SNS and, in
general, open spinal dysraphisms are the most likely
diagnoses.
A last comment about the prenatal diagnostic issue
regards the possible advantages of three-dimensional
ultrasound. Since this anomaly alters dramatically the
anatomy of the fetal breech, it is likely that the use
of surface-rendering reconstruction might have signif-
icantly contributed to the diagnosis; in addition, the
employment of the multiplanar imaging technique might
have allowed for a detailed study of the anatomic rela-
tionship between the various elements of the complex
malformation.
The management of SNS is basically tailored on the
different anomalies present in each case. It aims pri-
marily at the restoration of the intestinal function with
separation of the neuroenteric fistulas, necessary to avoid
fecal contamination of cerebrospinal fluid, if required
(this did not apply to the index case for there was
no neuroenteric communication in this case). The sec-
ond issue is the excision of the lipomyelomeningocele,
which should ensue as soon as possible, even in asymp-
tomatic neonates, to avoid or reduce irreversible neuro-
logical complications (sensory loss, bladder dysfunction,
motor loss, foot deformities and leg pain) associated with
delayed release of a tethered cord. In our case, the sur-
gical approach consisted of a two-stage procedure: the
initial operation, at two months of age, included the exci-
sion of the protruding colon segment and the posterior
sagittal anorectoplasty; the neurosurgical intervention,
performed at three years of age, consisted of the excision
of the lipomyelomeningocele and the release of the teth-
ered cord. However, in this case, the moderately severe
bladder and intestinal dysfunctions persisted unchanged
after the operation.
In conclusion, we have reported the prenatal find-
ings and the post-natal surgical management of a com-
plex form of spinal dysraphism, the split notochord
syndrome, featuring a very rare cluster of anomalies
Copyright  2005 John Wiley & Sons, Ltd. Prenat Diagn 2005; 25: 23–27.
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(SNS, colostomy-like dorsal opening without exposed
intestinal mucosa, anal atresia, rectourethral fistula,
lipomyelomeningocele). This report demonstrates that
SNS can be suspected prenatally whenever a spinal
defect is detected together with an unusual gastrointesti-
nal one, the congenital colostomy in our case, though it
has to be emphasized that SNS represent extremely rare
malformations. The prenatal recognition of this malfor-
mative cluster is important for a proper prenatal coun-
selling and in utero transport to tertiary referral centres.
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CHAPTER 5 
OTHER CHALLENGING WOMEN CONDITIONS AND 
COMPLICATION 
5.1 Introduction 
There is no formal or universally accepted definition of a "high-risk" preg-
nancy. Generally, however, a high-risk pregnancy involves at least one of the 
following: the woman or baby is more likely to become ill or die than usual, or 
complications before or after delivery are more likely to occur than usual. The 
term high-risk pregnancy is a catch-all term that's used to describe women who 
are on the risk continuum at any point during their pregnancy. 
A pregnancy may be treated as high risk if: 
• The woman is over 35 years or under 17 years; 
• It is a multiple pregnancy; 
• The woman has a chronic health condition such as diabetes, heart prob-
lems, or a blood-clotting disorder that has the potential to affect your 
pregnancy; 
• The woman has a history of gynecological problems such as pelvic in-
flammatory disease (PID), endometriosis, or large symptomatic fibroids; 
• The woman has a history of pregnancy loss (miscarriage, ectopic preg-
nancy, or stillbirth) or premature birth; 
• The woman has infectious diseases, including HIV, that could be trans-
mitted to the baby during pregnancy or at the time of birth; 
• The pregnancy is the result of assisted reproductive technologies; 
• The woman had two or more second-trimester abortions; 
• The woman was exposed by her mother to DES during pregnancy (which 
may increase the chances of having difficulty carrying a pregnancy to 
term); 
• The woman conceived while using an IUD; 
• The woman has a child with a genetic disorder or is a carrier for a genetic 
disorder (something that may increase the risk of giving birth to a child 
with that particular genetic disorder). 
Any pregnancy can become high risk for maternal or fetal complications as: 
• vaginal bleeding or spotting; 
• swelling in the face or fingers; 
• a leakage of fluid or increased vaginal discharge; 
• persistent vomiting that is not related to morning sickness; 
• fetal malformations or non reassuring foetal conditions. 
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5.2 Our Experience: Materials and methods 
Advances in obstetrical medicine have made motherhood a possibility for 
large numbers of women who might have been discouraged from starting a 
family a generation ago. 
The Department of Prenatal Care of the University of Naples Federico II is a 
highly specialized centre for high risk pregnancy. This highly specialised ap-
proach to various maternal and foetal conditions is guarantee by the presence of 
collaborative multidisciplinary teams depending on the diseases and of the In-
tensive Care Neonatal Department. 
Every year we follow pregnancies complicated by multiple conditions as dia-
betes, high blood pressure, maternal infectious diseases, genetic conditions 
with possible foetal transmission, endocrine disorders, maternal cardiac dis-
eases, foetal malformations, foetal anemia, ect. 
In particular some of these conditions have been so challenging in their clini-
cal management that we have judged it was worth to publish our experience. 
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5.3. Essential Thrombocythaemia 
Essential Thrombocythemia (ET) is a clonal hematopoietic disorder (1) char-
acterized by increased red blood cell mass. The resultant hyperviscosity of the 
blood predisposes such patients to thrombosis. 
Polycythemia vera should be suspected in patients with elevated hemoglobin 
or hematocrit levels, splenomegaly, or portal venous thrombosis. Secondary 
causes of increased red blood cell mass (e.g., heavy smoking, chronic pulmo-
nary disease, renal disease) are more common than polycythemia vera and must 
be excluded. Diagnosis is made using criteria developed by the Polycythemia 
Vera Study Group; major criteria include elevated red blood cell mass, normal 
oxygen saturation, and palpable splenomegaly. 
Pregnancies in women affected by ET can be complicated by recurrent abor-
tion, foetal growth restriction, stillbirth and placenta abruption. The increasing 
number of young people affected and the slight female preponderance suggest 
the elaboration of appropriate guide-lines for pregnant women. Present thera-
peutic approaches in pregnant patients vary from no treatment to treatment with 
platelet reductive agents as monotherapy or in combination with antithrombotic 
medications (acetylsalicilic acid – ASA ). 
Our experience with pregnant women affected by this conditions allowed us 
to publish a paper in an international journal. From 1991 to 2001 they had nine 
pregnancies; during 4 of them they were left untreated or under ASA treatment 
as a result of patient decision or resistance to the therapy, while in the course of 
the subsequent 5 pregnancies they received α Interferon (α-IFN) treatment, 
with or without ASA.  
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Objectives: In the past essential thrombocythemia was considered a disease of the elderly. At
present, the number of young people suffering from this disease is growing, with a slightly higher
frequency in females. We investigated the effects of interferon alfa therapy in these patients.
Study design: We describe 9 pregnancies in 4 women affected by essential thrombocythemia.
Results: Four pregnancies were carried out without interferon alfa therapy, and resulted in 2
intrauterine deaths, 1 spontaneous abortion, and 1 neonatal death. Interferon alfa was given
during another 5 pregnancies; among them, 2 ended in preterm deliveries with normal infants,
and 3 in full-term deliveries. The literature is reviewed.
Conclusion: Our cases and published series suggest that fetal outcome is improved by therapy,
and that interferon alfa may be the best therapeutic option.
 2004 Elsevier Inc. All rights reserved.Essential thrombocythemia (ET) is a clonal hemato-
poietic disorder1 that can be diagnosed in adherence to
the Polycythemia Vera Study Group (PVSG) criteria.2
Pregnancies in women aﬀected by ET can be compli-
cated by recurrent abortion, fetal growth restriction,
stillbirth, and placental abruption.2 The increasing num-
ber of young people aﬀected, and the slight female
preponderance suggest the elaboration of appropriate
guidelines for pregnant women. Present therapeutic
approaches in pregnant patients vary from no treatment
to treatment with platelet reductive agents as mono-
* Reprint requests: Pasquale Martinelli, MD, Dept. of Gynecology
and Obstetrics, Federico II, University of Naples, via Pansini 5,
Naples, Italy.
E-mail: martinel@unina.it0002-9378/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ajog.2004.05.001therapy or in combination with antithrombotic medi-
cations (acetylsalicylic acid [ASA]).2
We describe 4 women aﬀected by ET. From 1991 to
2001, they had 9 pregnancies; during 4 of them, they
were left untreated or under ASA treatment as a result
of patient decision or resistance to therapy, while in the
course of the subsequent 5 pregnancies, they received
interferon alfa (a-IFN) treatment, with or without
ASA.
Case report
The clinical characteristics of our patients at diagnosis
are described in Table I. Information about platelet
count, type, dose, and length of therapy for all of our
cases are summarized in Table II.
Martinelli et al 2017Table II Patient obstetric history
Platelet count*
Patient Pregnancy
Age at
pregnancy
Start of
pregnancy Peak Nadir
At
delivery
a-IFN
therapy schedule Length of therapy ASA
GA at
delivery
Pregnancy
outcome
1 I 24 814 NA NA NA None Yes 36 wks IUD
II 25 467y 560 362 280 3 MU, 3/W From preconception
to delivery
Yes 34 wks A&H
III 30 825 NA NA 875 None Yes SA
IV 31 650 NA NA 635 None Yes 30 wks NND
2 I 23 440y 399 328 315 3 MU, 1/W From preconception
to delivery
No FT A&H
II 27 458y 399 263 334 3 MU, 1/W From preconception
to delivery
Yes FT A&H
3 IIz 28 310y 317 265 380 3 MU, 1/W From 14wks to
delivery
Yes 36 wks A&H
4 I 30 800 NA NA NA None Yes 27 wks IUD
II 35 1742 1503 641 400 3 MU, 3/W From 8wks to
delivery
Yes FT A&H
GA, Gestational age; NA, not available; IUD, intrauterine death; A&H, alive and healthy; SA, spontaneous abortion; NND, neonatal death; FT, term.
* !103/mL.
y The first pregnancy occurred before ET diagnosis.
z Pregnancy started during a–IFN treatment.
Table I Patient characteristics at diagnosis of ET
Patient Age Plt ! 103/mL Spleen volume by US scan* Cytogenetics bcr/abl BM fibrosis
1 25 812 NA 46,XX Absent Absent
2 22 732 115 mL 46,XX Absent Absent
3 28 720 150 mL 46,XX Absent Absent
4 25 1200 1270 mL NA Absent NA
Plt, Platelet; US, ultrasound; BM, bone marrow; NA, not available.
* Normal spleen volume is considered 60 to 200 mL.32Patient 1
This patient had thrombocytosis (platelet count 814 !
103/mL) since 1992. At her ﬁrst pregnancy (October 1992
to May 1993), intrauterine death occurred while she was
receiving only ASA. In August 1993, a diagnosis of ET
was made at our institution, and a-IFN therapy at the
dose of 3 international megaunits (MU), 5 days per week,
was started. In November 1993, still under a-IFN
therapy, she became pregnant again. After counselling,
a-IFN was continued, and ASA (100 mg daily) was
added, starting from 12 weeks of gestation. At 34 weeks
of gestation we opted for cesarean section because of
mild asymmetric intrauterine growth restriction (IUGR)
with reduced amniotic ﬂuid, and pathologic umbilical
artery Doppler with absence of diastolic ﬂow. A healthy
female newborn of 2150 g weight (below the 25th
percentile) with Apgar score 8 and 9 at 1 and 5 minutes,
respectively, and normal number of platelets was de-
livered. Post partum, a modest rebound from 440! 103/
mL to 651! 103/mL after operation was recorded. a-IFN
therapy was discontinued to allow the patient tobreast-feed. After 6 months, a-IFN therapy was resumed
becauseof increasingplatelet count. Itwas thendeﬁnitively
stopped because of insuﬃcient response (the platelet count
was constantlyover 800!103/mL).Thepatient had2more
pregnancies under treatment with only ASA (100 mg
daily). The ﬁrst pregnancy, in October 1998, resulted in
a spontaneous abortion after a few weeks of gestation; the
other pregnancy, in July 2000, was complicated by sym-
metric IUGR, severe oligohydramnios, and absence of
diastolic ﬂow in the umbilical artery Doppler. A cesarean
sectionwas performed at 30weeks of gestation. TheApgar
score was 3 and 6 at 1 and 5 minutes, respectively, and the
infant died after a few days from prematurity.
Patient 2
This woman was diagnosed with ET in March 1997, and
soon started a-IFN therapy (3 MU 5 days per week)
because of her history of bleeding episodes. In June
1997, she became pregnant. After counselling, she
agreed to continue a-IFN therapy, and the dose was
2018 Martinelli et alTable III Summary of pregnancy outcome according to treatment (our series included)
Treatment Reference
No. of
pregnancies
SA
(%)
IUD
(%)
NND
(%)
Ectopic
pregnancy (%)
Elective
abortion (%)
Pregnancy outcome
FD (%) A&H (%)
None 1,3–5,7,10–13,
16–20,22,25
88 40 4 1 1 4 50 (57) 38 (43)
ASA 1,5,10–13,15,19–20,
22,24–26
86 25 7 1 33 (38) 53* (62)
ASA + IFN 6,7,14 8 1 1 (13) 7 (88)
IFN 2,5,21,23,27–28 11 2 2 (18) 9y (82)
ASA + dipyridamole 12,26 1 1 1
ASA + heparin 2,5,11,20,26,29 9 1 1 (11) 8 (89)
ASA + heparin + AT-III
antagonist
20 2 2
Hydroxyurea 10,12 2 1 1 1
ASA + hydroxyurea 1 1 1
Platelet pheresis 12,16,18 3 1 1 2
ASA + platelet pheresis + IFN 4 1 1
ASA + platelet pheresis 11,12 4 4
Others 10 2 2
Total 218 68 (31) 12 (6) 3 (1) 2 (1) 5 (2) 90 (41) 128 (59)
SA, Spontaneous abortion; IUD, intrauterine death; NND, neonatal death; FD, fetal death; A&H, alive and healthy.
* Down syndrome (1 case).
y Bone and genital malformation (1 case).reduced to 3 MU 3 days per week starting from 20 weeks
of gestation. ASAwas not prescribed because of patient’s
history of bleeding. She had an uneventful pregnancy and
was delivered of a normal male newborn weighing 3070 g
at 41 weeks of gestation, with Apgar scores 8 and 9 at 1
and 5minutes, respectively. The baby’s platelet count was
normal. The patient did not breast-feed in order to
continue the therapy with a-IFN (3 MU once per week).
In July 2002, she became pregnant again and continued
the maintenance treatment. After an uneventful preg-
nancy, she was delivered of a healthy male baby weighing
3000 g at 40 weeks of gestation, with Apgar scores 8 and 9
at 1 and 5 minutes, respectively, and normal platelet
count. She interrupted the therapy to breast-feed; the
follow-up of both children reports good health.
Patient 3
This patient was 28 years old when ET was diagnosed;
she had had her ﬁrst pregnancy before ET appearance in
1996, at the age of 25 years. Being symptomatic with
headache and erythromelalgia, she was treated with a-
IFN (3 MU 3 times per week). As soon as the second
pregnancy was documented (at 14 weeks of gestation),
the dose was reduced and ASA (100 mg daily) was
added. After counselling, this treatment was continued
throughout the pregnancy. The pregnancy was unevent-
ful, with normal growth of the fetus. At 36 weeks of
gestation she was delivered of a healthy female newborn,
weighing 3050 g, with Apgar scores 8 and 9 at 1 and 5
minutes, respectively, and normal platelet count. Lacta-tion was pharmacologically suppressed to continue the
treatment with a-IFN. No rebound thrombocytosis was
observed after delivery. After a few months, the therapy
was stopped for patient’s decision (platelets count 372
! 103/mL). At present, the follow-up shows normal
baby development without clinical complications.
Patient 4
This woman was diagnosed with ET in 1991 when she
was 25, and was given a-IFN (3 MU 3 times per week)
until 1995, when she decided to stop the therapy. In July
1996, intrauterine fetal death occurred at 27 weeks’ of
gestation. In August 2000, she became pregnant again,
and after counselling, at 8 weeks of gestation, therapy
with a-IFN was started again, combined with ASA, 100
mg daily. This treatment was continued throughout the
pregnancy. The pregnancy was uneventful with normal
fetal development. At 40 weeks of gestation the patient
was delivered of a female newborn, weighing 3210 g, with
Apgar scores 7 and 9 at 1 and 5 minutes, respectively.
The baby’s platelet count was normal. a-IFN was
interrupted to allow nursing, but it needed to be resumed
after 15 days because the platelet count was increasing
(896! 103/mL). The patient is still under a-IFN therapy,
and the baby is growing healthy.
Comment
The issue of when and how to treat patients with ET is
of particular concern in young patients because they will
Martinelli et al 2019be receiving therapy for many years, with increasing risk
for treatment-related side eﬀects. ET in pregnancy has
been reported to be complicated by recurrent abortion,
intrauterine death, stillbirth, premature delivery, pre-
eclampsia, and fetal growth restriction caused by pla-
cental infarction resulting from thrombosis. Maternal
complications, such as bleeding or thrombotic events,2
may also occur during pregnancy or post partum. To
improve pregnancy outcome and reduce maternal com-
plications, the use of antiplatelet drugs and/or cyto-
reductive agents is often considered, but the optimal
treatment is still controversial. Some believe that preg-
nancy outcome is not therapy dependent, and thus no
treatment is needed during pregnancy.3 On the other
hand, antiproliferative drugs such as hydroxyurea could
have adverse eﬀects on the fetus (abortion, congenital
malformations, or intrauterine growth restriction).2-4
Following early reports on safety and eﬃcacy during
pregnancy in women with ET,5 a-IFN is increasingly
being used during pregnancy, although pregnancy is still
listed as a contraindication to a-IFN treatment. a-IFN
is not mutagenic in vitro or teratogenic in animal
studies; it does not reduce fertility.4-7 The abortifacient
eﬀects observed in rhesus monkey occur at doses
markedly higher than those used in therapy.5,8 Some
reports have shown that IFN and IFN-like molecules
are produced by murine and human placenta (tropho-
blast interferons). They are expressed for a short period
in high concentrations, and have antiluteolytic, antivi-
ral, antiproliferative, and immunomodulatory eﬀects
through receptors on the endometrial epithelium.9
The treatment by ASA has a logical basis in order to
reduce ischemic placental damage. It is reported to be
eﬀective in many vaso-occlusive manifestations, but its
eﬃcacy in reducing pregnancy complications has not
been proven.3 It may increase the risk of hemorrhage,
thus being indicated in symptomatic ET pregnant women
without history of bleeding. According to some authors,
management of the ET patient should be based on risk
stratiﬁcation3,10 because patients over age 60 years or
who have a previous history of thrombosis are at high
risk. We think that even pregnancy should be considered
a risk factor, especially if the patient has experienced
complications during a previous pregnancy. All 4 of our
cases needed to be treated both because of their being
symptomatic since the onset of disease, and because of
their obstetric history, as summarized in Table II.
From a review of the literature and including our
series, 218 pregnancies in 114 women aﬀected by ET
have been analyzed in 27 reports.1-7,10-29 Fetal outcome
was the following: 128 live births (59%) (including 16
preterm deliveries and 1 postterm delivery), 67 miscar-
riages, 12 stillbirths, 5 elective abortions, 2 ectopic
pregnancies, 3 neonatal deaths, and 1 incompetent
cervix. Seven babies suﬀered from IUGR, 1 from Down
syndrome, and 1 from IUGR with bone and genitalmalformation. It is diﬃcult to draw general rules from
these data because of treatment heterogeneity and
absence of risk stratiﬁcation. Of the 114 women, 23
(19%) were symptomatic before pregnancy. a-IFN
treatment was scheduled in 20 of the 218 pregnancies
but was continued until delivery in only 17. As summa-
rized in Table III, the percentage of live babies was higher
(69%) in treated (any treatment) than in untreated
pregnancies (43%). In all but 3 patients treated with a-
IFN (as single agent or combined with ASA), pregnancy
resulted in live births without complications for either
fetus or mother, thus resulting in eﬀective and safe
deliveries in 85% of the pregnancies in which it was
administered. In our own series, a-IFN treatment led to
term delivery in the same women who experienced poor
outcome when a-IFN was not or could not be given
(Table II), a ﬁnding that can be considered as an internal
control. Even though normal pregnancies are described in
absence of treatment, we think that all pregnant women
with ET should be treated because the real number of
patients suﬀering from complications of ET may be
underestimated.2 As for metabolism and possible side
eﬀects of a-IFN in pregnancy, no conclusive data are
available. Pons et al30 studied the pharmacokinetics of a-
IFN in pregnantwomen in 1995 and demonstrated thata-
IFN was undetectable both in the amniotic ﬂuid and in
fetal blood, and that the pharmacokinetic parameters did
not diﬀer from that in nonpregnantwomen.30 Thus, at the
doses used,a-IFNdoes not seem to cross the placenta and
cannot cause any damage to embriogenesis or to the
developement of the immunologic system in the fetus.2 As
for safety of breast-feeding during IFN therapy, in our
patients, we either stopped IFN treatment or suppressed
lactation after delivery, although there is no evidence of
breast-feeding danger during by IFN. A slight elevation
of IFN concentration was reported by Kumar31 in the
milk of lactating women treated by high-dose (30 MU iv)
IFN. In a patient of our series (#1) who continued breast-
feeding during IFN treatment, a formal quantitative
assay of IFN concentration in the milk was prevented
by intrinsic milk toxicity on the cells used for the assay;
however, the milk from the patient was more toxic to the
target cells than the milk from a healthy control subject.
In conclusion, optimal management of ET patients is
still poorly deﬁned, and there are no established proto-
cols. Normally, only patients belonging to the high-risk
group need to be treated. However, we feel that during
pregnancy all women are at risk of complication and
should be treated. We suggest a-IFN to reduce platelet
count, combined with ASA if no hemorrhagic compli-
cation is present.
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5.4. Budd-Chiari syndrome 
One of the patients attended the Department of High Risk pregnancy was a 
patient with a porto-systemic shunt because of a previous Budd-Chiari Syn-
drome. Budd-Chiari syndrome (BCS) is an uncommon liver disease defined as 
an obstruction to hepatic venous outflow at any level from the small hepatic 
vein to the junction of the inferior vena cava and the right atrium. The charac-
teristic clinical triad is abdominal pain, hepatomegaly, and ascites. Heart failure 
and sinusoidal obstruction syndrome (formerly known as veno-occlusive dis-
ease) also impair hepatic venous outflow and share many features with BCS, 
but are considered separately as causes and treatments are different (1). The ob-
struction of the hepatic venous outflow leads to sinusoidal congestion, centri-
lobular necrosis, fibrosis and portal hypertension (2) as consequences variceal 
bleeding, refractory ascites, hepatorrenal syndrome and hepatopulmonary syn-
drome are very severe complications of BCS, with a potentially fatal outcome 
if no treated appropriately (3,4). Although the natural history of BCS is not 
well known, mortality is highest at first 2 years of diagnosis and was found to 
be independent of surgical portosystemic shunting and is affected by several 
prognostic indicators as the severity of encephalopathy, ascites, prothrombin 
time and serum levels of bilirubin. The main standard of treatment is based in 
anticoagulation unless contraindicated. 
Budd-Chiari syndrome is rare in pregnancy even though pregnancy tends to 
promote Budd-Chiari syndrome. Budd-Chiari syndrome usually presents in the 
last trimester or within several months postpartum (5). The serum bilirubin and 
alkaline phosphatase levels are typically moderately elevated, with normal to 
mildly elevated serum transaminase levels. Budd-Chiari syndrome is diagnosed 
by pulsed Doppler ultrasound, hepatic venography, or magnetic resonance an-
giography (6). Liver biopsy may reveal central venous congestion. 
The woman, we followed during pregnancy, was also affected by a protein C 
deficiency and had a bicornute uterus. The experience of this complicated case 
was published in an international journal as reported above.  
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B
udd-Chiari Syndrome (BCS) is a rare disorder caused by
the obstruction of hepatic venous outflow, mainly due to
the thrombosis of hepatic veins or of the terminal portion
of the inferior vena cava (1). Although many cases are consider-
ed “idiopathic”, underlying inherited (deficiency of natural co-
agulation inhibitors, factor V Leiden and prothrombin G20210A
mutations) or acquired (myeloproliferative disorders, antiphosp-
holipid syndrome, paroxysmal nocturnal haemoglobinuria,
pregnancy, oral contraceptive use), conditions leading to throm-
bophilic states are often detectable and concur to the pathogen-
esis of BCS (1–7). Due to the rarity of the disease and to the low
number of women conceiving after BCS, few data are available
concerning counselling, management and outcome of pregnancy
in this setting.
Case report
We report the case of a 34-year-old woman admitted to our
institution at 10 weeks of her first pregnancy. Ten years earlier,
she underwent a porto-systemic shunt after BCS, and was then
prescribed life-long oral anticoagulant therapy, as protein C defi-
ciency (42%, normal values 70–120%; STA
®
functional Protein
C, Diagnostica Stago, Asnières-sur-Seine, France) was diag-
nosed. Screening for other congenital (plasma antithrombin,
protein S and homocysteine levels; activated protein C resist-
ance; genotyping for factorV Leiden and prothrombin G20210A
mutations) or acquired (lupus anticoagulant and anticardiolipin
antibodies; objective and laboratory data suggesting haemato-
logical, immunological or chronic inflammatory disorders)
thrombophilic conditions was negative. Type I protein C defi-
ciency was then confirmed by repeated measurements, also in-
cluding evaluation of antigen levels (46%, normal values
68–125%; ELISA with rabbit polyclonal antibodies, Dako A/S,
Glostrup, Denmark) and ruling out possible causes of acquired
deficiency (other indexes of liver biosynthesis and vitamin K-
dependent proteins were within normal ranges).
Warfarin had been withdrawn after the biochemical diagno-
sis of pregnancy (6
th
week) and substituted by nadroparin 5,700
UI twice daily. Ultrasonography showed a bicornuate uterus,
with a gestational sac and vital embryo in the right uterine horn
and a large intramural leiomyoma in the other uterine horn.
Ultrasound follow-up during pregnancy did not show abnor-
malities of the liver and of the hepatic vein flow, presence of fluid
in abdomen or foetal malformations and growth restriction. Bio-
chemical testing of liver enzymes, bilirubin, platelet count and
coagulation parameters (PT, aPTT; activated protein C resist-
ance; plasma fibrinogen, antithrombin, D-dimer) were in the
normal range throughout the pregnancy. Ultrasound and labor-
atory follow-up was performed every 3–4 weeks until the 20
th
week, then every two weeks. Pregnancy was uneventful until 29
weeks of gestation, when the patient was admitted because of se-
vere swelling of the legs, ascites and a premature rupture of
membranes (PROM), which prompted labour induction and the
need for urgent caesarean section because of podalic presen-
tation. At the opening of the abdominal wall, about five liters of
milky ascites were found. The male newborn (weight about 900
g; 1 and 5 minutes Apgar scores: 1 and 5, respectively; venous
and arterial umbilical pH: 7.0–7.1) died after two days because
of respiratory distress, although the lack of necroscopy did not
enable to rule out other possible reasons for his death. As ex-
pected due to the neonate’s prematurity, coagulation tests showed
abnormally prolonged PT and aPTT and low plasma levels of co-
agulation factors and inhibitors, including protein C.
Discussion
BCS is a rare and serious thrombotic disease with significant
morbidity and mortality. The underlying acquired and/or inhe-
rited thrombophilic conditions, often associated with this syn-
drome, contribute to the severity of prognosis, with the risk of
thrombotic recurrences and co-morbidity in patients with hae-
matological or immune disorders and cancer (1–7).
Early diagnosis and intervention to reduce portal hyperten-
sion, together with prolonged anticoagulation and the possibility
of liver transplantation [a 68% overall survival at ten years has
been recently reported (8)], have improved clinical outcomes
and life expectancy of patients with BCS. Therefore, concep-
tional and pregnancy issues in fertile women should be carefully
addressed.
The association of BCS with pregnancy is well recognised,
several cases having been reported since the early 1970’s (9–10).
© 2006 Schattauer GmbH, Stuttgart
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On the other hand, very few data are available concerning preg-
nancy in women with a history of BCS (11–12).
It is known that pregnancy can result in fatal complications
for the mother and/or for the infant in women with chronic liver
disease (13). Fertility is often decreased in advanced liver dis-
ease, and this may provide a degree of protection for such pa-
tients who would be at increased risk; however, pregnancy may
occur even in the presence of advanced liver disease, and it is
necessary to anticipate and plan for possible complications of the
specific liver disease. Counselling prior to pregnancy is the best
policy, with consideration of transplantation prior to childbear-
ing or of sterilization if it is more appropriate, based on the pa-
tient’s general and liver function evaluation (13). In this respect,
the presence of severe portal hypertension and high risk of va-
riceal bleeding (further increased during pregnancy) may play a
relevant role. In women with BCS, risks related to the possible
coexistence of thrombophilia and to anticoagulation also have to
be taken into account, as in the patient here reported.This woman
was carrier of protein C deficiency, a severe inherited thrombo-
philic condition (14). Increased risk of venous thromboembol-
ism is reported during pregnancy and puerperium in patients
with inherited deficiency of coagulation inhibitors, and such risk
is likely to be also greater in women with previous thromboem-
bolic events than in asymptomatic carriers (15–16). Antithrom-
botic prophylaxis with low-molecular-weight heparins (LMWH)
has been shown to be a safe and effective approach for women
carrying thrombophilic abnormalities and/or with a history of
venous thromboembolism in pregnancy (17–18). In this respect,
preconceptional advice may include the withdrawal of couma-
rins prior to childbearing, also in order to prevent the risk of em-
bryopathy (19).
Our patient started her pregnancy without such counselling,
and the presence of uterine abnormalities (bicornuate uterus
with a large intramural leiomyoma in the left horn) was un-
known. Bicornuate uterus is the most frequent congenital uterine
abnormality (20), whose prevalence is not negligible in the gen-
eral female population (0.4–4%). In such a condition, the inad-
equate vascularity to the developing embryo and placenta, the re-
duced uterine intraluminal volume or cervical incompetence
predispose to pregnancy complications [early miscarriage, pre-
term labour and breech presentations (20)].
To our knowledge, this is the first pregnancy described in a
woman with a history of BCS treated by porto-systemic shunt
and with a bicornuate uterus. The association of the two diseases
is only coincidental and contributed to the unsuccessful outcome
of pregnancy. The physiologic enlargement of the uterine horn
during pregnancy caused a compression of the shunt, leading to
the onset of severe ascites and, presumably, to the PROM with la-
bour induction. However, the relative contribution of the anat-
omic uterine abnormalities and of the ascites as factors trigger-
ing PROM cannot be established. The sudden and severe presen-
tation of ascites was rather unexpected in this patient, who under-
went a careful laboratory and ultrasound follow-up since the 20
th
week, and hampered the induction of enhancement of foetal lung
maturity planned at 30–32
th
week.
Despite the adverse outcome for the foetus, this report sup-
ports the concept that pregnancy in women with previous BCS
and porto-systemic shunt is possible, and that prophylaxis with
LMWH is safe and effective also in pregnant women with severe
thrombophilia, although the optimal regimen for prophylaxis
and its monitoring (LMWH would require anti-factor Xa levels,
often not available, as in this patient) are still subjects of debate
(21). Due to the low number of women conceiving after BCS,
recommendations and guidelines regarding future conception
and management during pregnancy in this setting have not yet
been defined. Our experience highlights the need for a careful
preconceptional counselling in these women, including advice
for liver and vascular disease, antithrombotic prophylaxis, espe-
cially when thrombophilic abnormalities coexist, and the search
for other maternal disease potentially affecting pregnancy out-
come.
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5.5. Abnormal setting of pregnancy: ectopic pregnancy.  
Ectopic pregnancy is one in which the products of conception develop out-
side the uterine cavity. By far the commonest site is the fallopian tube.  
Ruptured ectopic pregnancy accounts for 10 to 15 percent of all maternal 
deaths (1,2). Fortunately, after the advent of transvaginal ultrasonography and 
beta subunit of human chorionic gonadotropin (beta-hCG) tests, the incidence 
of rupture and case-fatality rates declined from 35.5 deaths per 10,000 ectopic 
pregnancies in 1970 to 3.8 per 10,000 in 1989(2). 
Risk factors most strongly associated with ectopic pregnancy include previ-
ous ectopic pregnancy, tubal surgery, and in utero diethylstilbestrol (DES) ex-
posure. A history of genital infections or infertility 
Ectopic pregnancy is most common in women of reproductive age who pre-
sent with abdominal pain and vaginal bleeding approximately seven weeks af-
ter amenorrhea. These findings are nonspecific and are common in patients 
who may miscarry(1). 
A normal or slightly enlarged uterus, vaginal bleeding, pelvic pain with ma-
nipulation of the cervix, and a palpable adnexal mass significantly increase the 
likelihood of an ectopic pregnancy. Significant abdominal tenderness suggests 
ruptured ectopic pregnancy, especially in a patient with hypotension who pre-
sents with guarding and rebound tenderness. 
Diagnostic tests for ectopic pregnancy include a urine pregnancy test; ultra-
sonography; beta-hCG measurement. 
Ultrasonography is the diagnostic test of choice, with limitations largely 
based on availability and the gestational age of the pregnancy (3). Ectopic 
pregnancy is suspected if transabdominal ultrasonography does not show an in-
trauterine gestational sac and the patient's beta-hCG level is greater than 6,500 
mIU per mL (6,500 IU per L) or if transvaginal ultrasonography does not show 
an intrauterine gestational sac and the patient's beta-hCG level is 1,500 mIU 
per mL (1,500 IU per L) or greater (2). 
Cervical pregnancy is a rare life-threatening form of ectopic pregnancy. In 
the past, hysterectomy was often the only choice available because of profuse 
hemorrhage that accompanied the attempts of removal of the cervical preg-
nancy. 
We present a case series of (4) women with cervical cervix. Some had a good 
outcome but other had a bad outcome because of concomitant conditions which 
affected the therapeutic protocol.  
5.5.1. References 
1. Della-Giustina D, Denny M. Ectopic pregnancy. Emerg Med Clin North Am 
2003;21:565-84. 
2. Tenore JL. Ectopic pregnancy. Am Fam Physician 2000;61:1080-8. 
3. Durston WE, Carl ML, Guerra W, Eaton A, Ackerson LM. Ultrasound avai-
lability in the evaluation of ectopic pregnancy in the ED: comparison of qua-
lity and cost-effectiveness with different approaches. Am J Emerg Med 
2000;18:408-17. 
4. Borrelli PT, Butler SA, Docherty SM, Staite EM, Borrelli AL, Iles RK. Hu-
man chorionic gonadotropin isoforms in the diagnosis of ectopic pregnancy. 
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Journal of Minimally Invasive Gynecology (2007) 14, 758–763s uterine artery embolization for cervical ectopic
regnancy always safe?
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Federico II,” Naples, Italy.Abstract. The study objective was to assess the feasibility and the efficacy of bilateral uterine artery
embolization (BUAE) for the treatment of cervical pregnancy. The design was a series of 3 cases of
viable cervical pregnancy diagnosed by transvaginal ultrasonography and treated by means of BUAE
and subsequent uterine curettage. Three women with viable cervical pregnancy underwent BUAE and
subsequent uterine curettage in the department of obstetrics and gynecology, High Risk Pregnancy
Center, University “Federico II” of Naples. Measurements included surgical outcomes and preservation
of fertility. The treatment was effective in all cases. Two patients resumed normal menstruation about
1 month after the procedure, whereas 1 patient underwent a hysterectomy 2 weeks after embolization
because of acute ischemic degeneration of a concomitant myoma. The conservative management of
cervical pregnancy with angiographic BUAE is a feasible and effective option, even if subsequent
hysterectomy may be required. Counseling is necessary.
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aCervical pregnancy is a rare form of ectopic pregnancy
n which the blastocyst implants and grows within the cer-
ical canal. Cervical pregnancy occurs in less than 1% of all
xtrauterine gestations.1 The incidence varies from 1/1000
o 1/18 000 pregnancies,2 but recently it was reported to be
/8628 pregnancies.3 This condition has been associated
ith a high morbidity rate and, in the past, frequently led to
ysterectomy as a life-saving procedure with consequent
hattering effects on future fertility.
The authors have no commercial, proprietary, or financial interest in the
roducts or companies described in this article.
Corresponding author: Pasquale Martinelli, Vico Acitillo 53, 80131,
aples, Italy.
E-mail: martinel@unina.it
tSubmitted March 12, 2007. Accepted for publication March 26, 2007.
553-4650/$ -see front matter © 2007 AAGL. All rights reserved.
oi:10.1016/j.jmig.2007.05.017Early diagnosis of cervical pregnancy has substan-
ially improved with the use of transvaginal ultrasonog-
aphy (TV-US) and pelvic magnetic resonance imaging
MRI). Moreover, the combination of these 2 techniques
ermits better definition of disease evolution. Actually,
onservative treatment with preoperative bilateral angio-
raphic uterine artery embolization (BUAE) followed by
urettage may be considered a valid approach. This strat-
gy is effective both in terms of surgical outcomes, such
s control of blood flow and prevention of severe hem-
rrhage, as well as in preserving fertility.
On the basis of these considerations, the aim of this study
as to describe a series of 3 cases of viable cervical preg-
ancy diagnosed by TV-US and treated by means of BUAE
nd subsequent uterine curettage, underlining the safety of
he technique but also its potential risk.
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Table 1 shows the main characteristics of the 3 patients.
able 2 shows the management of cervical pregnancy in our
eries with related side effects and outcomes.
atient No. 1
A 39-year old woman (gravida 3, para 0, cesarean sec-
ions 2) was admitted to our department with a diagnosis of
ervical pregnancy at 9 weeks, 5 days’ gestation. The pa-
ient reported a -thalassemia carrier status. She described
er last menstruation as poor vaginal bleeding. On speculum
xamination, the cervix had a bluish color. Transvaginal ultra-
onography revealed a gestational sac with yolk sac and em-
ryo with positive cardiac activity within the cervical canal
aving a crown-rump length (CRL) of 32 mm (Figure 1). The
atient was hemodynamically stable with a hemoglobin level
f 12.8 g/dL.
To better evaluate the cervix and the invasion of tropho-
lastic tissue, pelvic MRI was also performed. The MRI
ndings agreed with ultrasonography findings (Figure 2). Con-
ervative management was planned because the patient
anted to preserve her fertility, although a detailed consent
or hysterectomy in case of emergency was required and
btained. She did not receive medical therapy, such as
dministration of methotrexate. With the patient under gen-
ral anesthesia, BUAE was performed, as detailed below, to
revent massive hemorrhage, and dilation and suction cu-
ettage was performed.
No blood transfusion was required, and the patient was
ischarged 4 days after the surgical intervention. The patient
Table 1 Summary of patients’ characteristics
Patient Age (yrs)
Spontaneous
pregnancy
Po
fa
1 39 Yes TC
2 40 Yes Co
3 43 Yes Un
TC  cesarian section.
Table 2 Management of cervical pregnancy in our series, side
Patient
No.
Other therapy
before UAE
Pre-embolization
hemorrhage
Arteries
embolized
Post
trea
1 None None Bilateral uterine Dila
2 MTX None Bilateral uterine Vacu
D
3 None None Bilateral uterine Dila
h
MTX  methotrexate; UAE  uterine artery embolization.esumed menstruation 35 days after embolization, although
er menses were irregular for the next 6 months.
atient No. 2
A 40-year-old woman (gravida 2, para 1, cesarean section
) was referred from another hospital to our department with
iagnosis of cervical pregnancy at 11 weeks, 4 days’ gestation.
he patient did not report any dilation and curettage, but a
istory of conization for cervical intraepithelial neoplasia II.
During treatment in the previous hospital, the woman
eceived 2-cycle methotrexate treatment. In particular, the
rst methotrexate administration was systemic, whereas the
econd was intra-amniotic.
Transvaginal ultrasonography performed on admission
n our department revealed a still-viable embryo. The ges-
ational sac was within the cervical canal, the CRL of the
mbryo was 45 mm, and the fetal heart rate was 155 beats/
in. A T2-weighted MRI confirmed the cervical pregnancy
ith the placenta-like mass and 1 fetus in the uterine cervix.
Because the patient wanted to preserve her fertility, conserva-
ive management was planned. Thus the patient was informed
fthe eventual risks related to the procedure and the possibility
f undergoing hysterectomy, and informed consent was
igned.
Bilateral uterine artery embolization, as detailed below,
ollowed by a vacuum evacuation and curettage of the
ervical canal was performed. The estimated blood loss was
inimal, and the patient did not receive transfusion. She
as discharged after 6 days, because we waited for a sig-
ificant decline of serum -human chorionic growth hor-
l causative Gestational age at
diagnosis (wks) Live embryo
11 Yes
n 12 Yes
9 Yes
s, and outcome
ization surgical Postembolization
hemorrhage Side effects and follow-up
d curettage None None; regular menses
acuation
and curettage
None None; irregular menses for
3 months
d curettage 
tomy
None Status febrile, degenerative
leiomyomata, postopera-
tive infertilitytentia
ctors
nizatio
knowneffect
embol
tment
tion an
um ev
ilation
tion an
ysterec
ms
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umed 38 days after embolization.
atient No. 3
A 43-year-old woman (gravida 3, para 0, cesarean sec-
ion 3) was admitted to our department with a diagnosis of
ervical pregnancy at 8 weeks, 2 days’ gestation. The pa-
ient had an unremarkable medical history (no previous
ntrauterine procedures or pelvic inflammatory disease).
ransvaginal ultrasonography revealed a gestational sac be-
ow the closed internal cervical os and an intramural ante-
ior uterine myoma with a main diameter of 62 mm.
igure 1 Patient No. 1. Transvaginal ultrasonographic scan of
he cervical pregnancy. The gestational sac with the vital embryo
s located in the cervical canal (C). The uterine body is empty (U).
igure 2 Patient No. 1. Magnetic resonance imaging findings
nclude an empty uterus (short arrow) and a gestational sac in thenervical canal with trophoblastic invasion (long arrow).The embryo was viable and had a CRL of 21 mm. The
ervical pregnancy and the location and size of leiomyoma
ere confirmed by MRI. Treatment modalities, together
ith their benefits and potential risks, were discussed with
he patient who signed an informed consent form. Conser-
ative management was planned because patient desired
uture fertility. Dilation and suction curettage was per-
ormed with the patient under general anesthesia after
UAE was performed to prevent hemorrhagic complica-
ions. The BUAE is detailed below. Angiography of the
ight uterine artery before embolization showed tortuous
nd dilated arteries in the distal branches because they were
upporting the myoma (Figure 3).
The estimated blood loss was less than 100 mL, and no
ransfusion was required. Blood pressure was 115/70 mm Hg.
ne day after the procedure, the patient developed a fever.
ostoperative ultrasound scanning performed on the fourth
ay showed a normal cervix but ultrasonographic findings
f degenerative myoma. The white blood cell count of 18
09/L and the cultures indicated a mixed aerobic and anaer-
bic infection. Antibiotic therapy was started.
Because of the persistence of the febrile status and the
orsening of the ultrasonographic findings, we decided to
erform a simple hysterectomy. The patient was monitored
y daily white blood cell count and hemoglobin measure-
ents and continued to receive antibiotic therapy for an-
ther week. Two days after hysterectomy the patient had a
ormal corporeal temperature, and the white blood cell
ount returned to the normal range.
Pathologic examination of the removed uterus revealed
igure 3 Patient No. 3. Pre-embolization angiogram of the right
terine artery. The right uterine artery before embolization showed
ortuous arteries in its distal branches dilated because supporting
he myoma.ecrosis, degeneration, and inflammation of myoma tissue
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761Martinelli et al Safety of embolization for ectopic pregnancyaused by the temporary reduction of the uterine flow. The
atient was discharged in stable condition after 3 weeks.
escription of the procedure
The BUAE was performed with patients under general
nesthesia. The procedure consisted of a percutaneous cath-
terization of the right femoral artery and both hypogastric
rteries via a 5F head hunter–shaped catheter. Selective
mbolization of the uterine arteries was performed with
pongostan/Surgifoam (gelatin-based absorbable hemo-
tats; Johnson and Johnson Management, Berkshire, UK)
or patients 1 and 2 and Embosphere microspheres 500 to
00 m (acrylic polymer impregnated with gelatin; Bio-
phere Medical, Rockland, MA) followed by Bead Block
ompressible Microspheres 700 to 900 m (polyvinyl al-
ohol, water soluble synthetic resin; Terumo Medical Corp.,
omerset, NJ) for patient 3.
Cessation of vascular uterine circle and complete ab-
ence of the myoma vascularization was provided by con-
rol angiography (Figure 4). No complication was observed
mmediately after each procedure.
iscussion
The use of in vitro fertilization, embryo transfer, and
icrosurgical techniques have recently increased the rate of
ctopic pregnancies which are diagnosed earlier because of
V-US. However, cervical pregnancy remains a rare event
ith an unknown cause, although the frequency of this
igure 4 Patient No. 3. Postembolization angiogram of the right
terine artery. The vascularity of the mass and myoma was sig-
ificantly reduced, and the distal arteries are not present.isease can be influenced by a combination of iatrogenic cvents, such as previous dilation and curettage, previous
esarean section, previous cervical surgery, or Asherman’s
yndrome.2,4
The first ultrasound report of this uncommon type of
ctopic pregnancy was reported in 1978 by Raskin.5 Even if
o maternal death has been reported in the literature since
953, patients with cervical pregnancy are considered a
igh-risk group for severe and potentially life-threatening
emorrhage, which may lead to hysterectomy and fertility
oss.6
The early diagnosis of cervical pregnancy has improved
ith the use of ultrasound scanning, leading to a significant
ecline of complications. In particular, ultrasound scanning
as been able to differentiate between cervical pregnancy
nd the cervical stage of miscarriage.7 Transvaginal ultra-
onography improves visualization and allows diagnosis by
irect visualization of an intracervical ectopic gestational
ac or trophoblastic mass. In cases of cervical pregnancy the
mplantation appears within the cervical canal and is not
ccompanied by decidual reaction. Therefore the tropho-
lastic tissue is usually directly attached to the cervical
issue with marked vascularization. A better definition of the
terine cervical invasion by trophoblast is possible with
RI. In fact, the use of MRI improves the evaluation of the
issue’s invasion because it allows the visualization of pro-
iferating chorionic villi into the fibromuscular layer.6
Cervical pregnancy is frequently associated with exten-
ive hemorrhage, which, in severe cases, may be stopped
nly by hysterectomy. However, current treatment options
ermit effective conservative management in women who
ant to preserve their fertility. In recent years, several
ertility-sparing techniques, such as cervical cerclage after
urettage,4 curettage and packing, local excision and repair,
igation of the cervical branch of the uterine arteries,8 sys-
emic or local methotrexate application,9–11 local intra-sac
Cl injections,12 use of a Foley catheter balloon for com-
ression,13,14 and BUAE15–17 or combination of these,18
ave been proposed.
Since 1982, methotrexate administration represents the
ost conservative approach. Furthermore, its effectiveness
s reduced in particular conditions, such as serum -hCG
oncentration greater than 10 000 IU/L or a gestational age
reater than 9 weeks, presence of fetal activity, and CRL
reater than 10 mm.19 Methotrexate may be also adminis-
ered as a medical pretreatment to a planned hysterectomy
r a very cautious dilation and curettage, because it de-
reases vascularization of ectopic mass.20
Another method to decrease the mass vascularization is
UAE, which stops nutritional support to the trophoblast.
he removal of gestational sac and placental tissue is usu-
lly followed by bleeding from the vessels supplying the
lacenta. By selective embolization of 1 or both uterine
rteries, the bleeding is usually controlled. This procedure
an be performed alone or in association with methotrexate
dministration. Table 3 shows the main case or series of
ases of cervical pregnancy treated with BUAE.
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762 Journal of Minimally Invasive Gynecology, Vol 14, No 6, November/December 2007Bilateral uterine artery embolization for the management of
ervical pregnancy was first described in 1990.15 It was useful
o greatly reduce bleeding caused by ectopic pregnancy. With
atients under general anesthesia or conscious sedation, a spe-
ial catheter is introduced through the femoral artery. Cathe-
erization is extended to the internal iliac artery and then to the
terine arteries and is followed by injection of a thrombotic
ubstance (polyvinyl alcohol, gelatin sponge). Bilateral uterine
rtery embolization was never performed at a gestational age
ater than the seventh week until 1999, when it was first
uccessfully performed at 12 weeks.16
Although BUAE could be useful in emergency condi-
ions after heavy vaginal bleeding,29 we performed BUAE
efore dilation and curettage to prevent hemorrhage as
Table 3 Main case reports of cervical pregnancy
Authors
No. of reported
cases Type of in
Nappi et al16 1 Methotrex
 vacu
curetta
cathete
Takano et al17 1 Selective
Trambert et al21 5
2
1
One selec
Two selec
One selec
methotre
Has et al22 1 BUAE 
admini
evacua
Yitzhak et al23 1 Methotrex
admini
bilatera
emboli
Su et al24 1 Selective
Gui et al25 1 BUAE 
admini
curetta
1 BUAE 
admini
curetta
Sherer et al26 1 Methotrex
BUAE 
cathete
Vilos et al27 1 Transfemo
evacua
produc
Einarsson et al28 1 Systemic
uterine
-hCG  -human chorionic growth hormone; BUAE  bilateral utehowed by other authors.16,30 With this prophylactic proce- wure we decreased the risks of hemorrhagic complications,
educing blood flow from the descending cervical arteries
nd allowing the evacuation of the products of conception
ith low blood loss. In this series, the immediate success
ate for controlling the bleeding was 100%. This result is in
greement with a series of 8 cervical pregnancies treated by
eans of selective embolotherapy either as emergency or
onemergency procedure.21 In that report, BUAE was per-
ormed with or without methotrexate administration, no
ase required the hysterectomy, and the control of the he-
ostasis was obtained in all cases.21
The clinical course and follow-up was uneventful for 2
atients who resumed normal menstruation 1 month after
UAE. The patient with the uterine myoma was treated
tion Outcomes
ministration  BUAE
cuation and
amponade with Foley
n the cervical canal
Successful hemostasis
Preservation of uterus
Stopping of vaginal bleeding
Immediate decrease of -hCG
Preservation of uterus
lvic embolization
lvic embolization
lvic embolization 
ministration
Successful hemostasis
Preservation of uterus
One blood transfusion required
rexate
n  vacuum
d curettage
Minimal hemorrhage
Preservation of uterus
Long-term amenorrhea after
the procedure
tra-arterial
n  selective
gastric artery
Successful hemostasis
Preservation of uterus
Rapid decrease of -hCG
Preservation of uterus
rexate
n  BUAE 
Preservation of uterus
rexate
n  BUAE 
Preservation of uterus
ministration 
onade with Foley
in the cervical canal
Complete resolution
Preservation of uterus
AE  resectoscopic
the gestational
Minimal maternal morbidity
Preservation of uterus
trexate  selective
lization
Spontaneous expulsion
Vaginal bleeding requiring a
tamponade with a Foley
catheter
Preservation of uterus
ery embolization.terven
ate ad
um eva
ge  t
r withi
BUAE
tive pe
tive pe
tive pe
xate ad
methot
stratio
tion an
ate in
stratio
l hypo
zation
BUAE
methot
stratio
ge
methot
stratio
ge
ate ad
tamp
r with
ral BU
tion of
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embo
rine artith hysterectomy after 2 weeks because of a febrile status
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763Martinelli et al Safety of embolization for ectopic pregnancyesistant to antibiotic therapy because of ischemic degener-
tion of the myoma.
A comprehensive Medline search from 1975 revealed
hat this appeared to be the second case of cervical preg-
ancy with coexisting leiomyomata. In the first case report-
d,22 the management of the cervical pregnancy consisted of
UAE followed by intraamniotic injection of methotrexate
0 mg. No remarkable bleeding was observed, but the
atient complained of amenorrhea until 11 months after the
ntervention. 22
Although a long-term outcome study on uterine emboliza-
ion of leiomyomata reported the failure of the procedure, with
ailure defined as subsequent hysterectomy, myomectomy, or
epeated embolization in 13.7%, 4.4%, and 1.6% of cases,
espectively,31 when the cervical pregnancy is associated with
uterine leiomyomata, the prognosis for future fertility could
e poor, as noted in our third case. In this regard, with BUAE
e intended to reduce blood loss and decrease the size of
yoma. In fact, Has et al22 showed a reduction in myoma size
fter BUAE of about 70%. Furthermore, myoma degeneration
ay be a potential complication because of the deep and acute
eduction in uterine vascularization.
onclusion
Even if modern diagnostic and treatment options provide
n opportunity for conservative treatment of cervical preg-
ancy, during counseling it is critical to explain carefully
hat potential complications can make extirpative treatment
ecessary.
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